Amgen (AMGN) 10-K 12 Feb 20 2019 FY Annual report Financial data

Cover page

Cover page - USD ($)	12 Months Ended
	Dec. 31, 2019	Feb. 06, 2020	Jun. 30, 2019
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2019
Document Transition Report	false
Entity File Number	001-37702
Entity Registrant Name	Amgen Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	95-3540776
Entity Address, Address Line One	One Amgen Center Drive
Entity Address, City or Town	Thousand Oaks
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91320-1799
City Area Code	805
Local Phone Number	447-1000
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 110,809,019,075
Entity Common Stock, Shares Outstanding		589,806,819
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Specified portions of the registrant’s Proxy Statement with respect to the 2020 Annual Meeting of Stockholders to be held May 19, 2020, are incorporated by reference into Part III of this annual report.
Entity Central Index Key	0000318154
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Common Stock | The NASDAQ Global Select Market
Entity Information [Line Items]
Title of 12(b) Security	Common stock, $0.0001 par value
Trading Symbol	AMGN
Security Exchange Name	NASDAQ
1.250% Senior Notes Due 2022 | New York Stock Exchange
Entity Information [Line Items]
Title of 12(b) Security	1.250% Senior Notes Due 2022
Trading Symbol	AMGN22
Security Exchange Name	NYSE
2.00% Senior Notes Due 2026 | New York Stock Exchange
Entity Information [Line Items]
Title of 12(b) Security	2.00% Senior Notes Due 2026
Trading Symbol	AMGN26
Security Exchange Name	NYSE

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenues:
Product sales	$ 23,362	$ 23,747	$ 22,849
Total revenues	23,362	23,747	22,849
Operating expenses:
Cost of sales	4,356	4,101	4,069
Research and development	4,116	3,737	3,562
Selling, general and administrative	5,150	5,332	4,870
Other	66	314	375
Total operating expenses	13,688	13,484	12,876
Operating income	9,674	10,263	9,973
Interest expense, net	1,289	1,392	1,304
Interest and other income, net	753	674	928
Income before income taxes	9,138	9,545	9,597
Provision for income taxes	1,296	1,151	7,618
Net income	$ 7,842	$ 8,394	$ 1,979
Earnings per share:
Basic (in usd per share)	$ 12.96	$ 12.70	$ 2.71
Diluted (in usd per share)	$ 12.88	$ 12.62	$ 2.69
Shares used in the calculation of earnings per share:
Basic (in shares)	605	661	731
Diluted (in shares)	609	665	735
Product sales [Member]
Revenues:
Product sales	$ 22,204	$ 22,533	$ 21,795
Other [Member]
Revenues:
Product sales	1,158	1,214	1,054
Total revenues	$ 1,158	$ 1,214	$ 1,054

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Net income	$ 7,842	$ 8,394	$ 1,979
Other comprehensive income (loss), net of reclassification adjustments and taxes:
(Losses) gains on foreign currency translation	(48)	(141)	81
(Losses) gains on cash flow hedges	(66)	247	(288)
Gains (losses) on available-for-sale securities	360	(185)	(6)
Other (losses) gains	(5)	(2)	5
Other comprehensive income (loss), net of taxes	241	(81)	(208)
Comprehensive income	$ 8,083	$ 8,313	$ 1,771

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 6,037	$ 6,945
Marketable securities	2,874	22,359
Trade receivables, net	4,057	3,580
Inventories	3,584	2,940
Other current assets	1,888	1,794
Total current assets	18,440	37,618
Property, plant and equipment, net	4,928	4,958
Intangible assets, net	19,413	7,443
Goodwill	14,703	14,699
Other assets	2,223	1,698
Total assets	59,707	66,416
Current liabilities:
Accounts payable	1,371	1,207
Accrued liabilities	8,511	7,862
Current portion of long-term debt	2,953	4,419
Total current liabilities	12,835	13,488
Long-term debt	26,950	29,510
Long-term deferred tax liabilities	606	864
Long-term tax liabilities	8,037	8,770
Other noncurrent liabilities	1,606	1,284
Contingencies and commitments
Stockholders’ equity:
Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding—591.4 shares in 2019 and 629.6 shares in 2018	31,531	31,246
Accumulated deficit	(21,330)	(17,977)
Accumulated other comprehensive loss	(528)	(769)
Total stockholders’ equity	9,673	12,500
Total liabilities and stockholders’ equity	$ 59,707	$ 66,416

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Millions	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock and additional paid-in capital, par value (in usd per share)	$ 0.0001	$ 0.0001
Common stock and additional paid-in capital, shares authorized	2,750	2,750
Common stock and additional paid-in capital, shares outstanding	591.4	629.6

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Number of shares of common stock	Common stock and additional paid-in capital [Member]	Accumulated deficit [Member]	Accumulated other comprehensive loss [Member]
Beginning Balance, Shares at Dec. 31, 2016		738.2
Beginning Balance at Dec. 31, 2016	$ 29,875		$ 30,784	$ (438)	$ (471)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,979			1,979
Other comprehensive income (loss), net of tax	(208)				(208)
Dividends declared on common stock	(3,487)			(3,487)
Issuance of common stock in connection with the Company’s equity award programs, Shares		2.5
Issuance of common stock in connection with the Company’s equity award programs	52		52
Stock-based compensation expense	347		347
Tax impact related to employee stock-based compensation expense	(191)		(191)
Repurchases of common stock, Shares		(18.5)
Repurchases of common stock	(3,126)			(3,126)
Ending Balance, Shares at Dec. 31, 2017		722.2
Ending Balance at Dec. 31, 2017	25,241		30,992	(5,072)	(679)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	8,394			8,394
Other comprehensive income (loss), net of tax	(81)				(81)
Dividends declared on common stock	(3,482)			(3,482)
Issuance of common stock in connection with the Company’s equity award programs, Shares		1.9
Issuance of common stock in connection with the Company’s equity award programs	56		56
Stock-based compensation expense	327		327
Tax impact related to employee stock-based compensation expense	(129)		(129)
Repurchases of common stock, Shares		(94.5)
Repurchases of common stock	$ (17,855)			(17,855)
Ending Balance, Shares at Dec. 31, 2018	629.6	629.6
Ending Balance at Dec. 31, 2018	$ 12,500		31,246	(17,977)	(769)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	7,842			7,842
Other comprehensive income (loss), net of tax	241				241
Dividends declared on common stock	(3,555)			(3,555)
Issuance of common stock in connection with the Company’s equity award programs, Shares		2
Issuance of common stock in connection with the Company’s equity award programs	97		97
Stock-based compensation expense	323		323
Tax impact related to employee stock-based compensation expense	(135)		(135)
Repurchases of common stock, Shares		(40.2)
Repurchases of common stock	$ (7,640)			(7,640)
Ending Balance, Shares at Dec. 31, 2019	591.4	591.4
Ending Balance at Dec. 31, 2019	$ 9,673		$ 31,531	$ (21,330)	$ (528)

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares	Dec. 11, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Stockholders' Equity [Abstract]
Common stock, dividends declared per share (in usd per share)	$ 1.60	$ 5.95	$ 5.41	$ 4.77

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net income	$ 7,842	$ 8,394	$ 1,979
Depreciation, amortization and other	2,206	1,946	1,955
Stock-based compensation expense	308	311	329
Deferred income taxes	(289)	(363)	(1,330)
Other items, net	186	(386)	(334)
Changes in operating assets and liabilities, net of acquisitions:
Trade receivables, net	(504)	(378)	(58)
Inventories	(66)	(3)	133
Other assets	10	35	(24)
Accounts payable	164	(143)	424
Accrued income taxes, net	(585)	(361)	523
Long-term tax liabilities	(146)	258	6,681
Other liabilities	396	1,214	231
Net cash provided by operating activities	9,150	11,296	11,177
Cash flows from investing activities:
Purchases of marketable securities	(9,394)	(18,741)	(33,607)
Proceeds from sales of marketable securities	8,842	28,356	24,240
Proceeds from maturities of marketable securities	20,548	5,412	6,174
Purchases of property, plant and equipment	(618)	(738)	(664)
Cash paid for acquisitions, net of cash acquired	(13,617)	195	(19)
Other	(52)	(145)	(148)
Net cash provided by (used in) investing activities	5,709	14,339	(4,024)
Cash flows from financing activities:
Net proceeds from issuance of debt	0	0	4,476
Repayment of debt	(4,514)	(1,121)	(4,405)
Repurchases of common stock	(7,702)	(17,794)	(3,160)
Dividends paid	(3,509)	(3,507)	(3,365)
Withholding taxes arising from shares withheld for share-based payments	(137)	(126)	(191)
Other	95	58	51
Net cash used in financing activities	(15,767)	(22,490)	(6,594)
(Decrease) increase in cash and cash equivalents	(908)	3,145	559
Cash and cash equivalents at beginning of year	6,945	3,800	3,241
Cash and cash equivalents at end of year	$ 6,037	$ 6,945	$ 3,800

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics. Principles of consolidation The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates. Revenues Product sales and sales deductions Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates. Historically, such amounts have represented less than 1% of the aggregate sales deductions charged against product sales. Returns are estimated through comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial. Our payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers. Indirect taxes collected from customers and remitted to government authorities and that are related to sales of the Company’s products, primarily in Europe, are excluded from revenues. As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in Selling, general and administrative expense in the Consolidated Statements of Income. Other revenues Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty estimates are based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below. Arrangements with multiple-performance obligations From time to time, we enter into arrangements for the research and development (R&D), manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial performance milestone payments; royalty payments; and/or profit sharing. In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur. Research and development costs R&D costs are expensed as incurred and include primarily salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems’ costs; and amortization of acquired technology used in R&D with alternative future uses. R&D expenses also include costs and cost recoveries associated with third-party R&D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations and Note 21, Subsequent events. Selling, general and administrative costs Selling, general and administrative (SG&A) costs are composed primarily of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $789 million , $674 million and $620 million during the years ended December 31, 2019 , 2018 and 2017 , respectively. SG&A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations. Leases Adoption of new lease standard In February 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that lessees recognize the assets and liabilities that arise from leases on the balance sheet, including leases classified as operating leases, and that they disclose qualitative and quantitative information about leasing arrangements. The FASB subsequently issued additional amendments to address issues arising from the implementation of the new lease standard. We adopted this standard as of January 1, 2019, using the modified-retrospective method, which provides a method for recording existing leases at adoption. We used the adoption date as our date of initial application, and thus, comparative-period financial information is not presented for periods prior to the adoption date. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. Adoption of the new standard resulted in total lease liabilities of $510 million and right-of-use (ROU) assets of $439 million as of January 1, 2019. The difference between the initial lease liabilities and the ROU assets is related primarily to previously existing lease liabilities. The standard did not materially impact our Consolidated Statements of Income and had no impact on our Consolidated Statements of Cash Flows. Our accounting policies under the new standard are described below. See Note 13, Leases. Lease recognition At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate. Stock-based compensation We have stock-based compensation plans under which various types of equity-based awards are granted, including restricted stock units (RSUs), performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation. Income taxes We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (UTBs) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTBs in income tax expense. See Note 6, Income taxes. Acquisitions We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (IPR&D) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree’s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. Contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions, and Note 17, Fair value measurement. Cash equivalents We consider cash equivalents to be only those investments that are highly liquid, readily convertible to cash and which mature within three months from the date of purchase. Interest-bearing securities We consider our interest-bearing securities investment portfolio available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in Accumulated other comprehensive income (loss) (AOCI). Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company’s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement. Inventories Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories. Derivatives We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments. Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment. Goodwill and other intangible assets Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets. The fair values of IPR&D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. There are often major risks and uncertainties associated with IPR&D projects as we are required to obtain regulatory approvals in order to be able to market the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. Capitalized IPR&D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors’ products could result in partial or full impairment of the related intangible assets. We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets. Contingencies In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Foreign currency translation The net assets of international subsidiaries whose local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries’ earnings are translated into U.S. dollars using average exchange rates. Other recent accounting pronouncements In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. The new standard is effective for interim and annual periods beginning on January 1, 2020. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. We have substantially completed our impact assessment and do not currently anticipate a material impact on our consolidated financial statements.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Business combinations	Acquisitions Otezla ® (apremilast) On November 21, 2019, we acquired worldwide rights to Otezla ® , the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, along with certain related assets and liabilities, from Celgene Corporation (Celgene). Otezla ® is used primarily for the treatment of patients with moderate-to-severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate and is approved in more than 50 markets outside the United States, including the European Union and Japan. The acquisition was accounted for as an asset acquisition under GAAP because substantially all the value of the assets acquired was concentrated in the global intellectual property rights of Otezla ® . Otezla ® ’s operations have been included in our consolidated financial statements commencing on the acquisition date. The following table summarizes the consideration transferred and the allocation of the estimated accumulated cost, including tax adjustments, to the assets acquired and liabilities assumed (in millions): Amounts Cash purchase price $ 13,400 Transaction costs 40 Accumulated cost (consideration transferred) $ 13,440 Intangible assets: Developed-product-technology rights $ 13,007 Marketing-related rights 195 Inventory 367 Deferred tax liability, net (24 ) Deferred credit (96 ) Other liabilities, net (9 ) Total assets acquired, net $ 13,440 Amgen allocated the accumulated cost of the acquisition to the assets acquired based on their relative fair values. The accumulated cost of the acquisition includes direct acquisition-related costs and applicable taxes. Goodwill is not recognized in the accounting for an asset acquisition. Rather, the excess of the accumulated cost over the fair value of the net assets acquired is reallocated to the nonfinancial assets acquired. The developed-product-technology rights acquired relate to Otezla ® . The estimated fair value was determined by using a multi-period excess earnings income approach, which is based on the present value of the incremental after-tax cash flows attributable only to the intangible asset. The developed-product-technology rights will be amortized over a weighted-average period of 8.5 years by using the straight-line method. The estimated fair value of marketing-related rights, which relate to assembled workforce, was determined using a replacement cost approach, which consists of developing an estimate of the current cost of a similar new asset having the nearest equivalent utility to the asset being valued. The assembled workforce will be amortized over a period of 5 years by using the straight-line method. The estimated fair value of the acquired inventory was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyer’s effort are applied. Inventory fair value adjustments will be amortized as inventory turns over, which we estimate to approximate 2.5 years . Nuevolution AB On July 15, 2019, we acquired all of the outstanding stock of Nuevolution AB (Nuevolution), a publicly traded, Denmark-based biotechnology company with a leading small molecule drug discovery platform, for total consideration of $183 million in cash. The transaction, which was accounted for as a business combination, expands our ability to discover novel small molecules against difficult-to-drug targets and with greater speed and efficiency. Nuevolution’s operations, which are not material, have been included in our consolidated financial statements commencing on the acquisition date. We allocated the consideration to acquire Nuevolution to finite-lived intangible assets of $150 million , comprised primarily of technology rights for a drug discovery platform with an estimated useful life of 10 years ; goodwill of $26 million , which is not tax deductible; deferred tax liabilities of $22 million ; and other net assets of $29 million . The estimated fair values of intangible assets were determined primarily by using a probability-weighted-income approach, which discounts expected future cash flows to present value by using a discount rate that represents the estimated rate that market participants would use to value the intangible assets. Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis to determine the acquisition date fair values of certain assets acquired, tax-related items and the residual impact on goodwill. Kirin-Amgen, Inc. During the first quarter of 2018, we acquired the remaining 50% ownership of Kirin-Amgen, Inc. (K-A), from Kirin Holdings Company, Limited (Kirin), making K-A a wholly owned subsidiary of Amgen. Upon its acquisition, K-A’s operations have been included in our consolidated financial statements commencing on the share acquisition date. The acquisition relieved Amgen of future royalty obligations to K-A. Prior to the share acquisition date, we owned 50% of K-A and accounted for our interest in K-A by using the equity method of accounting. The transaction was accounted for as a step acquisition of a business in which we were required to remeasure our existing 50% ownership interest at fair value. In addition, we were required to effectively settle our preexisting relationship with K-A, which resulted in a loss. Together the gain on the remeasurement of our existing ownership interest and the loss from the settlement of the preexisting relationship resulted in a net gain of $80 million , which was recorded in Interest and other income, net, in the Consolidated Statements of Income. The primary means of consideration for this transaction was a payment of $780 million in cash. The aggregate share acquisition date consideration to acquire the remaining 50% ownership in K-A and the fair value of Amgen’s preacquisition investment consisted of the following (in millions): Amounts Total cash paid to Kirin $ 780 Fair value of contingent consideration obligation 45 Loss on settlement of preexisting relationship (168 ) Total consideration transferred to acquire K-A 657 Fair value of Amgen’s investment in K-A 825 Total acquisition date fair value $ 1,482 In connection with this acquisition, we are obligated to make single-digit royalty payments to Kirin contingent upon sales of brodalumab. The estimated fair value of this contingent consideration obligation was $45 million as of the share acquisition date. The fair values of assets acquired and liabilities assumed consisted of cash of $977 million , licensing rights of $470 million , deferred tax liabilities of $102 million , other assets and liabilities of $131 million and goodwill of $6 million . The estimated fair value of acquired licensing rights was determined by using a probability-related-income approach, which is based on the present value of the incremental after-tax cash flows attributable only to the intangible asset. The projected cash flows were based on certain assumptions, including estimates of future revenues and expenses and the time and resources needed to maintain the assets through commercialization. The licensing rights will be amortized over a weighted-average period of four years by using the straight-line method. The excess of the share acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $6 million was recorded as goodwill, which is not deductible for tax purposes. The $131 million in other assets and liabilities represents primarily receivables for royalties earned by K-A but not yet received, offset partially by payables representing R&D expenses incurred but not yet reimbursed by K-A. Pro forma results of operations for this acquisition have not been presented because this acquisition was not material to our consolidated results of operations.

Revenues

Revenues	12 Months Ended
	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenues	Revenues We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. Rest-of-world (ROW) revenues relate to products that are sold primarily in Europe. Revenues were as follows (in millions): Year ended December 31, 2019 U.S. ROW Total Enbrel ® (etanercept) $ 5,050 $ 176 $ 5,226 Neulasta ® (pegfilgrastim) 2,814 407 3,221 Prolia ® (denosumab) 1,772 900 2,672 XGEVA ® (denosumab) 1,457 478 1,935 Aranesp ® (darbepoetin alfa) 758 971 1,729 KYPROLIS ® (carfilzomib) 654 390 1,044 EPOGEN ® (epoetin alfa) 867 — 867 Sensipar ® /Mimpara ® (cinacalcet) 252 299 551 Other products 2,907 2,052 4,959 Total product sales (1) 16,531 5,673 22,204 Other revenues 693 465 1,158 Total revenues $ 17,224 $ 6,138 $ 23,362 Year ended December 31, 2018 U.S. ROW Total ENBREL $ 4,807 $ 207 $ 5,014 Neulasta ® 3,866 609 4,475 Prolia ® 1,500 791 2,291 Aranesp ® 942 935 1,877 XGEVA ® 1,338 448 1,786 Sensipar ® /Mimpara ® 1,436 338 1,774 EPOGEN ® 1,010 — 1,010 KYPROLIS ® 583 385 968 Other products 1,947 1,391 3,338 Total product sales (1) 17,429 5,104 22,533 Other revenues 929 285 1,214 Total revenues $ 18,358 $ 5,389 $ 23,747 Year ended December 31, 2017 U.S. ROW Total ENBREL $ 5,206 $ 227 $ 5,433 Neulasta ® 3,931 603 4,534 Aranesp ® 1,114 939 2,053 Prolia ® 1,272 696 1,968 Sensipar ® /Mimpara ® 1,374 344 1,718 XGEVA ® 1,157 418 1,575 EPOGEN ® 1,096 — 1,096 KYPROLIS ® 562 273 835 Other products 1,419 1,164 2,583 Total product sales (1) 17,131 4,664 21,795 Other revenues 898 156 1,054 Total revenues $ 18,029 $ 4,820 $ 22,849 ____________ (1) Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2019 , 2018 and 2017 . In the United States, we sell primarily to pharmaceutical wholesale distributors that we utilize as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance. We had product sales to three customers, each of them accounting for more than 10% of total revenues for each of the years ended December 31, 2019 , 2018 and 2017 . For the year ended December 31, 2019 , on a combined basis, these customers accounted for 81% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions): Years ended December 31, 2019 2018 2017 AmerisourceBergen Corporation: Gross product sales $ 12,301 $ 12,091 $ 10,742 % of total gross revenues 33 % 33 % 31 % McKesson Corporation: Gross product sales $ 11,795 $ 11,434 10,625 % of total gross revenues 31 % 31 % 30 % Cardinal Health, Inc.: Gross product sales $ 6,538 $ 7,475 $ 7,049 % of total gross revenues 17 % 20 % 20 % As of December 31, 2019 and 2018 , amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 73% and 76% , respectively, of net trade receivables on a combined basis. As of December 31, 2019 and 2018 , 27% and 23% , respectively, of trade receivables, net, were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2019 and 2018 was not material.

Stock-based compensation

Stock-based compensation	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock-based compensation	Stock-based compensation Our Amended and Restated 2009 Equity Incentive Plan (the Amended 2009 Plan) authorizes for issuance to employees of Amgen, employees of Amgen subsidiaries and nonemployee members of our Board of Directors shares of our common stock pursuant to grants of equity-based awards, including RSUs, stock options and performance units. The pool of shares available under the Amended 2009 Plan is reduced by one share for each stock option granted and by 1.9 shares for other types of awards granted, including RSUs and performance units (full-value awards). In general, if any shares subject to an award granted under the Amended 2009 Plan expire or become forfeited, terminated or canceled without the issuance of shares, the shares subject to such awards are added back into the authorized pool on the same basis that they were removed. In addition, under the Amended 2009 Plan, shares withheld to pay for minimum statutory tax obligations with respect to full-value awards are added back into the authorized pool on the basis of 1.9 shares. As of December 31, 2019 , the Amended 2009 Plan provides for future grants and/or issuances of up to 28 million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose. The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions): Years ended December 31, 2019 2018 2017 RSUs $ 168 $ 165 $ 174 Performance units 105 117 133 Stock options 35 29 22 Total stock-based compensation expense, pretax 308 311 329 Tax benefit from stock-based compensation expense (67 ) (67 ) (118 ) Total stock-based compensation expense, net of tax $ 241 $ 244 $ 211 Restricted stock units and stock options Eligible employees generally receive an annual grant of RSUs and, for certain executive-level employees, stock options, with the size and type of award generally determined by the employee’s salary grade and performance level. Certain management and professional-level employees typically receive RSU grants upon commencement of employment. Nonemployee members of our Board of Directors also receive an annual grant of RSUs. Our RSU and stock option grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including upon death, disability, termination in connection with a change in control and the retirement of employees who meet certain service and/or age requirements. RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date. RSUs accrue dividend equivalents, which are typically payable in shares, only when and to the extent the underlying RSUs vest and are issued to the recipient. Restricted stock units The grant date fair value of an RSU equals the closing price of our common stock on the grant date, as RSUs accrue dividend equivalents during their vesting period. The weighted-average grant date fair values of RSUs granted during the years ended December 31, 2019 , 2018 and 2017 , were $182.12 , $179.18 and $163.99 , respectively. The following table summarizes information regarding our RSUs: Year ended December 31, 2019 Units (in millions) Weighted-average grant date fair value Balance nonvested as of December 31, 2018 3.1 $ 168.11 Granted 1.2 $ 182.12 Vested (1.0 ) $ 163.21 Forfeited (0.2 ) $ 170.52 Balance nonvested as of December 31, 2019 3.1 $ 174.97 The total grant date fair values of RSUs that vested during the years ended December 31, 2019 , 2018 and 2017 , were $160 million , $167 million and $182 million , respectively. Stock options The exercise price of stock options is set as the closing price of our common stock on the grant date, and the related number of shares granted is fixed at that point in time. Awards expire 10 years from the date of grant. We use the Black–Scholes option valuation model to estimate the grant date fair value of stock options. The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows: Years ended December 31, 2019 2018 2017 Closing price of our common stock on grant date $ 177.31 $ 177.46 $ 162.60 Expected volatility (average of implied and historical volatility) 23.5 % 24.6 % 22.7 % Expected life (in years) 5.8 5.8 5.8 Risk-free interest rate 2.4 % 2.8 % 2.1 % Expected dividend yield 3.1 % 2.9 % 2.8 % Fair value of stock options granted $ 30.47 $ 34.60 $ 27.54 The following table summarizes information regarding our stock options: Year ended December 31, 2019 Options (in millions) Weighted- average exercise price Weighted- average remaining contractual life (in years) Aggregate intrinsic value (in millions) Balance unexercised as of December 31, 2018 4.4 $ 143.57 Granted 1.4 $ 177.31 Exercised (0.7 ) $ 107.13 Expired/forfeited (0.3 ) $ 171.01 Balance unexercised as of December 31, 2019 4.8 $ 157.00 7.2 $ 406 Vested or expected to vest as of December 31, 2019 4.6 $ 156.02 7.1 $ 390 Exercisable as of December 31, 2019 1.3 $ 117.13 4.3 $ 162 The total intrinsic values of options exercised during the years ended December 31, 2019 , 2018 and 2017 , were $68 million , $53 million and $60 million , respectively. The actual tax benefits realized from tax deductions from option exercises during the years ended December 31, 2019 , 2018 and 2017 , were $15 million , $12 million and $21 million , respectively. As of December 31, 2019 , $308 million of unrecognized compensation cost was related to nonvested restricted stock units and unvested stock options, which is expected to be recognized over a weighted-average period of 1.8 years. Performance units Certain management-level employees also receive annual grants of performance units, which give the recipient the right to receive common stock that is contingent upon achievement of specified preestablished goals over the performance period, which is generally three years . The performance goals for the units granted during the years ended December 31, 2019 , 2018 and 2017 , which are accounted for as equity awards, are based on (i) Amgen’s stockholder return compared with a comparator group of companies, which are considered market conditions and are therefore reflected in the grant date fair values of the units, and (ii) Amgen’s stand-alone financial performance measures, which are considered performance conditions. The expense recognized for awards is based on the grant date fair value of a unit multiplied by the number of units expected to be earned with respect to the related performance conditions, net of estimated forfeitures. Depending on the outcome of these performance goals, a recipient may ultimately earn a number of units greater or less than the number of units granted. Shares of our common stock are issued on a one-for-one basis for each performance unit earned. In general, performance unit awards vest at the end of the performance period. The performance award program provides for accelerated or continued vesting in certain circumstances as defined in the plan, including upon death, disability, a change in control and retirement of employees who meet certain service and/or age requirements. Performance units accrue dividend equivalents that are typically payable in shares only when and to the extent the underlying performance units vest and are issued to the recipient, including with respect to market and performance conditions that affect the number of performance units earned. We use a payout simulation model to estimate the grant date fair value of performance units. The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows: Years ended December 31, 2019 2018 2017 Closing price of our common stock on grant date $ 177.31 $ 177.93 $ 162.60 Volatility 22.1 % 23.8 % 25.9 % Risk-free interest rate 2.3 % 2.6 % 1.4 % Fair value of units granted $ 188.40 $ 189.21 $ 178.87 The payout simulation model assumes correlations of returns of the stock prices of our common stock and the common stocks of the comparator groups of companies and stock price volatilities of the comparator groups of companies to simulate stockholder returns over the performance periods and their resulting impact on the payout percentages based on the contractual terms of the performance units. As of December 31, 2019 and 2018 , 2.0 million and 2.0 million performance units were outstanding with weighted-average grant date fair values of $185.64 and $180.12 per unit, respectively. During the year ended December 31, 2019 , 0.8 million performance units with a weighted-average grant date fair value of $188.40 were granted, and 0.2 million performance units with a weighted-average grant date fair value of $186.66 were forfeited. The total fair values of performance units paid during the years ended December 31, 2019 , 2018 and 2017 were $176 million , $133 million and $219 million , respectively, based on the number of performance units earned multiplied by the closing stock price of our common stock on the last day of the performance period. As of December 31, 2019 , $113 million of unrecognized compensation cost was related to nonvested performance units, which is expected to be recognized over a weighted-average period of one year

Defined contribution plan

Defined contribution plan	12 Months Ended
	Dec. 31, 2019
Retirement Benefits [Abstract]
Defined contribution plan	Defined contribution plan The Company has defined contribution plans to which certain employees of the Company and participating subsidiaries may defer compensation for income tax purposes. Participants are eligible to receive matching contributions based on their contributions, in addition to other Company contributions. Defined contribution plan expenses were $220 million , $173 million and $196 million for the years ended December 31, 2019 , 2018 and 2017 , respectively.

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income taxes	Income taxes Income before income taxes included the following (in millions): Years ended December 31, 2019 2018 2017 Domestic $ 4,371 $ 4,856 $ 4,436 Foreign 4,767 4,689 5,161 Total income before income taxes $ 9,138 $ 9,545 $ 9,597 The provision for income taxes included the following (in millions): Years ended December 31, 2019 2018 2017 Current provision: Federal $ 1,284 $ 1,270 $ 8,615 State 39 17 5 Foreign 277 227 275 Total current provision 1,600 1,514 8,895 Deferred (benefit) provision: Federal (276 ) (317 ) (1,120 ) State (22 ) (7 ) — Foreign (6 ) (39 ) (157 ) Total deferred (benefit) provision (304 ) (363 ) (1,277 ) Total provision for income taxes $ 1,296 $ 1,151 $ 7,618 Deferred income taxes reflect the tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, tax credit carryforwards and the tax effects of net operating loss (NOL) carryforwards. Significant components of our deferred tax assets and liabilities were as follows (in millions): December 31, 2019 2018 Deferred income tax assets: NOL and credit carryforwards $ 800 $ 810 Accrued expenses 457 428 Expenses capitalized for tax 170 185 Stock-based compensation 91 95 Other 269 174 Total deferred income tax assets 1,787 1,692 Valuation allowance (517 ) (509 ) Net deferred income tax assets 1,270 1,183 Deferred income tax liabilities: Acquired intangible assets (1,288 ) (1,509 ) Debt (210 ) (184 ) Other (286 ) (267 ) Total deferred income tax liabilities (1,784 ) (1,960 ) Total deferred income taxes, net $ (514 ) $ (777 ) Valuation allowances are provided to reduce the amounts of our deferred tax assets to an amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts. The valuation allowance increased in 2019 due primarily to the Company’s expectation that some state R&D credits will not be utilized. As of December 31, 2019 , we had $20 million of federal tax credit carryforwards available to reduce future federal income taxes and have provided no valuation allowance for those federal tax credit carryforwards. The federal tax credit carryforwards expire between 2023 and 2035. We had $605 million of state tax credit carryforwards available to reduce future state income taxes and have provided a valuation allowance for $482 million of those state tax credit carryforwards. A portion of the state credits for which no valuation allowance has been provided will expire between 2022 and 2034. As of December 31, 2019 , we had $144 million of federal NOL carryforwards available to reduce future federal income taxes and have provided a valuation allowance for $6 million of those federal NOL carryforwards. The federal NOL carryforwards, for which no valuation allowance has been provided, expire between 2020 and 2035. We had $196 million of state NOL carryforwards available to reduce future state income taxes and have provided a valuation allowance for $196 million of those state NOL carryforwards. We had $2.0 billion of foreign NOL carryforwards available to reduce future foreign income taxes and have provided a valuation allowance for $516 million of those foreign NOL carryforwards. For the foreign NOLs with no valuation allowance provided, $822 million has no expiry; and the remainder will expire between 2020 and 2024. The reconciliations of the total gross amounts of UTBs were as follows (in millions): Years ended December 31, 2019 2018 2017 Beginning balance $ 3,061 $ 2,953 $ 2,543 Additions based on tax positions related to the current year 215 173 447 Additions based on tax positions related to prior years 22 13 1 Reductions for tax positions of prior years (11 ) (17 ) (5 ) Reductions for expiration of statute of limitations — — (5 ) Settlements — (61 ) (28 ) Ending balance $ 3,287 $ 3,061 $ 2,953 Substantially all of the UTBs as of December 31, 2019 , if recognized, would affect our effective tax rate. Interest and penalties related to UTBs are included in our provision for income taxes. During the years ended December 31, 2019 , 2018 and 2017 , we recognized $198 million , $137 million and $56 million , respectively, of interest and penalties through the income tax provision in the Consolidated Statements of Income. As of December 31, 2019 and 2018 , accrued interest and penalties associated with UTBs were $667 million and $469 million , respectively. The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows: Years ended December 31, 2019 2018 2017 Federal statutory tax rate 21.0 % 21.0 % 35.0 % 2017 Tax Act, net repatriation tax — % — % 70.7 % Foreign earnings (4.5 )% (4.3 )% (15.8 )% 2017 Tax Act, net deferred tax remeasurement — % — % (6.9 )% Credits, Puerto Rico Excise Tax (2.6 )% (2.5 )% (2.2 )% 2017 Tax Act, net impact on intercompany sales — % (1.8 )% — % Interest on uncertain tax positions 1.6 % 1.2 % 0.6 % Credits, primarily federal R&D (1.0 )% (0.8 )% (0.6 )% Share-based payments (0.3 )% (0.2 )% (0.7 )% Other, net — % (0.5 )% (0.7 )% Effective tax rate 14.2 % 12.1 % 79.4 % The effective tax rates for the years ended December 31, 2019 and 2018 differ from the federal statutory rate due primarily to impacts of the jurisdictional mix of income and expenses. The effective tax rate for 2017 differs from the federal statutory rate primarily as a result of the Tax Cuts and Jobs Act (the 2017 Tax Act). Primarily all of the benefit to our effective tax rate from foreign earnings results from the Company’s operations conducted in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes and are subject to tax incentive grants through 2035. Additionally, the Company’s operations conducted in Singapore is subject to a tax incentive grant through 2034. These earnings are also subject to U.S. tax at a reduced rate of 10.5%. The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred. Income taxes paid during the years ended December 31, 2019 , 2018 and 2017 , were $1.9 billion , $1.9 billion and $1.5 billion , respectively. One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes may arise with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. As previously disclosed, we received a Revenue Agent Report (RAR) from the Internal Revenue Service (IRS) for the years 2010, 2011 and 2012. The RAR proposes to make significant adjustments that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. In November 2017, we received a modified RAR that revised the IRS’s calculation but continued to propose substantial adjustments. We disagree with the proposed adjustments and are pursuing resolution with the IRS administrative appeals office, which currently has jurisdiction over the matter. If we deem necessary, we will vigorously contest the proposed adjustments through the judicial process. Final resolution of this complex matter is not likely within the next 12 months and could have a material impact on our consolidated financial statements. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes, the ultimate resolution of any tax matters may result in payments substantially greater or less than amounts accrued. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009. In addition, we are currently under examination by a number of state and foreign tax jurisdictions.

Earnings per share

Earnings per share	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Earnings per share	Earnings per share The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which include primarily shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method. The computations for basic and diluted EPS were as follows (in millions, except per-share data): Years ended December 31, 2019 2018 2017 Income (Numerator): Net income for basic and diluted EPS $ 7,842 $ 8,394 $ 1,979 Shares (Denominator): Weighted-average shares for basic EPS 605 661 731 Effect of dilutive securities 4 4 4 Weighted-average shares for diluted EPS 609 665 735 Basic EPS $ 12.96 $ 12.70 $ 2.71 Diluted EPS $ 12.88 $ 12.62 $ 2.69 For each of the three years ended December 31, 2019 , the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.

Collaborations

Collaborations	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborations	Collaborations A collaborative arrangement is a contractual arrangement that involves a joint operating activity. Such arrangements involve two or more parties that are both (i) active participants in the activity and (ii) exposed to significant risks and rewards dependent on the commercial success of the activity. From time to time, we enter into collaborative arrangements for the R&D, manufacture and/or commercialization of products and/or product candidates. These collaborations generally provide for nonrefundable upfront license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration arrangements are performed with no guarantee of either technological or commercial success, and each arrangement is unique in nature. See Note 1, Summary of significant accounting policies, for additional discussion of revenues recognized for these types of arrangements. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Consolidated Statements of Income, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Our significant arrangements are discussed below. Novartis AG We are in a collaboration with Novartis AG (Novartis) to jointly develop and commercialize Aimovig ® (erenumab-aooe). In the United States, Amgen and Novartis jointly develop and collaborate on the commercialization of Aimovig ® . Amgen, as the principal, recognizes product sales of Aimovig ® in the United States, shares U.S. commercialization costs with Novartis and pays Novartis a significant royalty on net sales in the United States. Novartis holds global co-development rights and exclusive commercial rights outside the United States and Japan for Aimovig ® and other specified migraine programs. Novartis pays Amgen double-digit royalties on net sales of the products in the Novartis exclusive territories and funds a portion of global R&D expenses. In addition, Novartis will make a payment to Amgen of up to $100 million if certain commercial and expenditure thresholds are achieved with respect to Aimovig ® in the United States. Amgen manufactures and supplies Aimovig ® worldwide. The migraine collaboration will continue for the commercial lives of the products unless terminated in accordance with its terms. We are currently involved in litigation with Novartis over our collaboration agreements for the development and commercialization of Aimovig ® . See Note 19, Contingencies and commitments. During the year ended December 31, 2019 , net costs recovered from Novartis for migraine products were $187 million and were recorded primarily in Selling, general and administrative expense in the Consolidated Statements of Income. During the year ended December 31, 2018 , net costs paid to Novartis for migraine products were $44 million and were recorded primarily in Selling, general and administrative expense in the Consolidated Statements of Income. During the year ended December 31, 2017 , net costs recovered from Novartis for migraine products were $124 million and were recorded primarily in R&D expense in the Consolidated Statements of Income. During the years ended December 31, 2019 and 2018, royalties due to Novartis for the migraine products were $115 million and $43 million , respectively, and were recorded in Cost of sales in the Consolidated Statements of Income. During the years ended December 31, 2019 and 2018, royalties due from Novartis for the migraine products were not material. As a result of certain regulatory and commercial events, we received milestone payments from Novartis of $295 million during the year ended December 31, 2018 , which was recorded in Other revenues in the Consolidated Statements of Income. Bayer HealthCare LLC We are in a collaboration with Bayer HealthCare LLC (Bayer) to jointly develop and commercialize Nexavar ® (sorafenib) worldwide, except in Japan. The rights to develop and market Nexavar ® in Japan are reserved to Bayer. Nexavar ® is currently marketed and sold in more than 100 countries around the world for the treatment of unresectable liver cancer and advanced kidney cancer. In the United States, Nexavar ® is also approved for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment. In 2015, we amended the terms of our collaboration agreement with Bayer, which terminated the co-promotion agreement in the United States and transferred all U.S. operational responsibilities to Bayer, including commercial and medical affairs activities. Prior to the termination of the co-promotion agreement, we co-promoted Nexavar ® with Bayer and shared equally in the profits or losses in the United States. In lieu of this profit share, Bayer now pays Amgen a royalty on U.S. sales of Nexavar ® at a percentage rate in the high 30 s. Amgen no longer contributes sales force personnel or medical liaisons to support Nexavar ® in the United States. There are no changes to the global R&D or non-U.S. profit share arrangements in the original agreement, as discussed below. In all countries outside the United States and Japan, Bayer manages all commercialization activities and incurs all of the sales and marketing expenditures and mutually agreed R&D expenses, for which we continue to reimburse Bayer for half. In these countries, we continue to receive 50% of net profits on sales of Nexavar ® after deducting certain Bayer-related costs. The agreement with Bayer will terminate at the later of the date when patents expire that were issued in connection with product candidates discovered under the agreement or on the last day that we or Bayer market or sell products commercialized under the agreement anywhere in the world. Patents related to Nexavar ® begin to expire in 2020. During the years ended December 31, 2019 , 2018 and 2017 , Amgen recorded Nexavar ® net profits of $210 million , $164 million and $161 million , respectively, which were recognized as Other revenues in the Consolidated Statements of Income. During the years ended December 31, 2019 , 2018 and 2017 , Amgen recorded royalty income of $79 million , $91 million and $133 million , respectively, in Other revenues in the Consolidated Statements of Income, pursuant to the 2015 amendment to the collaboration agreement. Net R&D expenses related to the agreement were not material for the years ended December 31, 2019 , 2018 and 2017 . Other In addition to the collaborations discussed above, we have various other collaborations that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay additional amounts or we may receive additional amounts upon the achievement of various development and commercial milestones, which in the aggregate could be significant. We may also incur or have reimbursed to us significant R&D costs if the related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay significant royalties or we may receive significant royalties on future sales. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.

Investments

Investments	12 Months Ended
	Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Available-for-sale investments The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, all of which are considered available-for-sale, by type of security were as follows (in millions): Types of securities as of December 31, 2019 Amortized cost Gross unrealized gains Gross unrealized losses Fair values U.S. Treasury notes $ 359 $ 1 $ — $ 360 U.S. Treasury bills — — — — Other government-related debt securities: U.S. — — — — Foreign and other — — — — Corporate debt securities: Financial 1,108 13 — 1,121 Industrial 824 10 — 834 Other 195 3 — 198 Residential-mortgage-backed securities 181 1 — 182 Other mortgage- and asset-backed securities — — — — Money market mutual funds 5,250 — — 5,250 Other short-term interest-bearing securities 289 — — 289 Total available-for-sale investments $ 8,206 $ 28 $ — $ 8,234 Types of securities as of December 31, 2018 Amortized cost Gross unrealized gains Gross unrealized losses Fair values U.S. Treasury notes $ 2,710 $ — $ (47 ) $ 2,663 U.S. Treasury bills 8,191 — — 8,191 Other government-related debt securities: U.S. 112 — (2 ) 110 Foreign and other 972 1 (41 ) 932 Corporate debt securities: Financial 2,778 — (81 ) 2,697 Industrial 2,603 — (99 ) 2,504 Other 583 — (21 ) 562 Residential-mortgage-backed securities 1,458 — (36 ) 1,422 Other mortgage- and asset-backed securities 483 — (14 ) 469 Money market mutual funds 5,659 — — 5,659 Other short-term interest-bearing securities 3,515 — — 3,515 Total available-for-sale investments $ 29,064 $ 1 $ (341 ) $ 28,724 The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions): December 31, Consolidated Balance Sheets locations 2019 2018 Cash and cash equivalents $ 5,360 $ 6,365 Marketable securities 2,874 22,359 Total available-for-sale investments $ 8,234 $ 28,724 Cash and cash equivalents in the above table excludes bank account cash of $677 million and $580 million as of December 31, 2019 and 2018 , respectively. The fair values of available-for-sale investments by contractual maturity, except for mortgage- and asset-backed securities that do not have a single maturity date, were as follows (in millions): December 31, Contractual maturities 2019 2018 Maturing in one year or less $ 5,629 $ 17,424 Maturing after one year through three years 2,304 3,356 Maturing after three years through five years 119 5,168 Maturing after five years through ten years — 885 Mortgage- and asset-backed securities 182 1,891 Total available-for-sale investments $ 8,234 $ 28,724 For the years ended December 31, 2019 , 2018 and 2017 , realized gains on interest-bearing securities were $92 million , $29 million and $147 million , respectively, and realized losses on interest-bearing securities were $36 million , $394 million and $213 million , respectively. Realized gains and losses on interest-bearing securities are recorded in Interest and other income, net, in the Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method. As of December 31, 2019, aggregate gross unrealized losses of available-for-sale investments were not material. As of December 31, 2018, the fair values and gross unrealized losses of available-for-sale investments in an unrealized loss position aggregated by type and length of time that the securities have been in a continuous loss position were as follows (in millions): Less than 12 months 12 months or more Types of securities as of December 31, 2018 Fair values Unrealized losses Fair values Unrealized losses U.S. Treasury notes $ 1,219 $ (21 ) $ 1,444 $ (26 ) Other government-related debt securities: U.S. — — 110 (2 ) Foreign and other 631 (31 ) 240 (10 ) Corporate debt securities: Financial 1,968 (59 ) 718 (22 ) Industrial 1,898 (81 ) 529 (18 ) Other 529 (20 ) 28 (1 ) Residential-mortgage-backed securities 576 (14 ) 840 (22 ) Other mortgage- and asset-backed securities 17 — 451 (14 ) Total $ 6,838 $ (226 ) $ 4,360 $ (115 ) The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer. We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. The evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below our cost basis as well as adverse conditions related specifically to the security, such as any changes to the credit rating of the security and the intent to sell or whether we will more likely than not be required to sell the security before recovery of its amortized cost basis. Our assessment of whether a security is other-than-temporarily impaired could change in the future based on new developments or changes in assumptions related to that particular security. As of December 31, 2019 and 2018 , we believe the cost bases for our available-for-sale investments were recoverable in all material respects. Equity securities We held investments in equity securities with readily determinable fair values of $303 million and $176 million as of December 31, 2019 and 2018 , respectively, which are included in Other assets in the Consolidated Balance Sheets. Gains and losses recognized on equity securities with readily determinable fair values, including gains and losses recognized on sales, were not material for the years ended December 31, 2019 , 2018 and 2017 . We held investments of $176 million and $222 million in equity securities without readily determinable fair values as of December 31, 2019 and 2018 , respectively, which are included in Other assets in the Consolidated Balance Sheets. Adjustments to the carrying values of these securities were not material for the years ended December 31, 2019 , 2018 and 2017 . Limited partnership investments We held limited partnership investments of $320 million and $285 million as of December 31, 2019 and 2018 , respectively, which are included in Other assets in the Consolidated Balance Sheets. These investments are measured by using the net asset values of the underlying investments as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of December 31, 2019 , unfunded additional commitments to be made for these investments during the next several years were not material. Gains and losses recognized on our limited partnership investments were not material for the years ended December 31, 2019 , 2018 and 2017 .

Inventories

Inventories	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consisted of the following (in millions): December 31, 2019 2018 Raw materials $ 358 $ 257 Work in process 2,227 1,660 Finished goods 999 1,023 Total inventories $ 3,584 $ 2,940

Property, plant and equipment

Property, plant and equipment	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property, plant and equipment	Property, plant and equipment Property, plant and equipment consisted of the following (dollar amounts in millions): December 31, Useful life (in years) 2019 2018 Land — $ 263 $ 265 Buildings and improvements 10-40 3,757 3,616 Manufacturing equipment 8-12 2,655 2,418 Laboratory equipment 8-12 1,236 1,174 Capitalized software 3-5 1,154 1,124 Other 3-15 3,313 3,204 Construction in progress — 907 953 Property, plant and equipment, gross 13,285 12,754 Less accumulated depreciation and amortization (8,357 ) (7,796 ) Property, plant and equipment, net $ 4,928 $ 4,958 During the years ended December 31, 2019 , 2018 and 2017 , we recognized depreciation and amortization expense associated with our property, plant and equipment of $635 million , $630 million and $604 million , respectively. Geographic information Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions): December 31, 2019 2018 United States $ 2,433 $ 2,373 Puerto Rico 1,402 1,476 ROW 1,093 1,109 Total property, plant and equipment, net $ 4,928 $ 4,958

Goodwill and intangible assets

Goodwill and intangible assets	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets	Goodwill and other intangible assets Goodwill The changes in the carrying amounts of goodwill were as follows (in millions): Years ended December 31, 2019 2018 Beginning balance $ 14,699 $ 14,761 Addition from acquisitions 26 6 Currency translation adjustments (22 ) (68 ) Ending balance $ 14,703 $ 14,699 Other intangible assets Other intangible assets consisted of the following (in millions): December 31, 2019 2018 Gross carrying amounts Accumulated amortization Other intangible assets, net Gross carrying amounts Accumulated amortization Other intangible assets, net Finite-lived intangible assets: Developed-product-technology rights $ 25,575 $ (8,322 ) $ 17,253 $ 12,573 $ (7,479 ) $ 5,094 Licensing rights 3,761 (2,398 ) 1,363 3,772 (2,032 ) 1,740 Marketing-related rights 1,382 (965 ) 417 1,297 (1,019 ) 278 R&D technology rights 1,273 (947 ) 326 1,148 (872 ) 276 Total finite-lived intangible assets 31,991 (12,632 ) 19,359 18,790 (11,402 ) 7,388 Indefinite-lived intangible assets: IPR&D 54 — 54 55 — 55 Total other intangible assets $ 32,045 $ (12,632 ) $ 19,413 $ 18,845 $ (11,402 ) $ 7,443 Developed-product-technology rights consists of rights related to marketed products acquired in acquisitions. Licensing rights consists primarily of contractual rights acquired in acquisitions to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. R&D technology rights pertains to technologies used in R&D that have alternative future uses. Developed-product-technology rights and marketing-related rights include assets acquired with the Otezla ® acquisition. R&D technology rights includes assets acquired with the Nuevolution acquisition. See Note 2, Acquisitions. IPR&D consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. All IPR&D projects have major risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized values, if any, of acquired IPR&D projects may vary from their estimated fair values. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval. During the years ended December 31, 2019 , 2018 and 2017 , we recognized amortization associated with our finite-lived intangible assets of $1.4 billion , $1.3 billion and $1.3 billion , respectively. Amortization of intangible assets is included primarily in Cost of sales in the Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the years ending December 31, 2020, 2021, 2022, 2023 and 2024, are $2.8 billion , $2.6 billion , $2.5 billion , $2.4 billion and $2.4 billion

Leases

Leases	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Leases	Leases On January 1, 2019, we adopted a new accounting standard that amends the guidance for the accounting and reporting of leases. Certain required disclosures have been made on a prospective basis in accordance with the standard’s guidance. See Note 1, Summary of significant accounting policies. We lease certain facilities and equipment related primarily to administrative, R&D and sales and marketing activities. Leases with terms of 12 months or less are expensed on a straight-line basis over the term and are not recorded in the Consolidated Balance Sheets. Most leases include one or more options to renew, with renewal terms that may extend the lease term up to seven years . The exercise of lease renewal options is at our sole discretion. In addition, some of our lease agreements include rental payments adjusted periodically for inflation. Our lease agreements neither contain residual value guarantees nor impose significant restrictions or covenants. We sublease certain real estate to third parties. Our sublease portfolio consists of operating leases from former R&D and administrative space. The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions): Consolidated Balance Sheets locations December 31, 2019 Assets: Other assets $ 469 Liabilities: Accrued liabilities $ 140 Other noncurrent liabilities 388 Total lease liabilities $ 528 The components of net lease costs were as follows (in millions): Lease costs Year ended December 31, 2019 Operating (1) $ 204 Sublease income (33 ) Total net lease costs $ 171 ____________ (1) Includes short-term leases and variable lease costs, which were not material for the year ended December 31, 2019 . Maturities of lease liabilities as of December 31, 2019 , were as follows (in millions): Maturity dates Amounts 2020 $ 157 2021 150 2022 110 2023 88 2024 30 Thereafter 32 Total lease payments (1) 567 Less imputed interest (39 ) Present value of lease liabilities $ 528 ____________ (1) Includes future rental commitments for abandoned leases of $178 million . We expect to receive total future rental income of $141 million related to noncancelable subleases for abandoned facilities. The weighted-average remaining lease term and weighted-average discount rate of our leases were 4.1 years and 3.3% , respectively, as of December 31, 2019 . Cash and noncash information related to our leases was as follows (in millions): Year ended December 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 148 ROU assets obtained in exchange for lease obligations: Operating leases $ 163 As of December 31, 2019 , we have entered into leases that have not yet commenced, with total undiscounted future lease payments of $306 million . Theses leases will commence between 2020 and 2021 with lease terms from 5 years to 15 years . The following table summarizes minimum future rental commitments related to noncancelable operating leases under the prior lease guidance as of December 31, 2018 (in millions): Amounts 2019 $ 164 2020 126 2021 113 2022 64 2023 56 Thereafter 46 Total minimum operating lease commitments $ 569 Included in the table above are future rental commitments for abandoned leases in the amount of $222 million . As of December 31, 2018 , we expect to receive total future rental income of $203 million related to noncancelable subleases for abandoned facilities. Rental expenses on operating leases under the prior lease guidance for the years ended December 31, 2018 and 2017 , were $166 million and $159 million , respectively.

Other current assets and accrue

Other current assets and accrued liabilities	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Other current assets and accrued liabilities	Other current assets and accrued liabilities Other current assets consisted of the following (in millions): December 31, 2019 2018 Prepaid expenses $ 939 $ 907 Corporate partner receivables 485 444 Interest receivables 110 177 Other 354 266 Total other current assets $ 1,888 $ 1,794 Accrued liabilities consisted of the following (in millions): December 31, 2019 2018 Sales deductions $ 3,880 $ 3,170 Employee compensation and benefits 981 1,001 Dividends payable 946 914 Sales returns reserve 564 535 Other 2,140 2,242 Total accrued liabilities $ 8,511 $ 7,862

Financing arrangements

Financing arrangements	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Financing arrangements	Financing arrangements Our borrowings consisted of the following (in millions): December 31, 2019 2018 5.70% notes due 2019 (5.70% 2019 Notes) $ — $ 1,000 1.90% notes due 2019 (1.90% 2019 Notes) — 700 Floating Rate Notes due 2019 — 550 2.20% notes due 2019 (2.20% 2019 Notes) — 1,400 2.125% €675 million notes due 2019 (2.125% 2019 euro Notes) — 774 4.50% notes due 2020 (4.50% 2020 Notes) 300 300 2.125% notes due 2020 (2.125% 2020 Notes) 750 750 Floating Rate Notes due 2020 300 300 2.20% notes due 2020 (2.20% 2020 Notes) 700 700 3.45% notes due 2020 (3.45% 2020 Notes) 900 900 4.10% notes due 2021 (4.10% 2021 Notes) 1,000 1,000 1.85% notes due 2021 (1.85% 2021 Notes) 750 750 3.875% notes due 2021 (3.875% 2021 Notes) 1,750 1,750 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) 1,402 1,433 2.70% notes due 2022 (2.70% 2022 Notes) 500 500 2.65% notes due 2022 (2.65% 2022 Notes) 1,500 1,500 3.625% notes due 2022 (3.625% 2022 Notes) 750 750 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) 725 713 2.25% notes due 2023 (2.25% 2023 Notes) 750 750 3.625% notes due 2024 (3.625% 2024 Notes) 1,400 1,400 3.125% notes due 2025 (3.125% 2025 Notes) 1,000 1,000 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) 841 860 2.60% notes due 2026 (2.60% 2026 Notes) 1,250 1,250 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) 630 606 3.20% notes due 2027 (3.20% 2027 Notes) 1,000 1,000 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) 928 893 6.375% notes due 2037 (6.375% 2037 Notes) 552 552 6.90% notes due 2038 (6.90% 2038 Notes) 291 291 6.40% notes due 2039 (6.40% 2039 Notes) 466 466 5.75% notes due 2040 (5.75% 2040 Notes) 412 412 4.95% notes due 2041 (4.95% 2041 Notes) 600 600 5.15% notes due 2041 (5.15% 2041 Notes) 974 974 5.65% notes due 2042 (5.65% 2042 Notes) 487 487 5.375% notes due 2043 (5.375% 2043 Notes) 261 261 4.40% notes due 2045 (4.40% 2045 Notes) 2,250 2,250 4.563% notes due 2048 (4.563% 2048 Notes) 1,415 1,415 4.663% notes due 2051 (4.663% 2051 Notes) 3,541 3,541 Other notes due 2097 100 100 Unamortized bond discounts, premiums and issuance costs, net (868 ) (896 ) Fair value adjustments 296 (53 ) Total carrying value of debt 29,903 33,929 Less current portion (2,953 ) (4,419 ) Total long-term debt $ 26,950 $ 29,510 There are no material differences between the effective interest rates and the coupon rates of any of our borrowings, except for the 4.563% 2048 Notes and the 4.663% 2051 Notes, which have effective interest rates of 6.3% and 5.6% , respectively. Under the terms of all of our outstanding notes, except our Other notes due 2097, in the event of a change-in-control triggering event we may be required to purchase all or a portion of these debt securities at prices equal to 101% of the principal amounts of the notes plus accrued and unpaid interest. In addition, all of our outstanding notes—except our floating-rate notes, 0.41% 2023 Swiss franc Bonds and Other notes due 2097—may be redeemed at any time at our option—in whole or in part—at the principal amounts of the notes being redeemed plus accrued and unpaid interest and make-whole amounts, which are defined by the terms of the notes. Certain of the redeemable notes do not require the payment of make-whole amounts if redeemed during a specified period of time immediately prior to the maturity of the notes. Such time periods range from one month to six months prior to maturity. Debt issuances During the year ended December 31, 2017, we issued $4.5 billion principal amount of notes, consisting of the Floating Rate Notes due 2019, the 1.90% 2019 Notes, the Floating Rate Notes due 2020, the 2.20% 2020 Notes, the 2.65% 2022 Notes and the 3.20% 2027 Notes. We did not issue any debt or debt securities during the years ended December 31, 2019 and 2018 . As of December 31, 2019 , we have a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working-capital needs. During the year ended December 31, 2017, we issued and repaid an aggregate of $12.3 billion of commercial paper and had a maximum outstanding balance of $1.5 billion under our commercial paper program. During the years ended December 31, 2019 and 2018, we did not issue any commercial paper. Debt repayments We made debt repayments during the years ended December 31, 2019 , 2018 and 2017 as follows: • In 2019, we repaid $4.5 billion of debt, including the $1.4 billion aggregate principal amount of the 2.20% 2019 Notes, the $1.0 billion aggregate principal amount of the 5.70% 2019 Notes, the €675 million aggregate principal amount ( $864 million upon settlement of the related cross-currency swap) of the 2.125% 2019 euro Notes, the $700 million aggregate principal amount of the 1.90% 2019 Notes and the $550 million Floating Rate Notes due 2019. • In 2018, we repaid $1.1 billion of debt, including the $500 million aggregate principal amount of the 6.15% 2018 Notes and the €550 million aggregate principal amount of the 4.375% 2018 Notes revalued at $621 million upon maturity. • In 2017, we repaid $4.4 billion of debt, including the $605 million short-term floating-rate loan, the $1.25 billion aggregate principal amount of the 2.125% 2017 Notes, the $600 million aggregate principal amount of the Floating Rate Notes due 2017, the $850 million aggregate principal amount of the 1.25% 2017 Notes and the $1.1 billion aggregate principal amount of the 5.85% 2017 Notes. Interest rate swaps To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that effectively converted fixed-rate interest coupons for certain of our debt issuances to floating London Interbank Offered Rate (LIBOR)-based coupons over the lives of the respective notes. These interest rate swap contracts qualified and are designated as fair value hedges. The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions): December 31, 2019 2018 Notes Effective interest rates Notional amounts 2.20% 2019 Notes LIBOR + 0.6% $ — $ 1,400 3.45% 2020 Notes LIBOR + 1.1% 900 900 4.10% 2021 Notes LIBOR + 1.7% 1,000 1,000 3.875% 2021 Notes LIBOR + 2.0% 1,750 1,750 3.625% 2022 Notes LIBOR + 1.6% 750 750 3.625% 2024 Notes LIBOR + 1.4% 1,400 1,400 3.125% 2025 Notes LIBOR + 0.9% 1,000 1,000 2.60% 2026 Notes LIBOR + 0.3% 1,250 1,250 4.663% 2051 Notes LIBOR + 0.0% 1,500 1,500 Total notional amounts $ 9,550 $ 10,950 Cross-currency swaps In order to hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. The terms of these contracts effectively convert the interest payments and principal repayments on our 1.25% 2022 euro Notes, 0.41% 2023 Swiss franc Bonds, 2.00% 2026 euro Notes, 5.50% 2026 pound sterling Notes and 4.00% 2029 pound sterling Notes from euros, pounds sterling and Swiss francs to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges. For information regarding the terms of these contracts, see Note 18, Derivative instruments. Shelf registration statements and other facilities In 2019, we amended and restated our $2.5 billion syndicated, unsecured, revolving credit agreement, which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $750 million with the agreement of the banks. Each bank that is a party to the agreement has an initial commitment term of five years . This term may be extended for up to two additional one -year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.09% of the unused portion of the facility based on our current credit rating. Generally, we would be charged interest for any amounts borrowed under this facility, based on our current credit rating, at (i) LIBOR plus 1% or (ii) the highest of (A) the syndication agent bank base commercial lending rate, (B) the overnight federal funds rate plus 0.50% or (C) one-month LIBOR plus 1% . The agreement contains provisions relating to the determination of successor rates to address the possible phase-out or unavailability of designated reference rates. As of December 31, 2019 and 2018 , no amounts were outstanding under this facility. In February 2020, we filed a shelf registration statement with the SEC that allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depositary shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depositary shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration statement expires in February 2023. Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement includes a financial covenant, which requires that we maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (Consolidated EBITDA) to (ii) Consolidated Interest Expense, each as defined and described in the credit agreement. We were in compliance with all applicable covenants under these arrangements as of December 31, 2019 . Contractual maturities of debt obligations The aggregate contractual maturities of all borrowings due subsequent to December 31, 2019 , are as follows (in millions): Maturity dates Amounts 2020 $ 2,950 2021 3,500 2022 4,152 2023 1,474 2024 1,400 Thereafter 16,999 Total $ 30,475 Interest costs Interest costs are expensed as incurred except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest costs capitalized for the years ended December 31, 2019 , 2018 and 2017 , were not material. Interest paid, including the ongoing impact of interest rate and cross-currency swap contracts, during the years ended December 31, 2019 , 2018 and 2017 , was $1.3 billion , $1.5 billion and $1.3 billion , respectively.

Stockholders' equity

Stockholders' equity	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Stockholders' equity	Stockholders’ equity Stock repurchase program Activity under our stock repurchase program, on a trade date basis, was as follows (in millions): Years ended December 31, 2019 2018 2017 Shares* Dollars Shares* Dollars Shares Dollars First quarter 15.9 $ 3,031 56.4 $ 10,787 3.4 $ 555 Second quarter 13.1 2,349 18.2 3,190 6.2 1,006 Third quarter 6.2 1,170 8.7 1,713 4.4 769 Fourth quarter 5.1 1,090 11.1 2,165 4.5 796 Total stock repurchases 40.2 $ 7,640 94.5 $ 17,855 18.5 $ 3,126 * Total shares do not add due to rounding. In May 2019 and December 2019, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $5.0 billion and $4.0 billion , respectively. As of December 31, 2019 , $6.5 billion remained available under our stock repurchase program. Dividends Our Board of Directors declared quarterly dividends per share of $1.45 , $1.32 and $1.15 , which were paid in each of the four quarters of 2019 , 2018 , and 2017 , respectively. Historically, we have declared dividends in December of each year, which were paid in the first quarter of the following fiscal year and in March, July and October, which were paid in the second, third and fourth quarters, respectively, of the same fiscal year. Additionally, on December 11, 2019 , the Board of Directors declared a quarterly cash dividend of $1.60 per share of common stock, which will be paid on March 6, 2020, to all stockholders of record as of the close of business on February 14, 2020. Accumulated other comprehensive income (loss) The components of AOCI were as follows (in millions): Foreign currency translation Cash flow hedges Available-for-sale securities Other AOCI Balance as of December 31, 2016 $ (610 ) $ 282 $ (138 ) $ (5 ) $ (471 ) Foreign currency translation adjustments 77 — — — 77 Unrealized gains (losses) — 192 (46 ) — 146 Reclassification adjustments to income — (638 ) 41 — (597 ) Other gains — — — 5 5 Income taxes 4 158 (1 ) — 161 Balance as of December 31, 2017 (529 ) (6 ) (144 ) — (679 ) Cumulative effect of change in accounting principle, net of tax — — (9 ) — (9 ) Foreign currency translation adjustments (141 ) — — — (141 ) Unrealized gains (losses) — 61 (556 ) — (495 ) Reclassification adjustments to income — 262 365 — 627 Other losses — — — (2 ) (2 ) Income taxes — (76 ) 6 — (70 ) Balance as of December 31, 2018 (670 ) 241 (338 ) (2 ) (769 ) Foreign currency translation adjustments (48 ) — — — (48 ) Unrealized gains — 127 424 — 551 Reclassification adjustments to income — (211 ) (56 ) — (267 ) Other losses — — — (5 ) (5 ) Income taxes — 18 (8 ) — 10 Balance as of December 31, 2019 $ (718 ) $ 175 $ 22 $ (7 ) $ (528 ) With respect to the table above, income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for cash flow hedges were a $28 million expense and a $46 million benefit in 2019 , a $21 million expense and a $55 million expense in 2018 and a $68 million expense and a $226 million benefit in 2017 , respectively. Income tax expenses or benefits for unrealized gains and losses and the related reclassification adjustments to income for available-for-sale securities were a $22 million expense and a $14 million benefit in 2019 , a $9 million benefit and a $3 million expense in 2018 and a $9 million expense and an $8 million benefit in 2017 , respectively. Reclassifications out of AOCI and into earnings were as follows (in millions): Years ended December 31, Components of AOCI 2019 2018 2017 Consolidated Statements of Income locations Cash flow hedges: Foreign currency contract gains (losses) $ 101 $ (21 ) $ 65 Product sales Cross-currency swap contract gains (losses) 110 (241 ) 574 Interest and other income, net Forward interest rate contract losses — — (1 ) Interest expense, net 211 (262 ) 638 Income before income taxes (46 ) 55 (226 ) Provision for income taxes $ 165 $ (207 ) $ 412 Net income Available-for-sale securities: Net realized gains (losses) $ 56 $ (365 ) $ (41 ) Interest and other income, net (14 ) 3 (8 ) Provision for income taxes $ 42 $ (362 ) $ (49 ) Net income Other In addition to common stock, our authorized capital includes 5 million shares of preferred stock, $0.0001 par value. As of December 31, 2019 and 2018 , no shares of preferred stock were issued or outstanding.

Fair value measurement

Fair value measurement	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows: Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access Level 2 — Valuations for which all significant inputs are observable either directly or indirectly—other than Level 1 inputs Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement. The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions): Fair value measurement as of December 31, 2019, using: Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total Assets: Available-for-sale securities: U.S. Treasury notes $ 360 $ — $ — $ 360 U.S. Treasury bills — — — — Other government-related debt securities: U.S. — — — — Foreign and other — — — — Corporate debt securities: Financial — 1,121 — 1,121 Industrial — 834 — 834 Other — 198 — 198 Residential-mortgage-backed securities — 182 — 182 Other mortgage- and asset-backed securities — — — — Money market mutual funds 5,250 — — 5,250 Other short-term interest-bearing securities — 289 — 289 Equity securities 303 — — 303 Derivatives: Foreign currency contracts — 224 — 224 Cross-currency swap contracts — 66 — 66 Interest rate swap contracts — 259 — 259 Total assets $ 5,913 $ 3,173 $ — $ 9,086 Liabilities: Derivatives: Foreign currency contracts $ — $ 31 $ — $ 31 Cross-currency swap contracts — 315 — 315 Interest rate swap contracts — — — — Contingent consideration obligations — — 61 61 Total liabilities $ — $ 346 $ 61 $ 407 Fair value measurement as of December 31, 2018, using: Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total Assets: Available-for-sale securities: U.S. Treasury notes $ 2,663 $ — $ — $ 2,663 U.S. Treasury bills 8,191 — — 8,191 Other government-related debt securities: U.S. — 110 — 110 Foreign and other — 932 — 932 Corporate debt securities: Financial — 2,697 — 2,697 Industrial — 2,504 — 2,504 Other — 562 — 562 Residential-mortgage-backed securities — 1,422 — 1,422 Other mortgage- and asset-backed securities — 469 — 469 Money market mutual funds 5,659 — — 5,659 Other short-term interest-bearing securities — 3,515 — 3,515 Equity securities 176 — — 176 Derivatives: Foreign currency contracts — 182 — 182 Cross-currency swap contracts — 170 — 170 Interest rate swap contracts — 56 — 56 Total assets $ 16,689 $ 12,619 $ — $ 29,308 Liabilities: Derivatives: Foreign currency contracts $ — $ 26 $ — $ 26 Cross-currency swap contracts — 401 — 401 Interest rate swap contracts — 149 — 149 Contingent consideration obligations — — 72 72 Total liabilities $ — $ 576 $ 72 $ 648 Interest-bearing and equity securities The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets, with no valuation adjustment. As of December 31, 2019, our corporate debt securities are investment grade and have maturity dates of three years or less from the balance sheet date. Our corporate debt securities portfolio has weighted-average credit ratings of A– or equivalent by Standard & Poor’s Financial Services LLC (S&P) or Moody’s Investors Service, Inc. (Moody’s), and A by Fitch Ratings, Inc. (Fitch). We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs. Our residential-mortgage-backed-securities portfolio is composed entirely of senior tranches with credit ratings of AAA by S&P, Moody’s or Fitch. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment or default projections based on historical data; and other observable inputs. We value our other short-term interest-bearing securities at amortized cost, which approximates fair value given their near-term maturity dates. Derivatives All of our foreign currency forward and option derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, the LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 18, Derivative instruments. Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. See Note 18, Derivative instruments. Our interest rate swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 18, Derivative instruments. Contingent consideration obligations As a result of our acquisitions, we have incurred contingent consideration obligations. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&D and commercial sales organizations. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Consolidated Statements of Income. Changes in the carrying amounts of contingent consideration obligations for the years ended December 31, 2019 and 2018, were not material. During the year ended December 31, 2017, we recorded a $110 million reduction to contingent consideration obligations due substantially to amounts associated with the Dezima Pharma B.V. (Dezima) acquisition, discussed below. As a result of our acquisition of K-A in 2018, we are obligated to make single-digit royalty payments to Kirin contingent upon sales of brodalumab. See Note 2, Acquisitions. As a result of our acquisition of Dezima in 2015, we are obligated to pay its former shareholders up to $1.25 billion of additional consideration contingent upon achieving certain development and sales-related milestones and low single-digit royalties on net product sales above a certain threshold for AMG 899, an IPR&D asset. The fair values of the contingent consideration obligations had an aggregate value of $110 million at acquisition. During 2017, we decided to discontinue the internal development of AMG 899 and accordingly, we reduced from $116 million to $0 the related contingent consideration liabilities and recognized an impairment charge of $400 million on the IPR&D asset in Other operating expenses in the Consolidated Statements of Income. The remeasurement of these liabilities and the impairment charge are included in Other items, net, in the Consolidated Statements of Cash Flows. As a result of our acquisition of BioVex Group Inc. in 2011, we are obligated to pay its former shareholders up to $325 million upon achieving separate regulatory and sales-related milestones with regard to IMLYGIC ® (talimogene laherparepvec) if certain sales thresholds are met within specified periods of time. During the years ended December 31, 2019 and 2018 , there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis, except with respect to the 2018 discontinuance of the internal development of a program that resulted in an impairment of an IPR&D asset of $330 million , which was recognized in Other operating expenses in the Consolidated Statements of Income and included in Other items, net, in the Consolidated Statements of Cash Flows. Summary of the fair values of other financial instruments Cash equivalents The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments. Borrowings We estimated the fair values of our borrowings by using Level 2 inputs. As of December 31, 2019 and 2018 , the aggregate fair values of our borrowings were $33.7 billion and $35.0 billion , respectively, and the carrying values were $29.9 billion and $33.9 billion , respectively.

Derivative instruments

Derivative instruments	12 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative instruments	Derivative instruments The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes. Cash flow hedges We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates associated primarily with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are offset partially by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward and option contracts to hedge a portion of our projected international product sales primarily over a three-year time horizon , with, at any given point in time, a higher percentage of nearer-term projected product sales being hedged than in successive periods. As of December 31, 2019 , 2018 and 2017 , we had outstanding foreign currency forward contracts with aggregate notional amounts of $5.0 billion , $4.5 billion and $4.6 billion , respectively. As of December 31, 2018 and 2017 we had outstanding foreign currency option contracts with aggregate notional amounts of $21 million and $74 million , respectively, and no such outstanding contracts as of December 31, 2019. We have designated these foreign currency forward and foreign currency option contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Consolidated Balance Sheets, and we reclassify them to Product sales in the Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings. To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Consolidated Balance Sheets and reclassified to Interest and other income, net, in the Consolidated Statements of Income in the same periods during which the hedged debt affects earnings. The notional amounts and interest rates of our cross-currency swaps as of December 31, 2019 , were as follows (notional amounts in millions): Foreign currency U.S. dollars Hedged notes Notional amounts Interest rates Notional amounts Interest rates 1.25% 2022 euro Notes € 1,250 1.3 % $ 1,388 3.2 % 0.41% 2023 Swiss franc Bonds CHF 700 0.4 % $ 704 3.4 % 2.00% 2026 euro Notes € 750 2.0 % $ 833 3.9 % 5.50% 2026 pound sterling Notes £ 475 5.5 % $ 747 6.0 % 4.00% 2029 pound sterling Notes £ 700 4.0 % $ 1,111 4.5 % During the year ended December 31, 2019, our 2.125% 2019 euro Notes matured, and the related cross-currency swaps were settled. In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Consolidated Balance Sheets and are amortized into Interest expense, net, in the Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the year ended December 31, 2019 , and amounts expected to be recognized during the subsequent 12 months are not material. The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions): Years ended December 31, Derivatives in cash flow hedging relationships 2019 2018 2017 Foreign currency contracts $ 148 $ 348 $ (402 ) Cross-currency swap contracts (21 ) (287 ) 581 Forward interest rate contracts — — 13 Total unrealized gains $ 127 $ 61 $ 192 Fair value hedges To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of December 31, 2019 and 2018 , we had interest rate swap contracts with aggregate notional amounts of $9.6 billion and $11.0 billion , respectively, that hedge certain portions of our long-term debt issuances. For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt. The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions): Carrying amounts of hedged liabilities (1) Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities (2) December 31, December 31, Consolidated Balance Sheets locations 2019 2018 2019 2018 Current portion of long-term debt $ 903 $ 2,396 $ 4 $ (3 ) Long-term debt $ 8,814 $ 9,361 $ 292 $ (50 ) ____________ (1) Current portion of long-term debt includes $1.0 billion of carrying value with discontinued hedging relationships as of December 31, 2018 . Long-term debt includes $136 million and $137 million of carrying value with discontinued hedging relationships as of December 31, 2019 and 2018 , respectively. (2) Current portion of long-term debt includes $3 million of hedging adjustments on discontinued hedging relationships as of December 31, 2018 . Long-term debt includes $36 million and $37 million of hedging adjustments on discontinued hedging relationships as of December 31, 2019 and 2018 , respectively. Impact of hedging transactions The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Year ended December 31, 2019 Product sales Interest and other income, net Interest (expense), net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 22,204 $ 753 $ (1,289 ) The effects of cash flow and fair value hedging: Gains on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 101 $ — $ — Cross-currency swap contracts $ — $ 110 $ — (Losses) gains on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ (349 ) Derivatives designated as hedging instruments $ — $ — $ 352 Year ended December 31, 2018 Product sales Interest and other income, net Interest (expense), net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 22,533 $ 674 $ (1,392 ) The effects of cash flow and fair value hedging: Losses on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ (21 ) $ — $ — Cross-currency swap contracts $ — $ (241 ) $ — Gains (losses) on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ 65 Derivatives designated as hedging instruments $ — $ — $ (42 ) Year ended December 31, 2017 Product sales Interest and other income, net Interest (expense), net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 21,795 $ 928 $ (1,304 ) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 65 $ — $ — Cross-currency swap contracts $ — $ 574 $ — Forward interest rate contracts $ — $ — $ (1 ) Gains (losses) on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ 127 Derivatives designated as hedging instruments $ — $ — $ (85 ) __________ (1) (Losses) gains on hedged items do not completely offset gains (losses) on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships. No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of December 31, 2019, we expected to reclassify $47 million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months. Derivatives not designated as hedges To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of December 31, 2019 , 2018 and 2017 , the total notional amounts of these foreign currency forward contracts were $1.2 billion , $737 million and $757 million , respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the years ended December 31, 2019 , 2018 and 2017 . The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions): Derivative assets Derivative liabilities December 31, 2019 Consolidated Balance Sheets locations Fair values Consolidated Balance Sheets locations Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other assets $ 223 Accrued liabilities/ Other noncurrent liabilities $ 31 Cross-currency swap contracts Other current assets/ Other assets 66 Accrued liabilities/ Other noncurrent liabilities 315 Interest rate swap contracts Other current assets/ Other assets 259 Accrued liabilities/ Other noncurrent liabilities — Total derivatives designated as hedging instruments 548 346 Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets 1 Accrued liabilities — Total derivatives not designated as hedging instruments 1 — Total derivatives $ 549 $ 346 Derivative assets Derivative liabilities December 31, 2018 Consolidated Balance Sheets locations Fair values Consolidated Balance Sheets locations Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other assets $ 181 Accrued liabilities/ Other noncurrent liabilities $ 26 Cross-currency swap contracts Other current assets/ Other assets 170 Accrued liabilities/ Other noncurrent liabilities 401 Interest rate swap contracts Other current assets/ Other assets 56 Accrued liabilities/ Other noncurrent liabilities 149 Total derivatives designated as hedging instruments 407 576 Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets 1 Accrued liabilities — Total derivatives not designated as hedging instruments 1 — Total derivatives $ 408 $ 576 Our derivative contracts that were in liability positions as of December 31, 2019 , contain certain credit-risk-related contingent provisions that would be triggered if (i) we were to undergo a change in control and (ii) our, or the surviving entity’s, creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right but not the obligation to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.

Contingencies and commitments

Contingencies and commitments	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Contingencies and commitments	Contingencies and commitments Contingencies In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See Part I, Item 1A. Risk Factors— Our business may be affected by litigation and government investigations. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows. Certain recent developments concerning our legal proceedings and other matters are discussed below: Abbreviated New Drug Application (ANDA) Patent Litigation KYPROLIS ® (carfilzomib) ANDA Patent Litigation Onyx Therapeutics, Inc. v. Cipla Limited, et al . Between October 2016 and April 2018, Onyx Therapeutics, Inc. (Onyx Therapeutics, a wholly-owned subsidiary of Amgen), filed separate lawsuits in the U.S. District Court for the District of Delaware (the Delaware District Court) against: (1) Cipla Limited and Cipla USA, Inc. (collectively, Cipla); (2) Sagent Pharmaceuticals, Inc. (Sagent); (3) Breckenridge Pharmaceutical, Inc. (Breckenridge); and (4) Fresenius Kabi, USA LLC, Fresenius Kabi USA, Inc., Fresenius Kabi Pharmaceuticals Holding, Inc. and Fresenius Kabi Oncology Limited; (5) Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd.; (6) MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (collectively, MSN); (7) Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, DRL); (8) Qilu Pharma, Inc. and Qilu Pharmaceutical Co. Ltd. (collectively, Qilu); (9) Apotex Inc. and Apotex Corp. (Apotex); (10) InnoPharma, Inc. (InnoPharma); and (11) Aurobindo Pharma USA, Inc., each for infringement of one or more of our following patents, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) for KYPROLIS ® : U.S. Patent Nos. 7,232,818 (the ’818 Patent), 7,417,042 (the ’042 Patent), 7,491,704 (the ’704 Patent), 7,737,112 (the ’112 Patent), 8,129,346 (the ’346 Patent), 8,207,125 (the ’125 Patent), 8,207,126 (the ’126 Patent), 8,207,127 (the ’127 Patent) and 8,207,297 (the ’297 Patent). Each of these lawsuits were based on each defendant’s submission of an ANDA seeking U.S. Food and Drug Administration (FDA) approval to market a generic version of KYPROLIS ® . In each lawsuit, Onyx Therapeutics sought an order of the Delaware District Court making any FDA approval of the respective defendant’s ANDA effective no earlier than the expiration of the applicable patents. The Delaware District Court consolidated these lawsuits for purposes of discovery into a single case, Onyx Therapeutics, Inc. v. Cipla Limited, et al . In 2017, by stipulation with Onyx Therapeutics, Fresenius Kabi Pharmaceuticals Holding, Inc. and Fresenius Kabi Oncology Limited were dismissed from the lawsuit, leaving Fresenius Kabi, USA LLC and Fresenius Kabi USA, Inc. (collectively, Fresenius) as the remaining Fresenius defendants. In September 2017 and February 2018, respectively, by joint stipulation with Onyx Therapeutics, Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc. were each dismissed from the lawsuit and in February 2018, Qilu was dismissed from the lawsuit by joint stipulation between Onyx Therapeutics and Qilu. Between April and July of 2018, the Delaware District Court entered orders on stipulations between Onyx Therapeutics and each of Apotex, DRL, Sagent, Fresenius, Breckenridge, Aurobindo Pharma USA, Inc., Cipla and InnoPharma, respectively, that each defendant infringes the ’042, ’112, ’125, ’126 and ’127 Patents. Onyx Therapeutics provided those defendants, either through a stipulated order or other agreement, a covenant that it would not assert patent infringement of the ’818,’704,’346 and ’297 Patents against certain of the respective defendants’ ANDA applications and products. In June 2018, the Delaware District Court entered an order on a stipulation between Onyx Therapeutics and MSN that MSN infringes the ’112 Patent. In December 2018, Apotex, DRL, Fresenius, InnoPharma, Sagent, Breckenridge, Aurobindo Pharma USA, Inc. and Cipla amended their responses to the complaints to add the defense of unclean hands and to seek declarations of unenforceability of the asserted patents based on allegations of inequitable conduct. In January 2019, MSN amended its responses to the complaints to add the defense of unclean hands. On January 11, 2019, Onyx Therapeutics filed a separate lawsuit in the Delaware District Court against Breckenridge for infringement of the ’042, ’112 and ’125 Patents in connection with its ANDA that seeks approval to market generic versions of KYPROLIS ® . On March 4, 2019, the Delaware District Court entered an order on a stipulation between Onyx Therapeutics and Breckenridge, providing that Breckenridge infringes the asserted claims of the ’042, ’112 and ’125 Patents, and consolidated this lawsuit against Breckenridge into the existing consolidated case, Onyx Therapeutics, Inc. v. Cipla Limited, et al. , for all purposes. On May 6, 2019, the Delaware District Court commenced trial in the Onyx Therapeutics, Inc. v. Cipla Limited, et al . consolidated case. During trial, the Delaware District Court signed consent judgments filed by Onyx Therapeutics and each of Aurobindo Pharma USA, Inc., InnoPharma, Sagent, Apotex, Fresenius, DRL and Breckenridge, in which the parties stipulated to entry of: (1) judgment dismissing with prejudice all of the parties’ claims, counterclaims, affirmative defenses and demands; and (2) an injunction prohibiting infringement of the ’042, ’112 and ’125 Patents by the manufacture, use, sale, offer to sell or importation into the United States of the applicable defendant’s carfilzomib product unless specifically authorized pursuant to the applicable confidential settlement agreement. During trial, the Delaware District Court also entered a consent judgment between Onyx Therapeutics and MSN, in which the parties stipulated to entry of: (1) judgment dismissing with prejudice all of the parties’ claims, counterclaims, affirmative defenses and demands; and (2) an injunction prohibiting infringement of the ’112 Patent by the manufacture, use, sale, offer to sell or importation into the United States of MSN’s carfilzomib product unless specifically authorized pursuant to the confidential settlement agreement. On May 16, 2019, trial concluded between Onyx Therapeutics and the lone remaining defendant, Cipla. On January 17, 2020, the Delaware District Court issued an order advising the parties that the court expects to issue its post-trial opinion by, on or about, March 31, 2020. Otezla ® (apremilast) ANDA Patent Litigation Celgene Corp. v. Sandoz Inc., et al. Beginning in June 2018, Celgene filed 19 separate lawsuits in the U.S. District Court for the District of New Jersey (the New Jersey District Court) against Alkem Laboratories Ltd. (Alkem); Amneal Pharmaceuticals LLC; Annora Pharma Private Ltd. and Hetero USA Inc. (collectively, Hetero); Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc. (collectively, Aurobindo); Cipla Limited (Cipla Ltd); DRL; Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc. (collectively, Emcure); Glenmark Pharmaceuticals Ltd. (Glenmark); Macleods Pharmaceuticals Ltd. (Macleods); Mankind Pharma Ltd. (Mankind); MSN Laboratories Private Limited; Pharmascience Inc. (Pharmascience); Prinston Pharmaceutical Inc. (Prinston); Sandoz Inc.; Shilpa Medicare Ltd. (Shilpa); Teva Pharmaceuticals USA, Inc. and Actavis LLC (collectively, Actavis); Torrent Pharmaceuticals Ltd. (Torrent); Unichem Laboratories, Ltd. (Unichem); and Zydus Pharmaceuticals (USA) Inc., each for infringement of one or more of the following patents: U.S. Patent Nos. 6,962,940 (the ’940 Patent); 7,208,516 (the ’516 Patent); 7,427,638 (the ’638 Patent); 7,659,302 (the ’302 Patent); 7,893,101 (the ’101 Patent); 8,455,536 (the ’536 Patent); 8,802,717 (the ’717 Patent); 9,018,243 (the ’243 Patent) and 9,872,854 (the ’854 Patent), which are listed in the Orange Book for Otezla ® . Each of the defendants is seeking to market a generic version of Otezla ® before expiration of the asserted patents. The New Jersey District Court consolidated these 19 lawsuits for discovery and case management purposes into a single case, Celgene Corp. v. Sandoz Inc., et al. Each lawsuit seeks an order of the New Jersey District Court making any FDA approval of the respective defendant’s ANDA effective no earlier than the expiration of the applicable patents. Between August 8, 2018 and August 30, 2018, Celgene filed amended complaints against Alkem, Amneal Pharmaceuticals LLC, Aurobindo, Cipla Ltd, DRL, Glenmark, Pharmascience, Sandoz Inc., Actavis, Unichem and Zydus Pharmaceuticals (USA) Inc. additionally asserting U.S. Patent No. 9,724,330 (the ’330 Patent), which is listed in the Orange Book for Otezla ® . Between October 15 and November 27, 2018, Celgene filed amended complaints against Alkem, Amneal Pharmaceuticals LLC, Hetero, Aurobindo, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, MSN Laboratories Private Limited, Pharmascience, Prinston, Sandoz Inc., Actavis, Torrent, Unichem and Zydus Pharmaceuticals (USA) Inc. additionally asserting U.S. Patent No. 10,092,541 (the ’541 Patent), which is listed in the Orange Book for Otezla ® . Between March 1, 2019 and April 4, 2019, Celgene filed amended complaints against Hetero, MSN Laboratories Private Limited and Emcure for infringement of one or more of the above-listed patents. On October 1, 2019, Celgene filed an amended complaint against Mankind for infringement of the ’940, ’302, ’536, ’243 and ’330 Patents. On October 8, 2019, Celgene filed a separate lawsuit against Zydus Pharmaceuticals (USA) Inc. in the New Jersey District Court for infringement of U.S. Patent Nos. 8,093,283 (the ’283 Patent) and 8,629,173 (the ’173 Patent), which are not listed in the Orange Book for Otezla ® . On December 19, 2019, the New Jersey District Court consolidated this lawsuit for discovery and case management purposes into the existing consolidated case, Celgene Corp. v. Sandoz Inc., et al . Each defendant has filed an answer to the above-listed complaints and amended complaints disputing infringement and/or validity of the patents asserted against it. Along with their answers, each of Alkem, Hetero, Cipla Ltd, DRL, Emcure, Glenmark, Macleods, Mankind, Pharmascience, Sandoz Inc., Shilpa, Actavis, Torrent, Unichem and Zydus Pharmaceuticals (USA) Inc. filed declaratory judgment counterclaims asserting that some or all of the patents are not infringed and/or are invalid. In August 2019, based on a joint request by Celgene and Glenmark, the New Jersey District Court entered a consent judgment and injunction prohibiting the making, having made, using, selling, offering to sell, importing, or distributing of Glenmark’s apremilast product during the term of the ’940, ’638, ’302, ’101, ’536, ’243, ’330 and’541 Patents, unless authorized pursuant to a confidential settlement agreement. On December 20, 2019, following Amgen’s acquisition of the patents-in-suit and the new drug application for Otezla ® , Amgen and Celgene jointly moved the New Jersey District Court for an order (1) substituting Amgen for Celgene for all purposes in this litigation; (2) terminating Celgene from this litigation; and (3) changing the consolidated case caption and all related actions to reflect Amgen as the sole plaintiff. Defendants have opposed the motion. Sensipar ® (cinacalcet) ANDA Patent Litigation Amgen Inc. v. Amneal Pharmaceuticals LLC, et al. (formerly, Amgen Inc. v. Aurobindo Pharma Ltd. et al.) Consolidated Case Beginning in September 2016, Amgen filed 14 separate lawsuits in the Delaware District Court for infringement of our U.S. Patent No. 9,375,405 (the ’405 Patent) against a number of manufacturers of purported generic versions of our Sensipar ® product. In February 2017, the Delaware District Court consolidated these 14 lawsuits into a single case, Amgen Inc. v. Aurobindo Pharma Ltd. et al. In June 2017, Amgen filed an additional lawsuit in the Delaware District Court for infringement of the ’405 Patent which was consolidated into Amgen Inc. v. Aurobindo Pharma Ltd. et al . in August 2017. The ’405 Patent is entitled “Rapid Dissolution Formulation of a Calcium Receptor-Active Compound” and expires in 2026. All defendants responding to the complaint denied infringement and sought judgment that the ’405 Patent is invalid and/or not infringed. Between September and November of 2017, Amgen filed, and the Delaware District Court signed, stipulated dismissals of the lawsuit against Micro Labs Ltd. and Micro Labs USA, Inc., and the lawsuit against Apotex, as well as consent judgments filed by Amgen and each of (1) Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd. and Sun Pharmaceutical Industries, Inc. (collectively, Sun); (2) Ajanta Pharma Limited and Ajanta Pharma USA, Inc.; (3) Hetero USA Inc., Hetero Labs Ltd. and Hetero Labs Ltd. Unit V; and (4) Breckenridge. Each consent judgment stipulated to an entry of judgment of infringement and validity of the ’405 Patent and an injunction prohibiting the manufacture, use, sale, offer to sell, importation of or distribution into the United States of the respective defendant’s cinacalcet product during the term of the ’405 Patent unless specifically authorized pursuant to the confidential settlement agreement. On March 5, 2018, the Delaware District Court commenced trial on the infringement claims and defenses in the Amgen Inc. v. Aurobindo Pharma Ltd. et al. consolidated lawsuit against the defendants that remained in the lawsuit, collectively consisting of (1) Watson Laboratories, Inc. and Actavis Pharma, Inc. (collectively, Watson); (2) Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC (collectively, Amneal); (3) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus); and (4) Piramal Healthcare UK Limited (Piramal). Just prior to trial, the Delaware District Court signed consent judgments filed by Amgen and each of Cipla, and Strides Pharma Global Pte Limited and Strides Pharma, Inc. (collectively, Strides), and a consent judgment filed by Amgen and Aurobindo. In each consent judgment, the parties stipulated to an entry of judgment of infringement and validity of the ’405 Patent and an injunction prohibiting the manufacture, use, sale, offer to sell, importation of or distribution into the United States of the applicable defendant’s cinacalcet product during the term of the ’405 Patent unless specifically authorized pursuant to the applicable confidential settlement agreement. Just prior to trial, the Delaware District Court also entered orders dismissing each of DRL and Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan), on stipulations between Amgen and such parties, respectively, subject to the terms of confidential settlement agreements. On July 27, 2018, the Delaware District Court issued a trial order finding on the infringement claims and defenses in the Amgen Inc. v. Aurobindo Pharma Ltd. et al. consolidated lawsuit that Zydus infringes the ’405 Patent and that Amneal, Piramal and Watson do not infringe the ’405 Patent. On August 24, 2018, the Delaware District Court issued an order dismissing, without prejudice, the invalidity counterclaims of Amneal, Piramal and Watson and entered judgment of noninfringement of the ’405 Patent in favor of Amneal, Piramal and Watson. On September 20, 2018, Amgen filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court). On October 9, 2018, the Delaware District Court dismissed, without prejudice, the invalidity counterclaims of Zydus and entered judgment of infringement of the ’405 Patent by Zydus in favor of Amgen, including an order that the effective date of the FDA approval of Zydus’ generic version of Sensipar ® shall be no earlier than the expiry date of our ’405 Patent. On October 11, 2018, Zydus filed a notice of appeal to the Federal Circuit Court, and on October 24, 2018, the Federal Circuit Court consolidated the appeals of Zydus and Amgen. In December 2018, the FDA approved Watson’s generic version of Sensipar ® and Watson’s parent company, Teva Pharmaceutical Industries Ltd. (Teva), began selling its product at-risk notwithstanding that the appeals were pending at the Federal Circuit Court. On January 2, 2019, Amgen, Watson and Teva entered into a settlement agreement in which Teva agreed to stop selling its generic product until the mid-year 2021, or earlier under certain circumstances and to pay Amgen an undisclosed amount. On January 9, 2019, Watson and Amgen filed a motion asking the Delaware District Court to vacate its final judgment of noninfringement as to Watson and to enter a proposed consent judgment of infringement and validity of the ’405 Patent and an injunction prohibiting the making, having made, using, selling, offering to sell, or distributing Watson’s cinacalcet product in the United States or importing Watson’s cinacalcet product into the United States, consistent with the confidential settlement agreement. On January 11, 2019, the Federal Circuit Court stayed the pending appeal as to Watson in order for the Delaware District Court to rule on the motion of Watson and Amgen. On January 18, 2019 and January 23, 2019, respectively, Cipla and Sun filed oppositions to the motion of Watson and Amgen. On March 19, 2019, Amgen filed an emergency motion for an injunction pending appeal, seeking an order from the Delaware District Court enjoining defendant Piramal from making, using, selling, offering for sale or importing its generic cinacalcet product. Amgen’s motion follows an announcement that Slate Run Pharmaceuticals LLC (Slate Run), in partnership with Piramal, had begun selling Piramal’s generic cinacalcet product at-risk notwithstanding the appeals pending at the Federal Circuit Court. On April 15, 2019, the Delaware District Court signed an order enjoining Piramal and Slate Run from selling their generic cinacalcet product until certain events occur related to a decision by the Federal Circuit Court on the parties’ appeal. The order has no effect on the product that Piramal and Slate Run had already sold to third parties. On March 26, 2019, the Delaware District Court denied the joint motion for indicative ruling of Watson and Amgen. On April 10, 2019, Amgen filed an appeal to the Federal Circuit Court. On April 29, 2019, the Federal Circuit Court lifted the stay of Amgen’s appeal of the judgment of noninfringement as to Watson and consolidated it with Amgen’s appeal of the Delaware District Court’s denial of the joint motion for indicative ruling. On July 17, 2019, Amgen filed a motion requesting the Federal Circuit Court to vacate the Delaware District Court’s noninfringement judgment with respect to Watson and direct entry of the parties’ proposed consent judgment. On July 18, 2019, Cipla filed an opposition to Amgen’s motion and also moved to participate in the appeal as either an intervenor or as amicus curiae . On September 13, 2019, the Federal Circuit Court denied Amgen’s motion, lifted the stay of the briefing schedule which had been stayed pending disposition of Amgen’s motion to vacate and granted Cipla permission to file a brief as amicus curiae . On January 7, 2020, the Federal Circuit Court issued an opinion affirming the judgment of noninfringement with respect to Piramal, affirming the judgment of infringement with respect to Zydus and vacating and remanding to the Delaware District Court for further consideration the judgment of noninfringement with respect to Amneal. Amgen Inc. v. The ACME Laboratories Ltd. On September 11, 2019, Amgen filed a lawsuit in the Delaware District Court against The ACME Laboratories Ltd. (ACME) for infringement of Amgen’s ’405 Patent. On November 20, 2019, the Delaware District Court signed a consent judgment filed by Amgen and ACME in which the parties stipulated to an entry of judgment of infringement and validity of the ’405 Patent and an injunction prohibiting the manufacture, use, sale, offer to sell, importation of or distribution into the United States of ACME’s cinacalcet product during the term of the ’405 Patent unless specifically authorized pursuant to the confidential settlement agreement. ENBREL (etanercept) Patent Litigation Immunex Corporation, et al. v. Samsung Bioepis Co., Ltd. On April 30, 2019, two affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along with Hoffmann-La Roche Inc. (Roche), filed a lawsuit in the New Jersey District Court against Samsung Bioepis Co., Ltd. (Bioepis). This lawsuit stems from Bioepis’ submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen’s ENBREL. Amgen and Roche have asserted infringement of five patents: U.S. Patent Nos. 8,063,182 (the ’182 Patent); 8,163,522 (the ’522 Patent); 7,915,225 (the ’225 Patent); 8,119,605 (the ’605 Patent); and 8,722,631 (the ’631 Patent). By their complaint, Amgen and Roche seek an injunction to prohibit Bioepis from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. On August 5, 2019, defendant Bioepis responded to the complaint, denying infringement and seeking judgment that the patents-in-suit are invalid, unenforceable and/or not infringed. On January 9, 2020 and subject to the terms of a confidential stipulation and court order of January 6, 2020, the New Jersey District Court entered a consent injunction that prohibits Bioepis from making, using, offering to sell, selling or importing into the United States Bioepis’ etanercept product. Amgen and Bioepis entered into an agreement with respect to an injunction regarding etanercept as set out in the New Jersey District Court’s order of January 6, 2020. On January 15, 2020, the New Jersey District Court entered an order administratively staying the case pursuant to a joint request of Amgen and Bioepis. Immunex Corporation, et al. v. Sandoz Inc., et al. On February 26, 2016, two affiliates of Amgen Inc., Immunex Corporation and Amgen Manufacturing, Limited (collectively, Amgen), along with Hoffmann-La Roche Inc. (Roche), filed a lawsuit in the New Jersey District Court against Sandoz Inc., Sandoz International GmbH and Sandoz GmbH (collectively, Sandoz). This lawsuit stems from Sandoz’s submission of an application for FDA licensure of an etanercept product as biosimilar to Amgen’s ENBREL. Amgen and Roche have asserted infringement of five patents: the ’182, ’522, ’225, ’605 and ’631 Patents. By their complaint, Amgen and Roche seek an injunction to prohibit Sandoz from commercializing its biosimilar etanercept product in the United States prior to the expiry of such patents. All Sandoz defendants responded by denying infringement and/or asserting that the patents at issue are invalid. On August 11, 2016, and subject to the terms of a confidential stipulation, the New Jersey District Court entered a preliminary injunction prohibiting Sandoz from making, using, importing, selling or offering for sale Sandoz’s etanercept product. On August 30, 2016, the FDA approved Sandoz’s Erelzi TM , a biosimilar to ENBREL. On September 10, 2018, the New Jersey District Court entered an order that the making, using, offering to sell or selling in the United States or the importation into the United States by Sandoz of Sandoz’s biosimilar etanercept product infringes the ’182 and ’522 Patents. The New Jersey District Court held a bench trial from September 11, 2018 to September 25, 2018, focusing on Sandoz’s challenges to the validity of these patents. On August 9, 2019, the New Jersey District Court issued its decision upholding the validity of the ’182 and ’522 Patents. On October 8, 2019, by stipulation of Amgen and Sandoz, the New Jersey District Court entered final judgment and a permanent injunction prohibiting Sandoz from making, using, importing, selling or offering for sale Sandoz’s etanercept product, and, on the same day, Sandoz appealed the final judgment to the Federal Circuit Court. Following a motion by Sandoz, the Federal Circuit Court ordered an expedited briefing schedule for the appeal and briefing on appeal has been completed. Oral argument has been set for March 4, 2020. Repatha ® (evolocumab) Patent Litigation Amgen Inc., et al. v. Sanofi, et al. In October 2014, Amgen initiated a series of lawsuits that were consolidated by the Delaware District Court in December 2014 into a single case against Sanofi, Sanofi-Aventis U.S. LLC and Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively, Sanofi) and Regeneron Pharmaceuticals, Inc. (Regeneron), addressing seven of our patents: U.S. Patent Nos. 8,563,698; 8,829,165 (the ’165 Patent); 8,859,741 (the ’741 Patent); 8,871,913; 8,871,914; 8,883,983; and 8,889,834. These patents describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9). By its complaints, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron’s alirocumab, a monoclonal antibody targeting PCSK9. On January 29, 2016, the Delaware District Court granted Amgen’s motion to amend the complaint to add its affiliates, Amgen Manufacturing, Limited and Amgen USA Inc., as plaintiffs and to add the allegation that Sanofi and Regeneron’s infringement of Amgen’s patents is willful. On February 22, 2016, the Delaware District Court entered a stipulated order finding alirocumab and the drug product containing it, PRALUENT ® , infringe certain of Amgen’s patents, including claims 2, 7, 9, 15, 19 and 29 of the ’165 Patent and claim 7 of the ’741 Patent. On March 18, 2016, the Delaware District Court entered judgment in favor of Amgen following a five -day jury trial and a unanimous jury verdict that these patent claims from the ’165 Patent and the ’741 Patent are all valid. On January 3, 2017, the Delaware District Court denied Sanofi and Regeneron’s post-trial motions seeking a new trial and for judgment as a matter of law, and on January 5, 2017, granted Amgen’s motion for a permanent injunction prohibiting the infringing manufacture, use, sale, offer for sale or import of alirocumab in the United States. On January 12, 2017, Sanofi and Regeneron filed an appeal of the judgment and the permanent injunction to the Federal Circuit Court. On February 8, 2017, following a motion by Sanofi and Regeneron, the Federal Circuit Court entered a stay of the permanent injunction during the pendency of the appeal. On October 5, 2017, the Federal Circuit Court reversed in part the judgment of the Delaware District Court and remanded for a new trial two of the patent validity defenses (lack of written description and enablement of the claimed inventions), and affirmed the Delaware District Court’s judgment of infringement of claims 2, 7, 9, 15, 19 and 29 of the ’165 Patent and claim 7 of the ’741 Patent and the third patent validity defense (finding that the claimed inventions were not obvious to a person of ordinary skill in the field of the patents). On December 6, 2017, Amgen petitioned the Federal Circuit Court for rehearing en banc , which was denied. The Federal Circuit Court issued a March 2, 2018 mandate returning the case to the Delaware District Court for a new trial on two of Sanofi and Regeneron’s challenges to the validity of our patents (lack of written description and enablement of the claimed inventions) and for further consideration of a permanent injunction. On July 23, 2018, Amgen filed a petition for certiorari with the U.S. Supreme Court seeking review of the Federal Circuit Court’s conclusion that the judgment affirming the validity of Amgen’s patents was based, in part, on an erroneous application of the law of written description. On January 7, 2019, the U.S. Supreme Court denied Amgen’s petition for certiorari. On remand, the Delaware District Court scheduled a new trial on Sanofi and Regeneron’s challenges to the validity of our patents based on lack of written description and enablement of the claimed inventions. The Delaware District Court also entered judgment on the pleadings for Sanofi and Regeneron on Amgen’s claim of willful infringement. On February 25, 2019, a jury of the Delaware District Court unanimously upheld the validity of claims 19 and 29 of the ’165 Patent and claim 7 of the ’741 Patent. The jury also found that claims 7 and 15 of the ’165 Patent meet the enablement requirement, but are invalid for failure to meet the written description requirement. On March 18, 2019, Sanofi and Regeneron filed post-trial motions seeking to reverse judgment as a matter of law or for a new trial with respect to claims 19 and 29 of the ’165 Patent and claim 7 of the ’741 Patent, and Amgen filed a motion for a permanent injunction. On June 6, 13 and 21, 2019, the Delaware District Court held evidentiary hearings on Amgen’s motion for a permanent injunction against PRALUENT ® . On August 28, 2019, the Delaware District Court ruled on the post-trial motions, denying Sanofi and Regeneron’s request for a new trial and their request to reverse the jury verdict that the ’165 Patent and the ’741 Patent provide written description support for the claimed inventions. The Delaware District Court also ruled as a matter of law that claims 19 and 29 of the ’165 Patent and claim 7 of the ’741 Patent are invalid for failing to meet the enablement requirement, overturning the jury verdict. On October 23, 2019, Amgen filed a notice of appeal to the Federal Circuit Court. Patent Disputes in the International Region On February 24, 2016, the European Patent Office (EPO) granted European Patent No. 2,215,124 (EP 2,215,124) to Amgen. This patent describes and claims monoclonal antibodies to PCSK9 and methods of treatment. On February 24, 2016, Sanofi filed an opposition to the patent in the EPO seeking to invalidate it. In November 2016, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Groupe S.A. and Sanofi Winthrop Industrie S.A. filed a joint opposition against Amgen’s patent, and each of Eli Lilly and Company, Regeneron and Strawman Ltd. also filed oppositions to Amgen’s patent. On November 30, 2018, the EPO confirmed the validity of Amgen’s EP 2,215,124, which has been appealed to the Technical Board of Appeal. A two -day hearing is scheduled to begin on March 24, 2020. We are also involved in and expect future involvement in additional disputes regarding our PCSK9 patents in other jurisdictions and regions, including matters filed against us and that we have filed in the United Kingdom, Germany, France, The Netherlands, Italy, Spain and Japan. NEUPOGEN ® (filgrastim)/Neulasta ® (pegfilgrastim) Patent Litigation Amgen Inc., et al. v. Accord BioPharma (formerly, Amgen Inc., et al. v. Apotex Inc., et al.) On August 7, 2018, Amgen Inc. and its wholly-owned subsidiary, Amgen Manufacturing, Limited (collectively, Amgen), filed a lawsuit in the U.S. District Court for the Southern

Quarterly financial data (unaud

Quarterly financial data (unaudited)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Quarterly financial data (unaudited)	Quarterly financial data (unaudited) The following tables summarize the Company’s unaudited financial data on a quarterly basis. The sum of the quarterly earnings per-share amounts may not equal the amount reported for the full year because per-share amounts are computed independently for each quarter and for the full year based on respective weighted-average shares outstanding and dilutive securities. Quarterly financial data is summarized as follows (in millions, except per-share data): 2019 Quarters ended December 31 September 30 June 30 March 31 Product sales $ 5,881 $ 5,463 $ 5,574 $ 5,286 Gross profit from product sales $ 4,628 $ 4,427 $ 4,562 $ 4,231 Net income $ 1,703 $ 1,968 $ 2,179 $ 1,992 Earnings per share: Basic $ 2.87 $ 3.29 $ 3.59 $ 3.20 Diluted $ 2.85 $ 3.27 $ 3.57 $ 3.18 2018 Quarters ended December 31 September 30 June 30 March 31 Product sales $ 6,001 $ 5,510 $ 5,679 $ 5,343 Gross profit from product sales $ 4,905 $ 4,473 $ 4,655 $ 4,399 Net income $ 1,928 $ 1,859 $ 2,296 $ 2,311 Earnings per share: Basic $ 3.04 $ 2.88 $ 3.50 $ 3.27 Diluted $ 3.01 $ 2.86 $ 3.48 $ 3.25

Subsequent events

Subsequent events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent events	Subsequent events On January 2, 2020, Amgen acquired a 20.5% stake in BeiGene, Ltd. (BeiGene) for approximately $2.8 billion in cash as part of a collaboration to expand our oncology presence in China. We will account for this investment by using the equity method. Under the collaboration, BeiGene will commercialize XGEVA ® , KYPROLIS ® and BLINCYTO ® (blinatumomab) in China, and we will share profits and losses equally during the initial product-specific commercialization periods; thereafter, two of these products will revert to Amgen, and Amgen will pay royalties to BeiGene on sales in China of such products for a specified period. In addition, Amgen and BeiGene will jointly develop 20 of our oncology product candidates, with BeiGene sharing in global R&D costs of up to $1.25 billion and assuming commercialization rights in China for a specified period. Amgen and BeiGene will share profits in China equally until certain of these product rights revert to Amgen. After reversion, Amgen will pay royalties to BeiGene on sales in China for a specified period. For product sales outside of China, Amgen will pay BeiGene royalties.

SCHEDULE II - VALUATION AND QUA

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2018
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	SCHEDULE II AMGEN INC. VALUATION AND QUALIFYING ACCOUNTS Years ended December 31, 2019 , 2018 and 2017 (In millions) Allowance for doubtful accounts Balance at beginning of period Additions charged to costs and expenses Other additions Deductions Balance at end of period Year ended December 31, 2019 $ 48 $ — $ — $ 22 $ 26 Year ended December 31, 2018 $ 51 $ 1 $ — $ 4 $ 48 Year ended December 31, 2017 $ 51 $ 4 $ — $ 4 $ 51

Summary of significant accoun_2

Summary of significant accounting policies - (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Business	Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Principles of consolidation	Principles of consolidation The consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Revenues and Arrangements with multiple performance obligations	Revenues Product sales and sales deductions Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon delivery, based on an amount that reflects the consideration to which we expect to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and returns established at the time of sale. We analyze the adequacy of our accruals for sales deductions quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. Accruals for sales deductions are based primarily on estimates of the amounts earned or to be claimed on the related sales. These estimates take into consideration current contractual and statutory requirements, specific known market events and trends, internal and external historical data and forecasted customer buying patterns. Sales deductions are substantially product specific and therefore, for any given period, can be affected by the mix of products sold. Included in sales deductions are immaterial net adjustments related to prior-period sales due to changes in estimates. Historically, such amounts have represented less than 1% of the aggregate sales deductions charged against product sales. Returns are estimated through comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have amounted to less than 1% of gross product sales. Changes in estimates for prior-period sales return provisions have historically been immaterial. Our payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers. Indirect taxes collected from customers and remitted to government authorities and that are related to sales of the Company’s products, primarily in Europe, are excluded from revenues. As a practical expedient, sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in Selling, general and administrative expense in the Consolidated Statements of Income. Other revenues Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded when the related third-party product sale occurs. Royalty estimates are based on historical and forecasted sales trends. Corporate partner revenues are composed mainly of license fees and milestones earned and our share of commercial profits generated from collaborations. See Arrangements with multiple-performance obligations, discussed below. Arrangements with multiple-performance obligations From time to time, we enter into arrangements for the research and development (R&D), manufacture and/or commercialization of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including intellectual property rights/licenses, R&D services, manufacturing services and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to Amgen in the form of nonrefundable, upfront license fees; development and commercial performance milestone payments; royalty payments; and/or profit sharing. In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or by using an adjusted market assessment approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We utilize the sales- and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.
Research and development costs	Research and development costs R&D costs are expensed as incurred and include primarily salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems’ costs; and amortization of acquired technology used in R&D with alternative future uses. R&D expenses also include costs and cost recoveries associated with third-party R&D arrangements, including upfront fees and milestones paid to third parties in connection with technologies that had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 8, Collaborations and Note 21, Subsequent events.
Selling, general and administrative costs	Selling, general and administrative costs Selling, general and administrative (SG&A) costs are composed primarily of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; the U.S. healthcare reform federal excise fee on Branded Prescription Pharmaceutical Manufacturers and Importers; and other general and administrative costs. Advertising costs are expensed as incurred and were $789 million , $674 million and $620 million during the years ended December 31, 2019 , 2018 and 2017 , respectively. SG&A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaborative arrangements. Net payment or reimbursement of SG&A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 8, Collaborations.
Leases	Leases Adoption of new lease standard In February 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that lessees recognize the assets and liabilities that arise from leases on the balance sheet, including leases classified as operating leases, and that they disclose qualitative and quantitative information about leasing arrangements. The FASB subsequently issued additional amendments to address issues arising from the implementation of the new lease standard. We adopted this standard as of January 1, 2019, using the modified-retrospective method, which provides a method for recording existing leases at adoption. We used the adoption date as our date of initial application, and thus, comparative-period financial information is not presented for periods prior to the adoption date. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. Adoption of the new standard resulted in total lease liabilities of $510 million and right-of-use (ROU) assets of $439 million as of January 1, 2019. The difference between the initial lease liabilities and the ROU assets is related primarily to previously existing lease liabilities. The standard did not materially impact our Consolidated Statements of Income and had no impact on our Consolidated Statements of Cash Flows. Our accounting policies under the new standard are described below. See Note 13, Leases. Lease recognition At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other assets, Accrued liabilities and Other noncurrent liabilities in our Consolidated Balance Sheets. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.
Stock-based compensation	Stock-based compensation We have stock-based compensation plans under which various types of equity-based awards are granted, including restricted stock units (RSUs), performance units and stock options. The fair values of RSUs and stock option awards, which are subject only to service conditions with graded vesting, are recognized as compensation expense, generally on a straight-line basis over the service period, net of estimated forfeitures. The fair values of performance unit awards are recognized as compensation expense, generally on a straight-line basis from the grant date to the end of the performance period. See Note 4, Stock-based compensation.
Income taxes	Income taxes We provide for income taxes based on pretax income and applicable tax rates in the various jurisdictions in which we operate. Significant judgment is required in determining our provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the bases of assets and liabilities, as well as for loss and tax credit carryforwards for financial reporting purposes and amounts recognized for income tax purposes. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (UTBs) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTBs in income tax expense. See Note 6, Income taxes.
Acquisitions	Acquisitions We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (IPR&D) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree’s liability arising from an acquisition it consummated prior to our acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in earnings. In contrast, asset acquisitions are accounted for using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. Contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated. See Note 2, Acquisitions, and Note 17, Fair value measurement.
Cash equivalents	Cash equivalents We consider cash equivalents to be only those investments that are highly liquid, readily convertible to cash and which mature within three months from the date of purchase.
Interest-bearing securities	Interest-bearing securities We consider our interest-bearing securities investment portfolio available-for-sale, and accordingly, these investments are recorded at fair value, with unrealized gains and losses recorded in Accumulated other comprehensive income (loss) (AOCI). Investments with maturities beyond one year may be classified as short-term marketable securities in the Consolidated Balance Sheets due to their highly liquid nature and because they represent the Company’s investments that are available for current operations. See Note 9, Investments, and Note 17, Fair value measurement.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. See Note 10, Inventories.
Derivatives	Derivatives We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether the derivative has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 17, Fair value measurement, and Note 18, Derivative instruments.
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.
Goodwill and other intangible assets	Goodwill and other intangible assets Finite-lived intangible assets are recorded at cost, net of accumulated amortization, and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Goodwill and other intangible assets. The fair values of IPR&D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related R&D efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. There are often major risks and uncertainties associated with IPR&D projects as we are required to obtain regulatory approvals in order to be able to market the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. Capitalized IPR&D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors’ products could result in partial or full impairment of the related intangible assets. We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To date, an impairment of goodwill has not been recorded. See Note 12, Goodwill and other intangible assets.
Contingencies	Contingencies In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. Certain of these proceedings are discussed in Note 19, Contingencies and commitments. We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.
Foreign currency translation	Foreign currency translation The net assets of international subsidiaries whose local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates. The U.S. dollar effects that arise from translating net assets of these subsidiaries at changing rates are recognized in AOCI. The subsidiaries’ earnings are translated into U.S. dollars using average exchange rates.
Other recently adopted pronouncement and Other recent accounting pronouncements	Other recent accounting pronouncements In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. The new standard is effective for interim and annual periods beginning on January 1, 2020. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. We have substantially completed our impact assessment and do not currently anticipate a material impact on our consolidated financial statements.

Acquisitions - (Tables)

Acquisitions - (Tables)	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition	The following table summarizes the consideration transferred and the allocation of the estimated accumulated cost, including tax adjustments, to the assets acquired and liabilities assumed (in millions): Amounts Cash purchase price $ 13,400 Transaction costs 40 Accumulated cost (consideration transferred) $ 13,440 Intangible assets: Developed-product-technology rights $ 13,007 Marketing-related rights 195 Inventory 367 Deferred tax liability, net (24 ) Deferred credit (96 ) Other liabilities, net (9 ) Total assets acquired, net $ 13,440
Aggregate acquisition date consideration to acquire an entity	The aggregate share acquisition date consideration to acquire the remaining 50% ownership in K-A and the fair value of Amgen’s preacquisition investment consisted of the following (in millions): Amounts Total cash paid to Kirin $ 780 Fair value of contingent consideration obligation 45 Loss on settlement of preexisting relationship (168 ) Total consideration transferred to acquire K-A 657 Fair value of Amgen’s investment in K-A 825 Total acquisition date fair value $ 1,482

Revenues (Tables)

Revenues (Tables)	12 Months Ended
	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of revenue by product and by geographic area	Revenues were as follows (in millions): Year ended December 31, 2019 U.S. ROW Total Enbrel ® (etanercept) $ 5,050 $ 176 $ 5,226 Neulasta ® (pegfilgrastim) 2,814 407 3,221 Prolia ® (denosumab) 1,772 900 2,672 XGEVA ® (denosumab) 1,457 478 1,935 Aranesp ® (darbepoetin alfa) 758 971 1,729 KYPROLIS ® (carfilzomib) 654 390 1,044 EPOGEN ® (epoetin alfa) 867 — 867 Sensipar ® /Mimpara ® (cinacalcet) 252 299 551 Other products 2,907 2,052 4,959 Total product sales (1) 16,531 5,673 22,204 Other revenues 693 465 1,158 Total revenues $ 17,224 $ 6,138 $ 23,362 Year ended December 31, 2018 U.S. ROW Total ENBREL $ 4,807 $ 207 $ 5,014 Neulasta ® 3,866 609 4,475 Prolia ® 1,500 791 2,291 Aranesp ® 942 935 1,877 XGEVA ® 1,338 448 1,786 Sensipar ® /Mimpara ® 1,436 338 1,774 EPOGEN ® 1,010 — 1,010 KYPROLIS ® 583 385 968 Other products 1,947 1,391 3,338 Total product sales (1) 17,429 5,104 22,533 Other revenues 929 285 1,214 Total revenues $ 18,358 $ 5,389 $ 23,747 Year ended December 31, 2017 U.S. ROW Total ENBREL $ 5,206 $ 227 $ 5,433 Neulasta ® 3,931 603 4,534 Aranesp ® 1,114 939 2,053 Prolia ® 1,272 696 1,968 Sensipar ® /Mimpara ® 1,374 344 1,718 XGEVA ® 1,157 418 1,575 EPOGEN ® 1,096 — 1,096 KYPROLIS ® 562 273 835 Other products 1,419 1,164 2,583 Total product sales (1) 17,131 4,664 21,795 Other revenues 898 156 1,054 Total revenues $ 18,029 $ 4,820 $ 22,849 ____________ (1) Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2019 , 2018 and 2017 .
Revenues earned from major customers	Certain information with respect to these customers was as follows (dollar amounts in millions): Years ended December 31, 2019 2018 2017 AmerisourceBergen Corporation: Gross product sales $ 12,301 $ 12,091 $ 10,742 % of total gross revenues 33 % 33 % 31 % McKesson Corporation: Gross product sales $ 11,795 $ 11,434 10,625 % of total gross revenues 31 % 31 % 30 % Cardinal Health, Inc.: Gross product sales $ 6,538 $ 7,475 $ 7,049 % of total gross revenues 17 % 20 % 20 %

Stock-based compensation (Table

Stock-based compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Components of stock-based compensation expense recognized in the Consolidated Statements of Income	The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income (in millions): Years ended December 31, 2019 2018 2017 RSUs $ 168 $ 165 $ 174 Performance units 105 117 133 Stock options 35 29 22 Total stock-based compensation expense, pretax 308 311 329 Tax benefit from stock-based compensation expense (67 ) (67 ) (118 ) Total stock-based compensation expense, net of tax $ 241 $ 244 $ 211
Summary of RSUs	The following table summarizes information regarding our RSUs: Year ended December 31, 2019 Units (in millions) Weighted-average grant date fair value Balance nonvested as of December 31, 2018 3.1 $ 168.11 Granted 1.2 $ 182.12 Vested (1.0 ) $ 163.21 Forfeited (0.2 ) $ 170.52 Balance nonvested as of December 31, 2019 3.1 $ 174.97
Weighted-average assumptions used and the resulting weighted-average grant date fair value of stock options	The weighted-average assumptions used in the option valuation model and the resulting weighted-average grant date fair values of stock options granted were as follows: Years ended December 31, 2019 2018 2017 Closing price of our common stock on grant date $ 177.31 $ 177.46 $ 162.60 Expected volatility (average of implied and historical volatility) 23.5 % 24.6 % 22.7 % Expected life (in years) 5.8 5.8 5.8 Risk-free interest rate 2.4 % 2.8 % 2.1 % Expected dividend yield 3.1 % 2.9 % 2.8 % Fair value of stock options granted $ 30.47 $ 34.60 $ 27.54
Summary of stock options	The following table summarizes information regarding our stock options: Year ended December 31, 2019 Options (in millions) Weighted- average exercise price Weighted- average remaining contractual life (in years) Aggregate intrinsic value (in millions) Balance unexercised as of December 31, 2018 4.4 $ 143.57 Granted 1.4 $ 177.31 Exercised (0.7 ) $ 107.13 Expired/forfeited (0.3 ) $ 171.01 Balance unexercised as of December 31, 2019 4.8 $ 157.00 7.2 $ 406 Vested or expected to vest as of December 31, 2019 4.6 $ 156.02 7.1 $ 390 Exercisable as of December 31, 2019 1.3 $ 117.13 4.3 $ 162
Weighted average assumptions used and the resulting weighted average grant date fair value of performance units	The weighted-average assumptions used in the payout simulation model and the resulting weighted-average grant date fair values of performance units granted were as follows: Years ended December 31, 2019 2018 2017 Closing price of our common stock on grant date $ 177.31 $ 177.93 $ 162.60 Volatility 22.1 % 23.8 % 25.9 % Risk-free interest rate 2.3 % 2.6 % 1.4 % Fair value of units granted $ 188.40 $ 189.21 $ 178.87

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of income before income tax, domestic and foreign	Income before income taxes included the following (in millions): Years ended December 31, 2019 2018 2017 Domestic $ 4,371 $ 4,856 $ 4,436 Foreign 4,767 4,689 5,161 Total income before income taxes $ 9,138 $ 9,545 $ 9,597
Provision for income taxes	The provision for income taxes included the following (in millions): Years ended December 31, 2019 2018 2017 Current provision: Federal $ 1,284 $ 1,270 $ 8,615 State 39 17 5 Foreign 277 227 275 Total current provision 1,600 1,514 8,895 Deferred (benefit) provision: Federal (276 ) (317 ) (1,120 ) State (22 ) (7 ) — Foreign (6 ) (39 ) (157 ) Total deferred (benefit) provision (304 ) (363 ) (1,277 ) Total provision for income taxes $ 1,296 $ 1,151 $ 7,618
Significant components of deferred tax assets and liabilities	Significant components of our deferred tax assets and liabilities were as follows (in millions): December 31, 2019 2018 Deferred income tax assets: NOL and credit carryforwards $ 800 $ 810 Accrued expenses 457 428 Expenses capitalized for tax 170 185 Stock-based compensation 91 95 Other 269 174 Total deferred income tax assets 1,787 1,692 Valuation allowance (517 ) (509 ) Net deferred income tax assets 1,270 1,183 Deferred income tax liabilities: Acquired intangible assets (1,288 ) (1,509 ) Debt (210 ) (184 ) Other (286 ) (267 ) Total deferred income tax liabilities (1,784 ) (1,960 ) Total deferred income taxes, net $ (514 ) $ (777 )
Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)	The reconciliations of the total gross amounts of UTBs were as follows (in millions): Years ended December 31, 2019 2018 2017 Beginning balance $ 3,061 $ 2,953 $ 2,543 Additions based on tax positions related to the current year 215 173 447 Additions based on tax positions related to prior years 22 13 1 Reductions for tax positions of prior years (11 ) (17 ) (5 ) Reductions for expiration of statute of limitations — — (5 ) Settlements — (61 ) (28 ) Ending balance $ 3,287 $ 3,061 $ 2,953
Reconciliation between the federal statutory tax rate and effective tax rate	The reconciliations between the federal statutory tax rate applied to income before income taxes and our effective tax rate were as follows: Years ended December 31, 2019 2018 2017 Federal statutory tax rate 21.0 % 21.0 % 35.0 % 2017 Tax Act, net repatriation tax — % — % 70.7 % Foreign earnings (4.5 )% (4.3 )% (15.8 )% 2017 Tax Act, net deferred tax remeasurement — % — % (6.9 )% Credits, Puerto Rico Excise Tax (2.6 )% (2.5 )% (2.2 )% 2017 Tax Act, net impact on intercompany sales — % (1.8 )% — % Interest on uncertain tax positions 1.6 % 1.2 % 0.6 % Credits, primarily federal R&D (1.0 )% (0.8 )% (0.6 )% Share-based payments (0.3 )% (0.2 )% (0.7 )% Other, net — % (0.5 )% (0.7 )% Effective tax rate 14.2 % 12.1 % 79.4 %

Earnings per share (Tables)

Earnings per share (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Computation for basic and diluted earnings per share	The computations for basic and diluted EPS were as follows (in millions, except per-share data): Years ended December 31, 2019 2018 2017 Income (Numerator): Net income for basic and diluted EPS $ 7,842 $ 8,394 $ 1,979 Shares (Denominator): Weighted-average shares for basic EPS 605 661 731 Effect of dilutive securities 4 4 4 Weighted-average shares for diluted EPS 609 665 735 Basic EPS $ 12.96 $ 12.70 $ 2.71 Diluted EPS $ 12.88 $ 12.62 $ 2.69

Investments - (Tables)

Investments - (Tables)	12 Months Ended
	Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, all of which are considered available-for-sale, by type of security were as follows (in millions): Types of securities as of December 31, 2019 Amortized cost Gross unrealized gains Gross unrealized losses Fair values U.S. Treasury notes $ 359 $ 1 $ — $ 360 U.S. Treasury bills — — — — Other government-related debt securities: U.S. — — — — Foreign and other — — — — Corporate debt securities: Financial 1,108 13 — 1,121 Industrial 824 10 — 834 Other 195 3 — 198 Residential-mortgage-backed securities 181 1 — 182 Other mortgage- and asset-backed securities — — — — Money market mutual funds 5,250 — — 5,250 Other short-term interest-bearing securities 289 — — 289 Total available-for-sale investments $ 8,206 $ 28 $ — $ 8,234 Types of securities as of December 31, 2018 Amortized cost Gross unrealized gains Gross unrealized losses Fair values U.S. Treasury notes $ 2,710 $ — $ (47 ) $ 2,663 U.S. Treasury bills 8,191 — — 8,191 Other government-related debt securities: U.S. 112 — (2 ) 110 Foreign and other 972 1 (41 ) 932 Corporate debt securities: Financial 2,778 — (81 ) 2,697 Industrial 2,603 — (99 ) 2,504 Other 583 — (21 ) 562 Residential-mortgage-backed securities 1,458 — (36 ) 1,422 Other mortgage- and asset-backed securities 483 — (14 ) 469 Money market mutual funds 5,659 — — 5,659 Other short-term interest-bearing securities 3,515 — — 3,515 Total available-for-sale investments $ 29,064 $ 1 $ (341 ) $ 28,724
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets	The fair values of available-for-sale investments by location in the Consolidated Balance Sheets were as follows (in millions): December 31, Consolidated Balance Sheets locations 2019 2018 Cash and cash equivalents $ 5,360 $ 6,365 Marketable securities 2,874 22,359 Total available-for-sale investments $ 8,234 $ 28,724
Fair values of available-for-sale interest-bearing security investments by contractual maturity	The fair values of available-for-sale investments by contractual maturity, except for mortgage- and asset-backed securities that do not have a single maturity date, were as follows (in millions): December 31, Contractual maturities 2019 2018 Maturing in one year or less $ 5,629 $ 17,424 Maturing after one year through three years 2,304 3,356 Maturing after three years through five years 119 5,168 Maturing after five years through ten years — 885 Mortgage- and asset-backed securities 182 1,891 Total available-for-sale investments $ 8,234 $ 28,724
Available-for-sale securities, continuous unrealized loss position, fair value	As of December 31, 2018, the fair values and gross unrealized losses of available-for-sale investments in an unrealized loss position aggregated by type and length of time that the securities have been in a continuous loss position were as follows (in millions): Less than 12 months 12 months or more Types of securities as of December 31, 2018 Fair values Unrealized losses Fair values Unrealized losses U.S. Treasury notes $ 1,219 $ (21 ) $ 1,444 $ (26 ) Other government-related debt securities: U.S. — — 110 (2 ) Foreign and other 631 (31 ) 240 (10 ) Corporate debt securities: Financial 1,968 (59 ) 718 (22 ) Industrial 1,898 (81 ) 529 (18 ) Other 529 (20 ) 28 (1 ) Residential-mortgage-backed securities 576 (14 ) 840 (22 ) Other mortgage- and asset-backed securities 17 — 451 (14 ) Total $ 6,838 $ (226 ) $ 4,360 $ (115 )

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories consisted of the following (in millions): December 31, 2019 2018 Raw materials $ 358 $ 257 Work in process 2,227 1,660 Finished goods 999 1,023 Total inventories $ 3,584 $ 2,940

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Components of property, plant and equipment	Property, plant and equipment consisted of the following (dollar amounts in millions): December 31, Useful life (in years) 2019 2018 Land — $ 263 $ 265 Buildings and improvements 10-40 3,757 3,616 Manufacturing equipment 8-12 2,655 2,418 Laboratory equipment 8-12 1,236 1,174 Capitalized software 3-5 1,154 1,124 Other 3-15 3,313 3,204 Construction in progress — 907 953 Property, plant and equipment, gross 13,285 12,754 Less accumulated depreciation and amortization (8,357 ) (7,796 ) Property, plant and equipment, net $ 4,928 $ 4,958
Property, plant and equipment by geographic information	Certain geographic information with respect to property, plant and equipment, net (long-lived assets), was as follows (in millions): December 31, 2019 2018 United States $ 2,433 $ 2,373 Puerto Rico 1,402 1,476 ROW 1,093 1,109 Total property, plant and equipment, net $ 4,928 $ 4,958

Goodwill and other intangible a

Goodwill and other intangible assets - (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	The changes in the carrying amounts of goodwill were as follows (in millions): Years ended December 31, 2019 2018 Beginning balance $ 14,699 $ 14,761 Addition from acquisitions 26 6 Currency translation adjustments (22 ) (68 ) Ending balance $ 14,703 $ 14,699
Schedule of identifiable intangible assets	Other intangible assets consisted of the following (in millions): December 31, 2019 2018 Gross carrying amounts Accumulated amortization Other intangible assets, net Gross carrying amounts Accumulated amortization Other intangible assets, net Finite-lived intangible assets: Developed-product-technology rights $ 25,575 $ (8,322 ) $ 17,253 $ 12,573 $ (7,479 ) $ 5,094 Licensing rights 3,761 (2,398 ) 1,363 3,772 (2,032 ) 1,740 Marketing-related rights 1,382 (965 ) 417 1,297 (1,019 ) 278 R&D technology rights 1,273 (947 ) 326 1,148 (872 ) 276 Total finite-lived intangible assets 31,991 (12,632 ) 19,359 18,790 (11,402 ) 7,388 Indefinite-lived intangible assets: IPR&D 54 — 54 55 — 55 Total other intangible assets $ 32,045 $ (12,632 ) $ 19,413 $ 18,845 $ (11,402 ) $ 7,443

Leases - (Tables)

Leases - (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Summary information, components of lease costs and cash and noncash information on leases	Cash and noncash information related to our leases was as follows (in millions): Year ended December 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 148 ROU assets obtained in exchange for lease obligations: Operating leases $ 163 The following table summarizes information related to our leases, all of which are classified as operating, included in our Consolidated Balance Sheets (in millions): Consolidated Balance Sheets locations December 31, 2019 Assets: Other assets $ 469 Liabilities: Accrued liabilities $ 140 Other noncurrent liabilities 388 Total lease liabilities $ 528 The components of net lease costs were as follows (in millions): Lease costs Year ended December 31, 2019 Operating (1) $ 204 Sublease income (33 ) Total net lease costs $ 171 ____________ (1) Includes short-term leases and variable lease costs, which were not material for the year ended December 31, 2019 .
Maturities of lease liabilities	Maturities of lease liabilities as of December 31, 2019 , were as follows (in millions): Maturity dates Amounts 2020 $ 157 2021 150 2022 110 2023 88 2024 30 Thereafter 32 Total lease payments (1) 567 Less imputed interest (39 ) Present value of lease liabilities $ 528 ____________ (1) Includes future rental commitments for abandoned leases of $178 million . We expect to receive total future rental income of $141 million related to noncancelable subleases for abandoned facilities.
Minimum future rental commitments under non-cancelable operating leases	The following table summarizes minimum future rental commitments related to noncancelable operating leases under the prior lease guidance as of December 31, 2018 (in millions): Amounts 2019 $ 164 2020 126 2021 113 2022 64 2023 56 Thereafter 46 Total minimum operating lease commitments $ 569

Other current assets and accr_2

Other current assets and accrued liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Schedule of Other Current Assets	Other current assets consisted of the following (in millions): December 31, 2019 2018 Prepaid expenses $ 939 $ 907 Corporate partner receivables 485 444 Interest receivables 110 177 Other 354 266 Total other current assets $ 1,888 $ 1,794
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following (in millions): December 31, 2019 2018 Sales deductions $ 3,880 $ 3,170 Employee compensation and benefits 981 1,001 Dividends payable 946 914 Sales returns reserve 564 535 Other 2,140 2,242 Total accrued liabilities $ 8,511 $ 7,862

Financing arrangements (Tables)

Financing arrangements (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Carrying values and the fixed contractual coupon rates of long-term borrowings	Our borrowings consisted of the following (in millions): December 31, 2019 2018 5.70% notes due 2019 (5.70% 2019 Notes) $ — $ 1,000 1.90% notes due 2019 (1.90% 2019 Notes) — 700 Floating Rate Notes due 2019 — 550 2.20% notes due 2019 (2.20% 2019 Notes) — 1,400 2.125% €675 million notes due 2019 (2.125% 2019 euro Notes) — 774 4.50% notes due 2020 (4.50% 2020 Notes) 300 300 2.125% notes due 2020 (2.125% 2020 Notes) 750 750 Floating Rate Notes due 2020 300 300 2.20% notes due 2020 (2.20% 2020 Notes) 700 700 3.45% notes due 2020 (3.45% 2020 Notes) 900 900 4.10% notes due 2021 (4.10% 2021 Notes) 1,000 1,000 1.85% notes due 2021 (1.85% 2021 Notes) 750 750 3.875% notes due 2021 (3.875% 2021 Notes) 1,750 1,750 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) 1,402 1,433 2.70% notes due 2022 (2.70% 2022 Notes) 500 500 2.65% notes due 2022 (2.65% 2022 Notes) 1,500 1,500 3.625% notes due 2022 (3.625% 2022 Notes) 750 750 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) 725 713 2.25% notes due 2023 (2.25% 2023 Notes) 750 750 3.625% notes due 2024 (3.625% 2024 Notes) 1,400 1,400 3.125% notes due 2025 (3.125% 2025 Notes) 1,000 1,000 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) 841 860 2.60% notes due 2026 (2.60% 2026 Notes) 1,250 1,250 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) 630 606 3.20% notes due 2027 (3.20% 2027 Notes) 1,000 1,000 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) 928 893 6.375% notes due 2037 (6.375% 2037 Notes) 552 552 6.90% notes due 2038 (6.90% 2038 Notes) 291 291 6.40% notes due 2039 (6.40% 2039 Notes) 466 466 5.75% notes due 2040 (5.75% 2040 Notes) 412 412 4.95% notes due 2041 (4.95% 2041 Notes) 600 600 5.15% notes due 2041 (5.15% 2041 Notes) 974 974 5.65% notes due 2042 (5.65% 2042 Notes) 487 487 5.375% notes due 2043 (5.375% 2043 Notes) 261 261 4.40% notes due 2045 (4.40% 2045 Notes) 2,250 2,250 4.563% notes due 2048 (4.563% 2048 Notes) 1,415 1,415 4.663% notes due 2051 (4.663% 2051 Notes) 3,541 3,541 Other notes due 2097 100 100 Unamortized bond discounts, premiums and issuance costs, net (868 ) (896 ) Fair value adjustments 296 (53 ) Total carrying value of debt 29,903 33,929 Less current portion (2,953 ) (4,419 ) Total long-term debt $ 26,950 $ 29,510
Schedule of interest rate derivatives	The effective interest rates on notes for which we have entered into interest rate swap contracts and the related notional amounts of these contracts were as follows (dollar amounts in millions): December 31, 2019 2018 Notes Effective interest rates Notional amounts 2.20% 2019 Notes LIBOR + 0.6% $ — $ 1,400 3.45% 2020 Notes LIBOR + 1.1% 900 900 4.10% 2021 Notes LIBOR + 1.7% 1,000 1,000 3.875% 2021 Notes LIBOR + 2.0% 1,750 1,750 3.625% 2022 Notes LIBOR + 1.6% 750 750 3.625% 2024 Notes LIBOR + 1.4% 1,400 1,400 3.125% 2025 Notes LIBOR + 0.9% 1,000 1,000 2.60% 2026 Notes LIBOR + 0.3% 1,250 1,250 4.663% 2051 Notes LIBOR + 0.0% 1,500 1,500 Total notional amounts $ 9,550 $ 10,950
Aggregate contractual maturities of long-term debt obligations	The aggregate contractual maturities of all borrowings due subsequent to December 31, 2019 , are as follows (in millions): Maturity dates Amounts 2020 $ 2,950 2021 3,500 2022 4,152 2023 1,474 2024 1,400 Thereafter 16,999 Total $ 30,475

Stockholders' equity (Tables)

Stockholders' equity (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Summary of activity under our stock repurchase program	Activity under our stock repurchase program, on a trade date basis, was as follows (in millions): Years ended December 31, 2019 2018 2017 Shares* Dollars Shares* Dollars Shares Dollars First quarter 15.9 $ 3,031 56.4 $ 10,787 3.4 $ 555 Second quarter 13.1 2,349 18.2 3,190 6.2 1,006 Third quarter 6.2 1,170 8.7 1,713 4.4 769 Fourth quarter 5.1 1,090 11.1 2,165 4.5 796 Total stock repurchases 40.2 $ 7,640 94.5 $ 17,855 18.5 $ 3,126 * Total shares do not add due to rounding.
Components of accumulated other comprehensive income	The components of AOCI were as follows (in millions): Foreign currency translation Cash flow hedges Available-for-sale securities Other AOCI Balance as of December 31, 2016 $ (610 ) $ 282 $ (138 ) $ (5 ) $ (471 ) Foreign currency translation adjustments 77 — — — 77 Unrealized gains (losses) — 192 (46 ) — 146 Reclassification adjustments to income — (638 ) 41 — (597 ) Other gains — — — 5 5 Income taxes 4 158 (1 ) — 161 Balance as of December 31, 2017 (529 ) (6 ) (144 ) — (679 ) Cumulative effect of change in accounting principle, net of tax — — (9 ) — (9 ) Foreign currency translation adjustments (141 ) — — — (141 ) Unrealized gains (losses) — 61 (556 ) — (495 ) Reclassification adjustments to income — 262 365 — 627 Other losses — — — (2 ) (2 ) Income taxes — (76 ) 6 — (70 ) Balance as of December 31, 2018 (670 ) 241 (338 ) (2 ) (769 ) Foreign currency translation adjustments (48 ) — — — (48 ) Unrealized gains — 127 424 — 551 Reclassification adjustments to income — (211 ) (56 ) — (267 ) Other losses — — — (5 ) (5 ) Income taxes — 18 (8 ) — 10 Balance as of December 31, 2019 $ (718 ) $ 175 $ 22 $ (7 ) $ (528 )
Reclassifications out of accumulated other comprehensive income	Reclassifications out of AOCI and into earnings were as follows (in millions): Years ended December 31, Components of AOCI 2019 2018 2017 Consolidated Statements of Income locations Cash flow hedges: Foreign currency contract gains (losses) $ 101 $ (21 ) $ 65 Product sales Cross-currency swap contract gains (losses) 110 (241 ) 574 Interest and other income, net Forward interest rate contract losses — — (1 ) Interest expense, net 211 (262 ) 638 Income before income taxes (46 ) 55 (226 ) Provision for income taxes $ 165 $ (207 ) $ 412 Net income Available-for-sale securities: Net realized gains (losses) $ 56 $ (365 ) $ (41 ) Interest and other income, net (14 ) 3 (8 ) Provision for income taxes $ 42 $ (362 ) $ (49 ) Net income

Fair value measurement - (Table

Fair value measurement - (Tables)	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis	The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions): Fair value measurement as of December 31, 2019, using: Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total Assets: Available-for-sale securities: U.S. Treasury notes $ 360 $ — $ — $ 360 U.S. Treasury bills — — — — Other government-related debt securities: U.S. — — — — Foreign and other — — — — Corporate debt securities: Financial — 1,121 — 1,121 Industrial — 834 — 834 Other — 198 — 198 Residential-mortgage-backed securities — 182 — 182 Other mortgage- and asset-backed securities — — — — Money market mutual funds 5,250 — — 5,250 Other short-term interest-bearing securities — 289 — 289 Equity securities 303 — — 303 Derivatives: Foreign currency contracts — 224 — 224 Cross-currency swap contracts — 66 — 66 Interest rate swap contracts — 259 — 259 Total assets $ 5,913 $ 3,173 $ — $ 9,086 Liabilities: Derivatives: Foreign currency contracts $ — $ 31 $ — $ 31 Cross-currency swap contracts — 315 — 315 Interest rate swap contracts — — — — Contingent consideration obligations — — 61 61 Total liabilities $ — $ 346 $ 61 $ 407 Fair value measurement as of December 31, 2018, using: Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Total Assets: Available-for-sale securities: U.S. Treasury notes $ 2,663 $ — $ — $ 2,663 U.S. Treasury bills 8,191 — — 8,191 Other government-related debt securities: U.S. — 110 — 110 Foreign and other — 932 — 932 Corporate debt securities: Financial — 2,697 — 2,697 Industrial — 2,504 — 2,504 Other — 562 — 562 Residential-mortgage-backed securities — 1,422 — 1,422 Other mortgage- and asset-backed securities — 469 — 469 Money market mutual funds 5,659 — — 5,659 Other short-term interest-bearing securities — 3,515 — 3,515 Equity securities 176 — — 176 Derivatives: Foreign currency contracts — 182 — 182 Cross-currency swap contracts — 170 — 170 Interest rate swap contracts — 56 — 56 Total assets $ 16,689 $ 12,619 $ — $ 29,308 Liabilities: Derivatives: Foreign currency contracts $ — $ 26 $ — $ 26 Cross-currency swap contracts — 401 — 401 Interest rate swap contracts — 149 — 149 Contingent consideration obligations — — 72 72 Total liabilities $ — $ 576 $ 72 $ 648

Derivative instruments - (Table

Derivative instruments - (Tables)	12 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of notional amounts and interest rates for cross-currency swaps	The notional amounts and interest rates of our cross-currency swaps as of December 31, 2019 , were as follows (notional amounts in millions): Foreign currency U.S. dollars Hedged notes Notional amounts Interest rates Notional amounts Interest rates 1.25% 2022 euro Notes € 1,250 1.3 % $ 1,388 3.2 % 0.41% 2023 Swiss franc Bonds CHF 700 0.4 % $ 704 3.4 % 2.00% 2026 euro Notes € 750 2.0 % $ 833 3.9 % 5.50% 2026 pound sterling Notes £ 475 5.5 % $ 747 6.0 % 4.00% 2029 pound sterling Notes £ 700 4.0 % $ 1,111 4.5 %
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges	The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions): Years ended December 31, Derivatives in cash flow hedging relationships 2019 2018 2017 Foreign currency contracts $ 148 $ 348 $ (402 ) Cross-currency swap contracts (21 ) (287 ) 581 Forward interest rate contracts — — 13 Total unrealized gains $ 127 $ 61 $ 192
Derivatives in fair value hedging relationships	The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Consolidated Balance Sheets as follows (in millions): Carrying amounts of hedged liabilities (1) Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities (2) December 31, December 31, Consolidated Balance Sheets locations 2019 2018 2019 2018 Current portion of long-term debt $ 903 $ 2,396 $ 4 $ (3 ) Long-term debt $ 8,814 $ 9,361 $ 292 $ (50 ) ____________ (1) Current portion of long-term debt includes $1.0 billion of carrying value with discontinued hedging relationships as of December 31, 2018 . Long-term debt includes $136 million and $137 million of carrying value with discontinued hedging relationships as of December 31, 2019 and 2018 , respectively. (2) Current portion of long-term debt includes $3 million of hedging adjustments on discontinued hedging relationships as of December 31, 2018 . Long-term debt includes $36 million and $37 million of hedging adjustments on discontinued hedging relationships as of December 31, 2019 and 2018 , respectively.
Summary of amounts of income and expense line items	The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Year ended December 31, 2019 Product sales Interest and other income, net Interest (expense), net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 22,204 $ 753 $ (1,289 ) The effects of cash flow and fair value hedging: Gains on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 101 $ — $ — Cross-currency swap contracts $ — $ 110 $ — (Losses) gains on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ (349 ) Derivatives designated as hedging instruments $ — $ — $ 352 Year ended December 31, 2018 Product sales Interest and other income, net Interest (expense), net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 22,533 $ 674 $ (1,392 ) The effects of cash flow and fair value hedging: Losses on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ (21 ) $ — $ — Cross-currency swap contracts $ — $ (241 ) $ — Gains (losses) on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ 65 Derivatives designated as hedging instruments $ — $ — $ (42 ) Year ended December 31, 2017 Product sales Interest and other income, net Interest (expense), net Total amounts recorded in income and (expense) line items presented in the Consolidated Statements of Income $ 21,795 $ 928 $ (1,304 ) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 65 $ — $ — Cross-currency swap contracts $ — $ 574 $ — Forward interest rate contracts $ — $ — $ (1 ) Gains (losses) on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ 127 Derivatives designated as hedging instruments $ — $ — $ (85 ) __________ (1) (Losses) gains on hedged items do not completely offset gains (losses) on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships.
Fair values of derivatives included in the Consolidated Balance Sheets	The fair values of derivatives included in the Consolidated Balance Sheets were as follows (in millions): Derivative assets Derivative liabilities December 31, 2019 Consolidated Balance Sheets locations Fair values Consolidated Balance Sheets locations Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other assets $ 223 Accrued liabilities/ Other noncurrent liabilities $ 31 Cross-currency swap contracts Other current assets/ Other assets 66 Accrued liabilities/ Other noncurrent liabilities 315 Interest rate swap contracts Other current assets/ Other assets 259 Accrued liabilities/ Other noncurrent liabilities — Total derivatives designated as hedging instruments 548 346 Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets 1 Accrued liabilities — Total derivatives not designated as hedging instruments 1 — Total derivatives $ 549 $ 346 Derivative assets Derivative liabilities December 31, 2018 Consolidated Balance Sheets locations Fair values Consolidated Balance Sheets locations Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other assets $ 181 Accrued liabilities/ Other noncurrent liabilities $ 26 Cross-currency swap contracts Other current assets/ Other assets 170 Accrued liabilities/ Other noncurrent liabilities 401 Interest rate swap contracts Other current assets/ Other assets 56 Accrued liabilities/ Other noncurrent liabilities 149 Total derivatives designated as hedging instruments 407 576 Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets 1 Accrued liabilities — Total derivatives not designated as hedging instruments 1 — Total derivatives $ 408 $ 576

Contingencies and commitments -

Contingencies and commitments - (Tables)	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
U.S. repatriation tax commitments	The following table summarizes the remaining scheduled repatriation tax payments as of December 31, 2019 (in millions): Amounts 2020 $ 587 2021 587 2022 587 2023 1,100 2024 1,467 Thereafter 1,834 Total remaining U.S. repatriation tax commitments $ 6,162

Quarterly financial data (una_2

Quarterly financial data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Quarterly financial data (unaudited)	Quarterly financial data is summarized as follows (in millions, except per-share data): 2019 Quarters ended December 31 September 30 June 30 March 31 Product sales $ 5,881 $ 5,463 $ 5,574 $ 5,286 Gross profit from product sales $ 4,628 $ 4,427 $ 4,562 $ 4,231 Net income $ 1,703 $ 1,968 $ 2,179 $ 1,992 Earnings per share: Basic $ 2.87 $ 3.29 $ 3.59 $ 3.20 Diluted $ 2.85 $ 3.27 $ 3.57 $ 3.18 2018 Quarters ended December 31 September 30 June 30 March 31 Product sales $ 6,001 $ 5,510 $ 5,679 $ 5,343 Gross profit from product sales $ 4,905 $ 4,473 $ 4,655 $ 4,399 Net income $ 1,928 $ 1,859 $ 2,296 $ 2,311 Earnings per share: Basic $ 3.04 $ 2.88 $ 3.50 $ 3.27 Diluted $ 3.01 $ 2.86 $ 3.48 $ 3.25

Summary of significant accoun_3

Summary of significant accounting policies - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)segment	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Jan. 01, 2019USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of business segment | segment	1
Change in estimate of sales deductions for prior period sales as a pct of total sales deductions (less than)	1.00%
Sales return provisions as a percentage of gross product sales (less than)	1.00%
Advertising cost	$ 789	$ 674	$ 620
Present value of lease liabilities	528
Operating lease, Right-of-use asset	$ 469
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Present value of lease liabilities				$ 510
Operating lease, Right-of-use asset				$ 439
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue payment term	30 days
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue payment term	120 days

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) $ in Millions	Nov. 21, 2019USD ($)	Jul. 15, 2019USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2019USD ($)market	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Business Acquisition [Line Items]
Goodwill				$ 14,703	$ 14,699	$ 14,761
Kirin-Amgen, Inc. (K-A)
Business Acquisition [Line Items]
Percentage of voting interests acquired			50.00%
Ownership percentage			50.00%
Otezla
Business Acquisition [Line Items]
Approved markets | market				50
Cash paid	$ 13,400
Otezla | Developed Technology Rights
Business Acquisition [Line Items]
Weighted average period of amortization	8 years 6 months
Nuevolution
Business Acquisition [Line Items]
Consideration transferred		$ 183
Fair value of liabilities assumed, deferred tax liabilities		22
Fair value of assets acquired and liabilities assumed, net other assets and liabilities		29
Goodwill		$ 26
Nuevolution | R & D Technology rights
Business Acquisition [Line Items]
Weighted average period of amortization		10 years
Finite-lived Intangible Assets Acquired		$ 150
Kirin-Amgen, Inc. (K-A)
Business Acquisition [Line Items]
Consideration transferred			$ 657
Percentage of voting interests acquired			50.00%
Ownership interest in acquiree prior to acquisition (as a percent)			50.00%
Net gain on remeasurement			$ 80
Cash paid			780
Estimated fair values of contingent consideration obligations			45
Fair value of assets acquired, cash			977
Fair value of liabilities assumed, deferred tax liabilities			102
Fair value of assets acquired and liabilities assumed, net other assets and liabilities			131
Goodwill			$ 6
Kirin-Amgen, Inc. (K-A) | Licensing rights
Business Acquisition [Line Items]
Weighted average period of amortization			4 years
Fair value of assets acquired, licensing rights			$ 470
Assembled Workforce [Member] | Otezla | Marketing-Related Rights
Business Acquisition [Line Items]
Weighted average period of amortization	5 years
Inventories [Member] | Otezla
Business Acquisition [Line Items]
Acquired assets, weighted useful life	2 years 6 months

Acquisitions - Otezla (Details)

Acquisitions - Otezla (Details) - Otezla $ in Millions	Nov. 21, 2019USD ($)
Business Acquisition [Line Items]
Cash purchase price	$ 13,400
Transaction costs	40
Accumulated cost (consideration transferred)	13,440
Intangible assets:
Inventory	367
Deferred tax liability, net	(24)
Deferred credit	(96)
Other liabilities, net	(9)
Total assets acquired, net	13,440
Developed Technology Rights
Business Acquisition [Line Items]
Business acquired asset acquisition, Finite-lived intangible assets acquired	13,007
Marketing-Related Rights
Business Acquisition [Line Items]
Business acquired asset acquisition, Finite-lived intangible assets acquired	$ 195

Acquisitions - Aggregate Consid

Acquisitions - Aggregate Consideration Paid (Details) - USD ($) $ in Millions	Jul. 15, 2019	Mar. 31, 2018
Nuevolution
Business Acquisition [Line Items]
Total consideration transferred to acquire K-A	$ 183
Kirin-Amgen, Inc. (K-A)
Business Acquisition [Line Items]
Total cash paid to Kirin		$ 780
Fair value of contingent consideration obligation		45
Loss on settlement of preexisting relationship		(168)
Total consideration transferred to acquire K-A		657
Fair value of Amgen’s investment in K-A		825
Total acquisition date fair value		$ 1,482
R & D Technology rights | Nuevolution
Business Acquisition [Line Items]
Weighted average period of amortization	10 years

Revenues - Narrative (Details)

Revenues - Narrative (Details) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Sep. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2019USD ($)segmentcustomer	Dec. 31, 2018USD ($)customer	Dec. 31, 2017USD ($)customer
Revenue from Contract with Customer [Abstract]
Number of operating segments | segment									1
Revenue from External Customer [Line Items]
Number of major customers (as defined) accounting for more than 10% of total revenue | customer									3	3	3
Threshold as a percentage of total revenues for determining a major customer for additional disclosures									10.00%	10.00%	10.00%
Major customers (as defined) accounting for more than 10% of gross trade receivables | customer									3	3
Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables	73.00%				76.00%				73.00%	76.00%
Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis									81.00%
Total product sales									$ 23,362	$ 23,747	$ 22,849
Percentage of net trade receivables due from customers located outside the United States, primarily in Europe	27.00%				23.00%				27.00%	23.00%
US [Member]
Revenue from External Customer [Line Items]
Total product sales									$ 17,224	$ 18,358	18,029
ROW [Member]
Revenue from External Customer [Line Items]
Total product sales									6,138	5,389	4,820
Product sales [Member]
Revenue from External Customer [Line Items]
Total product sales	$ 5,881	$ 5,463	$ 5,574	$ 5,286	$ 6,001	$ 5,510	$ 5,679	$ 5,343	22,204	22,533	21,795
Product sales [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales									16,531	17,429	17,131
Product sales [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales									5,673	5,104	4,664
Enbrel® (etanercept) [Member]
Revenue from External Customer [Line Items]
Total product sales									5,226	5,014	5,433
Enbrel® (etanercept) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales									5,050	4,807	5,206
Enbrel® (etanercept) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales									176	207	227
Neulasta® (pegfilgrastim) [Member]
Revenue from External Customer [Line Items]
Total product sales									3,221	4,475	4,534
Neulasta® (pegfilgrastim) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales									2,814	3,866	3,931
Neulasta® (pegfilgrastim) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales									407	609	603
Prolia® (denosumab) [Member]
Revenue from External Customer [Line Items]
Total product sales									2,672	2,291	1,968
Prolia® (denosumab) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales									1,772	1,500	1,272
Prolia® (denosumab) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales									900	791	696
XGEVA® (denosumab) [Member]
Revenue from External Customer [Line Items]
Total product sales									1,935	1,786	1,575
XGEVA® (denosumab) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales									1,457	1,338	1,157
XGEVA® (denosumab) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales									478	448	418
Aranesp® (darbepoetin alfa) [Member]
Revenue from External Customer [Line Items]
Total product sales									1,729	1,877	2,053
Aranesp® (darbepoetin alfa) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales									758	942	1,114
Aranesp® (darbepoetin alfa) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales									971	935	939
Kyprolis [Member]
Revenue from External Customer [Line Items]
Total product sales									1,044	968	835
Kyprolis [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales									654	583	562
Kyprolis [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales									390	385	273
EPOGEN® (epoetin alfa) [Member]
Revenue from External Customer [Line Items]
Total product sales									867	1,010	1,096
EPOGEN® (epoetin alfa) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales									867	1,010	1,096
EPOGEN® (epoetin alfa) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales									0	0	0
Sensipar® / Mimpara® (cinacalcet) [Member]
Revenue from External Customer [Line Items]
Total product sales									551	1,774	1,718
Sensipar® / Mimpara® (cinacalcet) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales									252	1,436	1,374
Sensipar® / Mimpara® (cinacalcet) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales									299	338	344
Other products [Member]
Revenue from External Customer [Line Items]
Total product sales									4,959	3,338	2,583
Other products [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales									2,907	1,947	1,419
Other products [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales									2,052	1,391	1,164
Other revenues [Member]
Revenue from External Customer [Line Items]
Total product sales									1,158	1,214	1,054
Other revenues [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales									693	929	898
Other revenues [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales									$ 465	$ 285	156
AmerisourceBergen Corporation [Member]
Revenue from External Customer [Line Items]
Amount due from major customer (as defined) as a percentage of gross trade receivables									exceeded 10%	exceeded 10%
AmerisourceBergen Corporation [Member] | Product sales [Member]
Revenue from External Customer [Line Items]
Total product sales									$ 12,301	$ 12,091	10,742
McKesson Corporation [Member]
Revenue from External Customer [Line Items]
Amount due from major customer (as defined) as a percentage of gross trade receivables									exceeded 10%	exceeded 10%
McKesson Corporation [Member] | Product sales [Member]
Revenue from External Customer [Line Items]
Total product sales									$ 11,795	$ 11,434	10,625
Cardinal Health, Inc. [Member]
Revenue from External Customer [Line Items]
Amount due from major customer (as defined) as a percentage of gross trade receivables									exceeded 10%	exceeded 10%
Cardinal Health, Inc. [Member] | Product sales [Member]
Revenue from External Customer [Line Items]
Total product sales									$ 6,538	$ 7,475	$ 7,049

Revenues - Customer Concentrati

Revenues - Customer Concentration, Product Sales (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenue, Major Customer [Line Items]
Product sales									$ 23,362	$ 23,747	$ 22,849
Product [Member]
Revenue, Major Customer [Line Items]
Product sales	$ 5,881	$ 5,463	$ 5,574	$ 5,286	$ 6,001	$ 5,510	$ 5,679	$ 5,343	22,204	22,533	21,795
Product [Member] | AmerisourceBergen Corporation [Member]
Revenue, Major Customer [Line Items]
Product sales									$ 12,301	$ 12,091	$ 10,742
Gross product sales to major customer (as defined) as a percentage of total gross revenues									33.00%	33.00%	31.00%
Product [Member] | McKesson Corporation [Member]
Revenue, Major Customer [Line Items]
Product sales									$ 11,795	$ 11,434	$ 10,625
Gross product sales to major customer (as defined) as a percentage of total gross revenues									31.00%	31.00%	30.00%
Product [Member] | Cardinal Health, Inc. [Member]
Revenue, Major Customer [Line Items]
Product sales									$ 6,538	$ 7,475	$ 7,049
Gross product sales to major customer (as defined) as a percentage of total gross revenues									17.00%	20.00%	20.00%

Stock-based compensation (Textu

Stock-based compensation (Textual) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount by which the pool of available shares will be reduced for each stock option granted	1
The amount of common stock available under the plan for future grants and/or issuances (in shares)	28,000,000
Description of vesting of restricted stock units and stock options	RSUs and stock options generally vest in equal amounts on the second, third and fourth anniversaries of the grant date.
Total unrecognized compensation cost related to nonvested awards	$ 308
Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized	1 year 9 months 18 days
Period over which the grants of equity instruments vest	3 years
Number of common shares issued for each performance unit earned	1
RSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
The number of shares by which the pool of available shares will be reduced for other types of awards granted	1.9
Number of shares added back for tax withholding on full value awards	1.9
Weighted average grant date fair value, granted (in usd per share)	$ 182.12	$ 179.18	$ 163.99
Total fair value of units that vested during the year	$ 160	$ 167	$ 182
Units outstanding (in shares)	3,100,000	3,100,000
Weighted-average grant date fair value	$ 174.97	$ 168.11
Units granted (in shares)	1,200,000
Units, forfeited (in shares)	200,000
Weighted average grant date fair value, forfeited (in usd per share)	$ 170.52
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of stock options from date of grant	10 years
Total intrinsic value of stock options exercised during the year	$ 68	$ 53	60
Actual tax benefits realized from tax deductions from option exercises	$ 15	$ 12	$ 21
Performance units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
The number of shares by which the pool of available shares will be reduced for other types of awards granted	1.9
Number of shares added back for tax withholding on full value awards	1.9
Weighted average grant date fair value, granted (in usd per share)	$ 188.40	$ 189.21	$ 178.87
Total fair value of units that vested during the year	$ 176	$ 133	$ 219
Total unrecognized compensation cost related to nonvested awards	$ 113
Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized	1 year
Units outstanding (in shares)	2,000,000	2,000,000
Weighted-average grant date fair value	$ 185.64	$ 180.12
Units granted (in shares)	800,000
Units, forfeited (in shares)	200,000
Weighted average grant date fair value, forfeited (in usd per share)	$ 186.66

Stock-based compensation (Compo

Stock-based compensation (Components of Stock-based Compensation Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Components of stock-based compensation expense [Abstract]
Total stock-based compensation expense, pretax	$ 308	$ 311	$ 329
Tax benefit from stock-based compensation expense	(67)	(67)	(118)
Total stock-based compensation expense, net of tax	241	244	211
RSUs [Member]
Components of stock-based compensation expense [Abstract]
Total stock-based compensation expense, pretax	168	165	174
Performance units [Member]
Components of stock-based compensation expense [Abstract]
Total stock-based compensation expense, pretax	105	117	133
Stock options [Member]
Components of stock-based compensation expense [Abstract]
Total stock-based compensation expense, pretax	$ 35	$ 29	$ 22

Stock-based compensation (Summa

Stock-based compensation (Summary of RSUs) (Details) - RSUs [Member] - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Units
Balance nonvested at beginning of period (in shares)	3.1
Granted (in shares)	1.2
Vested (in shares)	(1)
Forfeited (in shares)	(0.2)
Balance nonvested at end of period (in shares)	3.1	3.1
Weighted-average grant date fair value
Balance nonvested at beginning of period (in usd per share)	$ 168.11
Granted (in usd per share)	182.12	$ 179.18	$ 163.99
Vested (in usd per share)	163.21
Forfeited (in usd per share)	170.52
Balance nonvested at end of period (in usd per share)	$ 174.97	$ 168.11

Stock-based compensation Stock-

Stock-based compensation Stock-based compensation (Summary of Stock Options) (Details) - Share-based Payment Arrangement, Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing price of our common stock on grant date (in usd per share)	$ 177.31	$ 177.46	$ 162.60
Volatility	23.50%	24.60%	22.70%
Expected life (in years)	5 years 9 months 18 days	5 years 9 months 18 days	5 years 9 months 18 days
Risk-free interest rate	2.40%	2.80%	2.10%
Expected dividend yield	3.10%	2.90%	2.80%
Granted (in usd per share)	$ 30.47	$ 34.60	$ 27.54

Stock-based compensation (Sum_2

Stock-based compensation (Summary of Stock Options) (Details) - Stock options [Member] $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Options
Balance unexercised at beginning of period (in shares) | shares	4.4
Granted (in shares) | shares	1.4
Exercised (in shares) | shares	(0.7)
Expired/forfeited (in shares) | shares	(0.3)
Balance unexercised at end of period (in shares) | shares	4.8
Vested or expected to vest (in shares) | shares	4.6
Exercisable (in shares) | shares	1.3
Weighted- average exercise price
Balance unexercised at beginning of period (in usd per share) | $ / shares	$ 143.57
Granted (in usd per share) | $ / shares	177.31
Exercised (in usd per share) | $ / shares	107.13
Expired/forfeited (in usd per share) | $ / shares	171.01
Balance unexercised at end of period (in shares) | $ / shares	157
Weighted-average exercise price, vested or expected to vest (in usd per share) | $ / shares	156.02
Weighted-average exercise price, exercisable (in usd per share) | $ / shares	$ 117.13
Stock options information [Abstract]
Weighted-average remaining contractual life (years), unexercised	7 years 2 months 12 days
Weighted-average remaining contractual life (years), vested or expected to vest	7 years 1 month 6 days
Weighted-average remaining contractual life (years), exercisable	4 years 3 months 18 days
Aggregate intrinsic value, unexercised | $	$ 406
Aggregate intrinsic value, vested or expected to vest | $	390
Aggregate intrinsic value, exercisable | $	$ 162

Stock-based compensation (Weigh

Stock-based compensation (Weighted-average Assumptions) (Details) - Performance units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Weighted-average assumptions and resulting weighted-average grant date fair values [Abstract]
Closing price of our common stock on grant date (in usd per share)	$ 177.31	$ 177.93	$ 162.60
Volatility	22.10%	23.80%	25.90%
Risk-free interest rate	2.30%	2.60%	1.40%
Fair value of unit (in usd per share)	$ 188.40	$ 189.21	$ 178.87

Defined contribution plan (Deta

Defined contribution plan (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Retirement Benefits [Abstract]
Expense attributed to Retirement and Savings Plan	$ 220	$ 173	$ 196

Income taxes (Income Before Inc

Income taxes (Income Before Income Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Examination [Line Items]
Income before income taxes	$ 9,138	$ 9,545	$ 9,597
Domestic [Member]
Income Tax Examination [Line Items]
Income before income taxes	4,371	4,856	4,436
Foreign [Member]
Income Tax Examination [Line Items]
Income before income taxes	$ 4,767	$ 4,689	$ 5,161

Income taxes (Provision for Inc

Income taxes (Provision for Income Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Current provision:
Federal	$ 1,284	$ 1,270	$ 8,615
State	39	17	5
Foreign	277	227	275
Total current provision	1,600	1,514	8,895
Deferred (benefit) provision:
Federal	(276)	(317)	(1,120)
State	(22)	(7)	0
Foreign	(6)	(39)	(157)
Total deferred (benefit) provision	(304)	(363)	(1,277)
Total provision for income taxes	$ 1,296	$ 1,151	$ 7,618

Income taxes (Components of Def

Income taxes (Components of Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Deferred income tax assets:
NOL and credit carryforwards	$ 800	$ 810
Accrued expenses	457	428
Expenses capitalized for tax	170	185
Stock-based compensation	91	95
Other	269	174
Total deferred income tax assets	1,787	1,692
Valuation allowance	(517)	(509)
Net deferred income tax assets	1,270	1,183
Deferred income tax liabilities:
Acquired intangible assets	(1,288)	(1,509)
Debt	(210)	(184)
Other	(286)	(267)
Total deferred income tax liabilities	(1,784)	(1,960)
Total deferred income taxes, net	$ (514)	$ (777)

Income taxes (Textual) (Details

Income taxes (Textual) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Tax Credit Carryforward [Line Items]
Interest and penalties related to unrecognized tax benefits recognized in income tax provision	$ 198,000,000	$ 137,000,000	$ 56,000,000
Accrued interest and penalties associated with unrecognized tax benefits	667,000,000	469,000,000
Income taxes paid	1,900,000,000	$ 1,900,000,000	$ 1,500,000,000
Federal [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards available to reduce income taxes	20,000,000
Tax credit carryforwards, valuation allowance	0
NOL carryforwards available to reduce income taxes	144,000,000
NOL carryforwards, valuation allowance	6,000,000
Federal [Member] | Operating Losses That Expire Between 2020 and 2035 [Member]
Tax Credit Carryforward [Line Items]
NOL carryforwards, valuation allowance	0
State [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards available to reduce income taxes	605,000,000
Tax credit carryforwards, valuation allowance	482,000,000
NOL carryforwards available to reduce income taxes	196,000,000
NOL carryforwards, valuation allowance	196,000,000
State [Member] | Expiration in tax years beginning 2022 [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards, valuation allowance	0
Foreign [Member]
Tax Credit Carryforward [Line Items]
NOL carryforwards available to reduce income taxes	2,000,000,000
NOL carryforwards, valuation allowance	516,000,000
NOLs with no valuation allowance and no expiration	822,000,000
Foreign [Member] | Operating Losses That Expire Between 2020 and 2024 [Member]
Tax Credit Carryforward [Line Items]
NOL carryforwards, valuation allowance	$ 0

Income taxes (Reconciliation of

Income taxes (Reconciliation of Total Gross Amounts of UTBs) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)
Beginning balance	$ 3,061	$ 2,953	$ 2,543
Additions based on tax positions related to the current year	215	173	447
Additions based on tax positions related to prior years	22	13	1
Reductions for tax positions of prior years	(11)	(17)	(5)
Reductions for expiration of statute of limitations	0	0	(5)
Settlements	0	(61)	(28)
Ending balance	$ 3,287	$ 3,061	$ 2,953

Income taxes (Reconciliation _2

Income taxes (Reconciliation of Federal Statutory Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Federal statutory tax rate	21.00%	21.00%	35.00%
2017 Tax Act, net repatriation tax	0.00%	0.00%	70.70%
Foreign earnings	(4.50%)	(4.30%)	(15.80%)
2017 Tax Act, net deferred tax remeasurement	0.00%	0.00%	(6.90%)
Credits, Puerto Rico Excise Tax	(2.60%)	(2.50%)	(2.20%)
2017 Tax Act, net impact on intercompany sales	0.00%	(1.80%)	0.00%
Interest on uncertain tax positions	1.60%	1.20%	0.60%
Credits, primarily federal R&D	(1.00%)	(0.80%)	(0.60%)
Share-based payments	(0.30%)	(0.20%)	(0.70%)
Other, net	0.00%	(0.50%)	(0.70%)
Effective tax rate	14.20%	12.10%	79.40%

Earnings per share (Details)

Earnings per share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income (Numerator):
Net income for basic and diluted EPS	$ 1,703	$ 1,968	$ 2,179	$ 1,992	$ 1,928	$ 1,859	$ 2,296	$ 2,311	$ 7,842	$ 8,394	$ 1,979
Shares (Denominator):
Weighted-average shares for basic EPS									605	661	731
Effect of dilutive securities (in shares)									4	4	4
Weighted-average shares for diluted EPS									609	665	735
Basic EPS (in usd per share)	$ 2.87	$ 3.29	$ 3.59	$ 3.20	$ 3.04	$ 2.88	$ 3.50	$ 3.27	$ 12.96	$ 12.70	$ 2.71
Diluted EPS (in usd per share)	$ 2.85	$ 3.27	$ 3.57	$ 3.18	$ 3.01	$ 2.86	$ 3.48	$ 3.25	$ 12.88	$ 12.62	$ 2.69

Collaborations - Novartis AG (D

Collaborations - Novartis AG (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 23,362	$ 23,747	$ 22,849
Other revenues [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	1,158	1,214	1,054
Collaborative Arrangement with Novartis AG [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential future milestone payment	100
Collaborative Arrangement with Novartis AG [Member] | Other revenues [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues		295
Collaborative Arrangement with Novartis AG [Member] | Selling, general and administrative [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost paid		44
Cost recoveries	187
Collaborative Arrangement with Novartis AG [Member] | Research and development [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost recoveries			$ 124
Collaborative Arrangement with Novartis AG [Member] | Cost of sales [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties due	$ 115	$ 43

Collaborations - Bayer HealthCa

Collaborations - Bayer HealthCare Pharmaceuticals Inc. (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)country	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 23,362	$ 23,747	$ 22,849
Collaborative Arrangement with Bayer [Member] | Nexavar [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of countries product is marketed and sold | country	100
Collaboration, royalty percentage in the high 30s	30.00%
Percentage of net profits after deducting certain partner related costs	50.00%
Collaborative Arrangement with Bayer [Member] | Nexavar [Member] | Other revenues [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration profit	$ 210	164	161
Collaborative Arrangement with Bayer [Member] | Royalty [Member] | Other revenues [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 79	$ 91	$ 133

Investments - Schedule (Details

Investments - Schedule (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Debt securities
Amortized cost	$ 8,206,000,000	$ 29,064,000,000
Gross unrealized gains	28,000,000	1,000,000
Gross unrealized losses	0	(341,000,000)
Fair values	8,234,000,000	28,724,000,000
U.S. Treasury notes [Member]
Debt securities
Amortized cost	359,000,000	2,710,000,000
Gross unrealized gains	1,000,000	0
Gross unrealized losses	0	(47,000,000)
Fair values	360,000,000	2,663,000,000
U.S. Treasury bills [Member]
Debt securities
Amortized cost	0	8,191,000,000
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	0	8,191,000,000
Other government-related debt securities - U.S. [Member]
Debt securities
Amortized cost	0	112,000,000
Gross unrealized gains	0	0
Gross unrealized losses	0	(2,000,000)
Fair values	0	110,000,000
Other government-related debt securities - Foreign and other [Member]
Debt securities
Amortized cost	0	972,000,000
Gross unrealized gains	0	1,000,000
Gross unrealized losses	0	(41,000,000)
Fair values	0	932,000,000
Corporate debt securities - Financial [Member]
Debt securities
Amortized cost	1,108,000,000	2,778,000,000
Gross unrealized gains	13,000,000	0
Gross unrealized losses	0	(81,000,000)
Fair values	1,121,000,000	2,697,000,000
Corporate debt securities - Industrial [Member]
Debt securities
Amortized cost	824,000,000	2,603,000,000
Gross unrealized gains	10,000,000	0
Gross unrealized losses	0	(99,000,000)
Fair values	834,000,000	2,504,000,000
Corporate debt securities - Other [Member]
Debt securities
Amortized cost	195,000,000	583,000,000
Gross unrealized gains	3,000,000	0
Gross unrealized losses	0	(21,000,000)
Fair values	198,000,000	562,000,000
Residential mortgage-backed securities [Member]
Debt securities
Amortized cost	181,000,000	1,458,000,000
Gross unrealized gains	1,000,000	0
Gross unrealized losses	0	(36,000,000)
Fair values	182,000,000	1,422,000,000
Other mortgage- and asset-backed securities [Member]
Debt securities
Amortized cost	0	483,000,000
Gross unrealized gains	0	0
Gross unrealized losses	0	(14,000,000)
Fair values	0	469,000,000
Money market mutual funds [Member]
Debt securities
Amortized cost	5,250,000,000	5,659,000,000
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	5,250,000,000	5,659,000,000
Other short-term interest-bearing securities [Member]
Debt securities
Amortized cost	289,000,000	3,515,000,000
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	$ 289,000,000	$ 3,515,000,000

Investments - Fair Values by Cl

Investments - Fair Values by Classification (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Consolidated Balance Sheets locations
Cash and cash equivalents	$ 6,037	$ 6,945
Marketable securities	2,874	22,359
Total available-for-sale investments	8,234	28,724
Available-for-sale investments [Member]
Consolidated Balance Sheets locations
Cash and cash equivalents	5,360	6,365
Marketable securities	2,874	22,359
Total available-for-sale investments	$ 8,234	$ 28,724

Investments - Available-for-sal

Investments - Available-for-sale (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Cash	$ 677	$ 580
Total realized gains	92	29	$ 147
Total realized losses	$ 36	$ 394	$ 213

Investments - Fair Values by Co

Investments - Fair Values by Contractual Maturity (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Maturing in one year or less	$ 5,629	$ 17,424
Maturing after one year through three years	2,304	3,356
Maturing after three years through five years	119	5,168
Maturing after five years through ten years	0	885
Mortgage- and asset-backed securities	182	1,891
Total available-for-sale investments	$ 8,234	$ 28,724

Investments - Unrealized Losses

Investments - Unrealized Losses and Fair Values (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values		$ 6,838
Less than 12 months, Unrealized losses		(226)
12 months or more, Fair values		4,360
12 months or more, Unrealized losses		(115)
Total realized losses	$ 36	394	$ 213
U.S. Treasury notes [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values		1,219
Less than 12 months, Unrealized losses		(21)
12 months or more, Fair values		1,444
12 months or more, Unrealized losses		(26)
Other government-related debt securities - U.S. [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values		0
Less than 12 months, Unrealized losses		0
12 months or more, Fair values		110
12 months or more, Unrealized losses		(2)
Other government-related debt securities - Foreign and other [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values		631
Less than 12 months, Unrealized losses		(31)
12 months or more, Fair values		240
12 months or more, Unrealized losses		(10)
Corporate debt securities - Financial [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values		1,968
Less than 12 months, Unrealized losses		(59)
12 months or more, Fair values		718
12 months or more, Unrealized losses		(22)
Corporate debt securities - Industrial [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values		1,898
Less than 12 months, Unrealized losses		(81)
12 months or more, Fair values		529
12 months or more, Unrealized losses		(18)
Corporate debt securities - Other [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values		529
Less than 12 months, Unrealized losses		(20)
12 months or more, Fair values		28
12 months or more, Unrealized losses		(1)
Residential mortgage-backed securities [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values		576
Less than 12 months, Unrealized losses		(14)
12 months or more, Fair values		840
12 months or more, Unrealized losses		(22)
Other mortgage- and asset-backed securities [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values		17
Less than 12 months, Unrealized losses		0
12 months or more, Fair values		451
12 months or more, Unrealized losses		$ (14)

Investments - Equity Securities

Investments - Equity Securities (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Equity securities	$ 303	$ 176
Equity securities without readily determinable fair value	$ 176	$ 222

Investments - Limited Partnersh

Investments - Limited Partnership Investments (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Limited Partnership [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Net Investment Income [Line Items]
Investments	$ 320	$ 285

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 358	$ 257
Work in process	2,227	1,660
Finished goods	999	1,023
Total inventories	$ 3,584	$ 2,940

Property, plant and equipment_2

Property, plant and equipment (Schedule) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Land	$ 263	$ 265
Buildings and improvements	3,757	3,616
Manufacturing equipment	2,655	2,418
Laboratory equipment	1,236	1,174
Capitalized software	1,154	1,124
Other	3,313	3,204
Construction in progress	907	953
Property, plant and equipment, gross	13,285	12,754
Less accumulated depreciation and amortization	(8,357)	(7,796)
Property, plant and equipment, net	4,928	4,958
Depreciation and amortization charges associated with property, plant and equipment	$ 635	$ 630	$ 604
Buildings and improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	10 years
Buildings and improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	40 years
Manufacturing equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	8 years
Manufacturing equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	12 years
Laboratory equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	8 years
Laboratory equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	12 years
Capitalized software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Capitalized software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	5 years
Other [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Other [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life (in years)	15 years

Property, plant and equipment_3

Property, plant and equipment (Geographic Information) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 4,928	$ 4,958
United States [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	2,433	2,373
Puerto Rico [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	1,402	1,476
ROW [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 1,093	$ 1,109

Goodwill and other intangible_2

Goodwill and other intangible assets - Goodwill Roll Forward (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill [Roll Forward]
Beginning balance	$ 14,699	$ 14,761
Addition from acquisitions	26	6
Currency translation adjustments	(22)	(68)
Ending balance	$ 14,703	$ 14,699

Goodwill and other intangible_3

Goodwill and other intangible assets - Identifiable Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Finite-lived intangible assets:
Gross carrying amounts	$ 31,991	$ 18,790
Accumulated amortization	(12,632)	(11,402)
Other intangible assets, net	19,359	7,388
Indefinite-lived intangible assets:
Identifiable intangible assets	32,045	18,845
Accumulated amortization	(12,632)	(11,402)
Identifiable intangible assets, net	19,413	7,443
IPR&D [Member]
Indefinite-lived intangible assets:
Indefinite-lived intangible assets	54	55
Developed Technology Rights
Finite-lived intangible assets:
Gross carrying amounts	25,575	12,573
Accumulated amortization	(8,322)	(7,479)
Other intangible assets, net	17,253	5,094
Licensing rights
Finite-lived intangible assets:
Gross carrying amounts	3,761	3,772
Accumulated amortization	(2,398)	(2,032)
Other intangible assets, net	1,363	1,740
Marketing-related rights [Member]
Finite-lived intangible assets:
Gross carrying amounts	1,382	1,297
Accumulated amortization	(965)	(1,019)
Other intangible assets, net	417	278
R&D technology rights [Member]
Finite-lived intangible assets:
Gross carrying amounts	1,273	1,148
Accumulated amortization	(947)	(872)
Other intangible assets, net	$ 326	$ 276

Goodwill and other intangible_4

Goodwill and other intangible assets - Narrative (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization charges associated with finite-lived intangible assets	$ 1.4	$ 1.3	$ 1.3
Total estimated amortization of finite-lived intangible assets for 2020	2.8
Total estimated amortization of finite-lived intangible assets for 2021	2.6
Total estimated amortization of finite-lived intangible assets for 2022	2.5
Total estimated amortization of finite-lived intangible assets for 2023	2.4
Total estimated amortization of finite-lived intangible assets for 2024	$ 2.4

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Renewal term			7 years
Weighted-average remaining lease term (in years)			4 years 1 month 6 days
Weighted-average discount rate			3.30%
Total undiscounted future lease payment			$ 306
Total lease payments			$ 567
Future minimum payments receivable	$ 203
Operating lease rent expense	166	$ 159
Minimum [Member]
Lessee, Lease, Description [Line Items]
Leases not yet commenced lease term			5 years
Maximum [Member]
Lessee, Lease, Description [Line Items]
Leases not yet commenced lease term			15 years
Abandoned Leases [Member]
Lessee, Lease, Description [Line Items]
Total lease payments	$ 222		$ 178

Leases - Summary of Leases (Det

Leases - Summary of Leases (Details) $ in Millions	Dec. 31, 2019USD ($)
Assets:
Other assets	$ 469
Liabilities:
Accrued liabilities	140
Other noncurrent liabilities	388
Total lease liabilities	$ 528

Leases - Components of Lease Co

Leases - Components of Lease Costs (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Leases [Abstract]
Operating	$ 204
Sublease income	(33)
Total net lease costs	$ 171

- Maturities of Lease Liabiliti

- Maturities of Lease Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Lessee, Lease, Description [Line Items]
2020	$ 157
2021	150
2022	110
2023	88
2024	30
Thereafter	32
Total lease payments	567
Less imputed interest	(39)
Present value of lease liabilities	528
Abandoned Leases [Member]
Lessee, Lease, Description [Line Items]
Total lease payments	178	$ 222
Expected total future rental income to be received	$ 141

Leases - Cash and Noncash Infor

Leases - Cash and Noncash Information of Leases (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 148
ROU assets obtained in exchange for lease obligations	$ 163

Leases - Prior to adoption (Det

Leases - Prior to adoption (Details) $ in Millions	Dec. 31, 2018USD ($)
Leases [Abstract]
2019	$ 164
2020	126
2021	113
2022	64
2023	56
Thereafter	46
Total minimum operating lease commitments	$ 569

Other current assets and accr_3

Other current assets and accrued liabilities Schedule of Other Assets (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Prepaid expenses	$ 939	$ 907
Corporate partner receivables	485	444
Interest receivables	110	177
Other	354	266
Total other current assets	$ 1,888	$ 1,794

Schedule of Accrued Liabilities

Schedule of Accrued Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Sales deductions	$ 3,880	$ 3,170
Employee compensation and benefits	981	1,001
Dividends payable	946	914
Sales returns reserve	564	535
Other	2,140	2,242
Total accrued liabilities	$ 8,511	$ 7,862

Financing arrangements (Princip

Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2019EUR (€)	Dec. 31, 2019CHF (SFr)	Dec. 31, 2019GBP (£)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Carrying values of long-term borrowings
Unamortized bond discounts, premiums and issuance costs, net	$ (868)				$ (896)
Fair value adjustments	296				(53)
Total carrying value of debt	29,903				33,929
Less current portion	(2,953)				(4,419)
Total long-term debt	$ 26,950				29,510
0.41% 2023 Swiss franc Bonds [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	0.41%	0.41%	0.41%	0.41%
5.50% pound-sterling-denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	5.50%	5.50%	5.50%	5.50%
Notes [Member]
Debt Instrument [Line Items]
Face amount						$ 4,500
Notes [Member] | 5.70% notes due 2019 (5.70% 2019 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	5.70%	5.70%	5.70%	5.70%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross					1,000
Notes [Member] | 1.90% notes due 2019 (1.90% 2019 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	1.90%	1.90%	1.90%	1.90%		1.90%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 0				700
Notes [Member] | Floating Rate Notes Due 2019 [Member]
Debt Instrument [Line Items]
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross					550
Notes [Member] | 2.20% notes due 2019 (2.20% 2019 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.20%	2.20%	2.20%	2.20%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross					1,400
Notes [Member] | 2.125% euro-denominated notes due 2019 (2.125% 2019 euro Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.125%	2.125%	2.125%	2.125%
Face amount | €		€ 675,000,000
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross					774
Notes [Member] | 4.50% notes due 2020 (4.50% 2020 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.50%	4.50%	4.50%	4.50%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 300				300
Notes [Member] | 2.125% notes due 2020 (2.125% 2020 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.125%	2.125%	2.125%	2.125%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 750				750
Notes [Member] | Floating Rate Notes Due 2020 [Member]
Debt Instrument [Line Items]
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 300				300
Notes [Member] | 2.20% notes due 2020 (2.20% 2020 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.20%	2.20%	2.20%	2.20%		2.20%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 700				700
Notes [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.45%	3.45%	3.45%	3.45%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 900				900
Notes [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.10%	4.10%	4.10%	4.10%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,000				1,000
Notes [Member] | 1.85% notes due 2021 (1.85% 2021 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	1.85%	1.85%	1.85%	1.85%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 750				750
Notes [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.875%	3.875%	3.875%	3.875%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,750				1,750
Notes [Member] | 1.25% notes due 2022 (1.25% 2022 euro Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	1.25%	1.25%	1.25%	1.25%
Face amount | €		€ 1,250,000,000
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,402				1,433
Notes [Member] | 2.70% notes due 2022 (2.70% 2022 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.70%	2.70%	2.70%	2.70%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 500				500
Notes [Member] | 2.65% notes due 2022 (2.65% 2022 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.65%	2.65%	2.65%	2.65%		2.65%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,500				1,500
Notes [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.625%	3.625%	3.625%	3.625%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 750				750
Notes [Member] | 0.41% 2023 Swiss franc Bonds [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	0.41%	0.41%	0.41%	0.41%
Face amount | SFr			SFr 700,000,000
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 725				713
Notes [Member] | 2.25% notes due 2023 (2.25% 2023 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.25%	2.25%	2.25%	2.25%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 750				750
Notes [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.625%	3.625%	3.625%	3.625%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,400				1,400
Notes [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.125%	3.125%	3.125%	3.125%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,000				1,000
Notes [Member] | 2.00% 2026 euro Notes [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.00%	2.00%	2.00%	2.00%
Face amount | €		€ 750,000,000
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 841				860
Notes [Member] | 2.60% notes due 2026 (2.60% 2026 notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.60%	2.60%	2.60%	2.60%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,250				1,250
Notes [Member] | 5.50% pound-sterling-denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	5.50%	5.50%	5.50%	5.50%
Face amount | £				£ 475,000,000
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 630				606
Notes [Member] | 3.20% notes due 2027 (3.20% 2027 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.20%	3.20%	3.20%	3.20%		3.20%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,000				1,000
Notes [Member] | 4.00% pound-sterling-denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.00%	4.00%	4.00%	4.00%
Face amount | £				£ 700,000,000
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 928				893
Notes [Member] | 6.375% notes due 2037 (6.375% 2037 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	6.375%	6.375%	6.375%	6.375%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 552				552
Notes [Member] | 6.90% notes due 2038 (6.90% 2038 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	6.90%	6.90%	6.90%	6.90%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 291				291
Notes [Member] | 6.40% notes due 2039 (6.40% 2039 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	6.40%	6.40%	6.40%	6.40%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 466				466
Notes [Member] | 5.75% notes due 2040 (5.75% 2040 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	5.75%	5.75%	5.75%	5.75%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 412				412
Notes [Member] | 4.95% notes due 2041 (4.95% 2041 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.95%	4.95%	4.95%	4.95%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 600				600
Notes [Member] | 5.15% notes due 2041 (5.15% 2041 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	5.15%	5.15%	5.15%	5.15%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 974				974
Notes [Member] | 5.65% notes due 2042 (5.65% 2042 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	5.65%	5.65%	5.65%	5.65%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 487				487
Notes [Member] | 5.375% notes due 2043 (5.375% 2043 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	5.375%	5.375%	5.375%	5.375%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 261				261
Notes [Member] | 4.40% notes due 2045 (4.40% 2045 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.40%	4.40%	4.40%	4.40%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 2,250				2,250
Notes [Member] | 4.563% notes due 2048 (4.563% 2048 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.563%	4.563%	4.563%	4.563%
Effective interest rate on note	6.30%	6.30%	6.30%	6.30%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 1,415				1,415
Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.663%	4.663%	4.663%	4.663%
Effective interest rate on note	5.60%	5.60%	5.60%	5.60%
Percentage of principal amount of notes that may be paid upon occurrence of change in control triggering event	101.00%
Carrying values of long-term borrowings
Long-term debt, gross	$ 3,541				3,541
Notes [Member] | Other notes due 2097 [Member]
Carrying values of long-term borrowings
Long-term debt, gross	$ 100				$ 100
Debt securities payable [Member] | Minimum [Member]
Debt Instrument [Line Items]
Redemption period without payment of make whole amount	1 month
Debt securities payable [Member] | Maximum [Member]
Debt Instrument [Line Items]
Redemption period without payment of make whole amount	6 months

Financing arrangements (Debt Is

Financing arrangements (Debt Issuances) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2019
Debt Instrument [Line Items]
Commercial paper, maximum borrowing capacity		$ 2,500,000,000
Commercial paper issued	$ 12,300,000,000
Commercial paper repaid	12,300,000,000
Commercial paper, maximum outstanding	1,500,000,000
Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes issued	$ 4,500,000,000
Notes [Member] | 1.90% notes due 2019 (1.90% 2019 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	1.90%	1.90%
Notes [Member] | 2.20% notes due 2020 (2.20% 2020 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.20%	2.20%
Notes [Member] | 2.65% notes due 2022 (2.65% 2022 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.65%	2.65%
Notes [Member] | 3.20% notes due 2027 (3.20% 2027 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.20%	3.20%

Financing arrangements (Debt Re

Financing arrangements (Debt Repayments) (Details) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2019EUR (€)	Dec. 31, 2018USD ($)	Dec. 31, 2018EUR (€)	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
Repayments of debt	$ 4,514		$ 1,121		$ 4,405
Repayments of short-term debt					$ 605
Notes [Member] | 2.20% notes due 2019 (2.20% 2019 Notes) [Member]
Debt Instrument [Line Items]
Repayments of debt	$ 1,400
Interest rate, stated percentage	2.20%	2.20%
Notes [Member] | 5.70% notes due 2019 (5.70% 2019 Notes) [Member]
Debt Instrument [Line Items]
Repayments of debt	$ 1,000
Interest rate, stated percentage	5.70%	5.70%
Notes [Member] | 2.125% euro-denominated notes due 2019 (2.125% 2019 euro Notes) [Member]
Debt Instrument [Line Items]
Repayments of debt	$ 864	€ 675
Interest rate, stated percentage	2.125%	2.125%
Notes [Member] | 1.90% notes due 2019 (1.90% 2019 Notes) [Member]
Debt Instrument [Line Items]
Repayments of debt	$ 700
Interest rate, stated percentage	1.90%	1.90%			1.90%
Notes [Member] | Floating Rate Notes Due 2019 [Member]
Debt Instrument [Line Items]
Repayments of debt	$ 550
Notes [Member] | 6.15% notes due 2018 (6.15% 2018 Notes) [Member]
Debt Instrument [Line Items]
Repayments of debt			$ 500
Interest rate, stated percentage			6.15%	6.15%
Notes [Member] | 4.375% euro-denominated notes due 2018 (4.375% 2018 euro Notes) [Member]
Debt Instrument [Line Items]
Repayments of debt			$ 621	€ 550
Interest rate, stated percentage			4.375%	4.375%
Notes [Member] | 2.125% notes due 2017 (2.125% 2017 Notes) [Member]
Debt Instrument [Line Items]
Repayments of debt					$ 1,250
Interest rate, stated percentage					2.125%
Notes [Member] | Floating rate notes due 2017 [Member]
Debt Instrument [Line Items]
Repayments of debt					$ 600
Notes [Member] | 1.25% notes due 2017 (1.25% 2017 Notes) [Member]
Debt Instrument [Line Items]
Repayments of debt					$ 850
Interest rate, stated percentage					1.25%
Notes [Member] | 5.85% notes due 2017 (5.85% 2017 Notes) [Member]
Debt Instrument [Line Items]
Repayments of debt					$ 1,100
Interest rate, stated percentage					5.85%

Financing arrangements (Interes

Financing arrangements (Interest Rate and Cross-currency Swaps) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
0.41% 2023 Swiss franc Bonds [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	0.41%
5.50% 2026 pound sterling Notes [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	5.50%
Notes payable [Member]
Debt Instrument [Line Items]
Notional amount	$ 9,550	$ 10,950
Notes payable [Member] | 2.20% notes due 2019 (2.20% 2019 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.20%
Notional amount	$ 0	1,400
Notes payable [Member] | 2.20% notes due 2019 (2.20% 2019 Notes) [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, effective interest rate	0.60%
Notes payable [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.45%
Notional amount	$ 900	900
Notes payable [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, effective interest rate	1.10%
Notes payable [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.10%
Notional amount	$ 1,000	1,000
Notes payable [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, effective interest rate	1.70%
Notes payable [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.875%
Notional amount	$ 1,750	1,750
Notes payable [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, effective interest rate	2.00%
Notes payable [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.625%
Notional amount	$ 750	750
Notes payable [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, effective interest rate	1.60%
Notes payable [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.625%
Notional amount	$ 1,400	1,400
Notes payable [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, effective interest rate	1.40%
Notes payable [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	3.125%
Notional amount	$ 1,000	1,000
Notes payable [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, effective interest rate	0.90%
Notes payable [Member] | 2.600% notes due 2026 (2.60% 2026 notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.60%
Notional amount	$ 1,250	1,250
Notes payable [Member] | 2.600% notes due 2026 (2.60% 2026 notes) [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, effective interest rate	0.30%
Notes payable [Member] | 4.663% 2051 Notes [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.663%
Notional amount	$ 1,500	$ 1,500
Notes payable [Member] | 4.663% 2051 Notes [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Derivative, effective interest rate	0.00%
Notes payable [Member] | 1.25% notes due 2022 (1.25% 2022 euro Notes) [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	1.25%
Notes payable [Member] | 0.41% 2023 Swiss franc Bonds [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	0.41%
Notes payable [Member] | 2.00% 2026 euro Notes [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	2.00%
Notes payable [Member] | 4.00% 2029 pound sterling Notes [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.00%

Financing arrangements (Shelf R

Financing arrangements (Shelf Registration Statements and Other Facilities) (Details) - Line of credit [Member]	12 Months Ended
	Dec. 31, 2019USD ($)renewal_option	Dec. 31, 2018USD ($)	Dec. 31, 2014USD ($)
Debt Instrument [Line Items]
Maximum current borrowing capacity under a syndicated, unsecured, revolving credit agreement			$ 2,500,000,000
Amount by which borrowing capacity under a syndicated unsecured revolving credit agreement may be increased upon our request at discretion of banks	$ 750,000,000
Initial commitment term of each bank which is a party to the agreement	5 years
Number of additional term extension options | renewal_option	2
Additional period for extension of commitment term	1 year
Annual commitment fees for syndicated, unsecured, revolving credit agreement	0.09%
Basis spread on variable rate	1.00%
Amount outstanding under syndicated, unsecured, revolving credit facility	$ 0	$ 0
Fed Funds Effective Rate Overnight Index Swap Rate [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	0.50%
LIBOR [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	1.00%
Description of variable rate basis	one-month LIBOR

Financing arrangements (Contrac

Financing arrangements (Contractual Maturities of Long-term Debt) (Details) $ in Millions	Dec. 31, 2019USD ($)
Maturities of Long-term Debt [Abstract]
2020	$ 2,950
2021	3,500
2022	4,152
2023	1,474
2024	1,400
Thereafter	16,999
Total	$ 30,475

Financing arrangements (Inter_2

Financing arrangements (Interest Costs) (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Interest paid, net of interest rate and cross currency swaps	$ 1.3	$ 1.5	$ 1.3

Stockholders' equity (Stock Rep

Stockholders' equity (Stock Repurchase Program) (Details) - USD ($) shares in Millions	3 Months Ended												12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	May 31, 2019
Equity [Abstract]
Stock repurchases, Shares	5.1	6.2	13.1	15.9	11.1	8.7	18.2	56.4	4.5	4.4	6.2	3.4	40.2	94.5	18.5
Stock repurchases	$ 1,090,000,000	$ 1,170,000,000	$ 2,349,000,000	$ 3,031,000,000	$ 2,165,000,000	$ 1,713,000,000	$ 3,190,000,000	$ 10,787,000,000	$ 796,000,000	$ 769,000,000	$ 1,006,000,000	$ 555,000,000	$ 7,640,000,000	$ 17,855,000,000	$ 3,126,000,000
Stock repurchase program, additional authorized amount	4,000,000,000												4,000,000,000			$ 5,000,000,000
Amount available for stock repurchases under a board approved stock repurchase plan	$ 6,500,000,000												$ 6,500,000,000

Stockholders' equity (Dividends

Stockholders' equity (Dividends) (Details) - $ / shares	Dec. 11, 2019	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Equity [Abstract]
Common stock, dividends paid per share (in usd per share)		$ 1.45	$ 1.45	$ 1.45	$ 1.45	$ 1.32	$ 1.32	$ 1.32	$ 1.32	$ 1.15	$ 1.15	$ 1.15	$ 1.15
Common stock, dividends declared per share (in usd per share)	$ 1.60													$ 5.95	$ 5.41	$ 4.77

Stockholders' equity (Component

Stockholders' equity (Components of AOCI) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2018
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	$ 12,500	$ 12,500	$ 25,241	$ 29,875
Cumulative effect of changes in accounting principles, net of taxes					$ 29
Foreign currency translation adjustments		(48)	(141)	81
Ending Balance		9,673	12,500	25,241
Foreign currency translation [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(670)	(670)	(529)	(610)
Foreign currency translation adjustments	(48)		(141)	77
Income taxes	0		0	4
Ending Balance		(718)	(670)	(529)
Cash flow hedges [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	241	241	(6)	282
Unrealized gains	127		61	192
Reclassification adjustments to income	211		262	(638)
Income taxes	18		(76)	158
Ending Balance		175	241	(6)
Available-for-sale securities [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(338)	(338)	(144)	(138)
Cumulative effect of changes in accounting principles, net of taxes					(9)
Unrealized gains	424		(556)	(46)
Reclassification adjustments to income	56		365	41
Income taxes	(8)		6	(1)
Ending Balance		22	(338)	(144)
Other [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(2)	(2)	0	(5)
Other losses		(5)	(2)	5
Ending Balance		(7)	(2)	0
AOCI [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	$ (769)	(769)	(679)	(471)
Cumulative effect of changes in accounting principles, net of taxes					$ (9)
Foreign currency translation adjustments		(48)	(141)	77
Unrealized gains		551	(495)	146
Reclassification adjustments to income		(267)	627	(597)
Other losses		(5)	(2)	5
Income taxes		10	(70)	161
Ending Balance		$ (528)	$ (769)	$ (679)

Stockholders' equity (Accumulat

Stockholders' equity (Accumulated Other Comprehensive Income (Loss), Textual) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Equity [Abstract]
Income tax expense or (benefit) for reclassification adjustments to income for available-for-sale securities	$ (14)	$ 3	$ (8)
Income taxes expense or (benefit) for unrealized gains and losses for available-for-sale securities	22	(9)	9
Income taxes expense or (benefit) for unrealized gains and losses for cash flow hedges	28	21	68
Income tax expense or (benefit) reclassification adjustments to income for cash flow hedges	$ (46)	$ 55	$ (226)

Stockholders' equity (Reclassif

Stockholders' equity (Reclassifications out of AOCI) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Revenues									$ 23,362	$ 23,747	$ 22,849
Interest and other income, net									753	674	928
Interest expense, net									(1,289)	(1,392)	(1,304)
Income before income taxes									9,138	9,545	9,597
Provision for income taxes									(1,296)	(1,151)	(7,618)
Net income	$ 1,703	$ 1,968	$ 2,179	$ 1,992	$ 1,928	$ 1,859	$ 2,296	$ 2,311	7,842	8,394	1,979
Product sales [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Revenues	$ 5,881	$ 5,463	$ 5,574	$ 5,286	$ 6,001	$ 5,510	$ 5,679	$ 5,343	22,204	22,533	21,795
Reclassification out of AOCI [Member] | Cash flow hedges [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Income before income taxes									211	(262)	638
Provision for income taxes									(46)	55	(226)
Net income									165	(207)	412
Reclassification out of AOCI [Member] | Available-for-sale securities [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net									56	(365)	(41)
Provision for income taxes									(14)	3	(8)
Net income									42	(362)	(49)
Reclassification out of AOCI [Member] | Foreign currency contract [Member] | Product sales [Member] | Cash flow hedges [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Revenues									101	(21)	65
Reclassification out of AOCI [Member] | Foreign currency contract [Member] | Cash flow hedge [Member] | Product sales [Member] | Cash flow hedges [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Revenues									101	(21)	65
Reclassification out of AOCI [Member] | Cross-currency swap contract [Member] | Cash flow hedges [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net									110	(241)	574
Reclassification out of AOCI [Member] | Cross-currency swap contract [Member] | Cash flow hedge [Member] | Cash flow hedges [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net									110	(241)	574
Reclassification out of AOCI [Member] | Forward interest rate contract [Member] | Cash flow hedges [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest expense, net											(1)
Reclassification out of AOCI [Member] | Forward interest rate contract [Member] | Cash flow hedge [Member] | Cash flow hedges [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest expense, net									$ 0	$ 0	$ (1)

Stockholders' equity (Other) (D

Stockholders' equity (Other) (Details) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Equity [Abstract]
Preferred stock shares authorized (in shares)	5,000,000
Preferred stock, par value (in usd per share)	$ 0.0001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Fair value measurement - (Fair

Fair value measurement - (Fair Value of Financial Assets and Liabilities on Recurring Basis) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Assets:
Interest-bearing securities	$ 8,234	$ 28,724
Equity securities	303	176
Derivatives:
Total assets	9,086	29,308
Derivatives:
Contingent consideration obligations	61	72
Total liabilities	407	648
Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	224	182
Derivatives:
Foreign currency and cross-currency swap contracts	31	26
Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	66	170
Derivatives:
Foreign currency and cross-currency swap contracts	315	401
Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	259	56
Derivatives:
Interest rate swap contracts	0	149
U.S. Treasury notes [Member]
Assets:
Interest-bearing securities	360	2,663
U.S. Treasury bills [Member]
Assets:
Interest-bearing securities	0	8,191
Other government-related debt securities - U.S. [Member]
Assets:
Interest-bearing securities	0	110
Other government-related debt securities - Foreign and other [Member]
Assets:
Interest-bearing securities	0	932
Corporate debt securities - Financial [Member]
Assets:
Interest-bearing securities	1,121	2,697
Corporate debt securities - Industrial [Member]
Assets:
Interest-bearing securities	834	2,504
Corporate debt securities - Other [Member]
Assets:
Interest-bearing securities	198	562
Residential mortgage-backed securities [Member]
Assets:
Interest-bearing securities	182	1,422
Other mortgage- and asset-backed securities [Member]
Assets:
Interest-bearing securities	0	469
Money market mutual funds [Member]
Assets:
Interest-bearing securities	5,250	5,659
Other short-term interest-bearing securities [Member]
Assets:
Interest-bearing securities	289	3,515
Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Equity securities	303	176
Derivatives:
Total assets	5,913	16,689
Derivatives:
Contingent consideration obligations	0	0
Total liabilities	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	0	0
Derivatives:
Interest rate swap contracts	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | U.S. Treasury notes [Member]
Assets:
Interest-bearing securities	360	2,663
Quoted prices in active markets for identical assets (Level 1) [Member] | U.S. Treasury bills [Member]
Assets:
Interest-bearing securities	0	8,191
Quoted prices in active markets for identical assets (Level 1) [Member] | Other government-related debt securities - U.S. [Member]
Assets:
Interest-bearing securities	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Other government-related debt securities - Foreign and other [Member]
Assets:
Interest-bearing securities	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Corporate debt securities - Financial [Member]
Assets:
Interest-bearing securities	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Corporate debt securities - Industrial [Member]
Assets:
Interest-bearing securities	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Corporate debt securities - Other [Member]
Assets:
Interest-bearing securities	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Residential mortgage-backed securities [Member]
Assets:
Interest-bearing securities	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Other mortgage- and asset-backed securities [Member]
Assets:
Interest-bearing securities	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Money market mutual funds [Member]
Assets:
Interest-bearing securities	5,250	5,659
Quoted prices in active markets for identical assets (Level 1) [Member] | Other short-term interest-bearing securities [Member]
Assets:
Interest-bearing securities	0	0
Significant other observable inputs (Level 2) [Member]
Assets:
Equity securities	0	0
Derivatives:
Total assets	3,173	12,619
Derivatives:
Contingent consideration obligations	0	0
Total liabilities	346	576
Significant other observable inputs (Level 2) [Member] | Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	224	182
Derivatives:
Foreign currency and cross-currency swap contracts	31	26
Significant other observable inputs (Level 2) [Member] | Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	66	170
Derivatives:
Foreign currency and cross-currency swap contracts	315	401
Significant other observable inputs (Level 2) [Member] | Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	259	56
Derivatives:
Interest rate swap contracts	0	149
Significant other observable inputs (Level 2) [Member] | U.S. Treasury notes [Member]
Assets:
Interest-bearing securities	0	0
Significant other observable inputs (Level 2) [Member] | U.S. Treasury bills [Member]
Assets:
Interest-bearing securities	0	0
Significant other observable inputs (Level 2) [Member] | Other government-related debt securities - U.S. [Member]
Assets:
Interest-bearing securities	0	110
Significant other observable inputs (Level 2) [Member] | Other government-related debt securities - Foreign and other [Member]
Assets:
Interest-bearing securities	0	932
Significant other observable inputs (Level 2) [Member] | Corporate debt securities - Financial [Member]
Assets:
Interest-bearing securities	1,121	2,697
Significant other observable inputs (Level 2) [Member] | Corporate debt securities - Industrial [Member]
Assets:
Interest-bearing securities	834	2,504
Significant other observable inputs (Level 2) [Member] | Corporate debt securities - Other [Member]
Assets:
Interest-bearing securities	198	562
Significant other observable inputs (Level 2) [Member] | Residential mortgage-backed securities [Member]
Assets:
Interest-bearing securities	182	1,422
Significant other observable inputs (Level 2) [Member] | Other mortgage- and asset-backed securities [Member]
Assets:
Interest-bearing securities	0	469
Significant other observable inputs (Level 2) [Member] | Money market mutual funds [Member]
Assets:
Interest-bearing securities	0	0
Significant other observable inputs (Level 2) [Member] | Other short-term interest-bearing securities [Member]
Assets:
Interest-bearing securities	289	3,515
Significant unobservable inputs (Level 3) [Member]
Assets:
Equity securities	0	0
Derivatives:
Total assets		0
Derivatives:
Contingent consideration obligations	61	72
Total liabilities	61	72
Significant unobservable inputs (Level 3) [Member] | Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Significant unobservable inputs (Level 3) [Member] | Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Significant unobservable inputs (Level 3) [Member] | Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	0	0
Derivatives:
Interest rate swap contracts	0	0
Significant unobservable inputs (Level 3) [Member] | U.S. Treasury notes [Member]
Assets:
Interest-bearing securities	0	0
Significant unobservable inputs (Level 3) [Member] | U.S. Treasury bills [Member]
Assets:
Interest-bearing securities	0	0
Significant unobservable inputs (Level 3) [Member] | Other government-related debt securities - U.S. [Member]
Assets:
Interest-bearing securities	0	0
Significant unobservable inputs (Level 3) [Member] | Other government-related debt securities - Foreign and other [Member]
Assets:
Interest-bearing securities	0	0
Significant unobservable inputs (Level 3) [Member] | Corporate debt securities - Financial [Member]
Assets:
Interest-bearing securities	0	0
Significant unobservable inputs (Level 3) [Member] | Corporate debt securities - Industrial [Member]
Assets:
Interest-bearing securities	0	0
Significant unobservable inputs (Level 3) [Member] | Corporate debt securities - Other [Member]
Assets:
Interest-bearing securities	0	0
Significant unobservable inputs (Level 3) [Member] | Residential mortgage-backed securities [Member]
Assets:
Interest-bearing securities	0	0
Significant unobservable inputs (Level 3) [Member] | Other mortgage- and asset-backed securities [Member]
Assets:
Interest-bearing securities	0	0
Significant unobservable inputs (Level 3) [Member] | Money market mutual funds [Member]
Assets:
Interest-bearing securities	0	0
Significant unobservable inputs (Level 3) [Member] | Other short-term interest-bearing securities [Member]
Assets:
Interest-bearing securities	$ 0	$ 0

Fair value measurement - Narrat

Fair value measurement - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2015	Dec. 31, 2011
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Length of time hedged in foreign currency contracts	3 years
Aggregate fair value of long-term debt, including current portion	$ 33,700,000,000	$ 35,000,000,000
Carrying value of long-term debt, including current portion	$ 29,903,000,000	33,929,000,000
Other operating income (expense) [Member] | IPR&D [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
IPR&D impairment charge		$ 330,000,000
Other operating income (expense) [Member] | AMG 899 [Member] | IPR&D [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
IPR&D impairment charge			$ 400,000,000
Dezima [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Maximum additional consideration due contingent on certain milestones				$ 1,250,000,000
Estimated fair values of contingent consideration obligations			110,000,000	$ 110,000,000
Dezima [Member] | AMG 899 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated fair values of contingent consideration obligations			0
Dezima [Member] | Other operating income (expense) [Member] | AMG 899 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated fair values of contingent consideration obligations			$ 116,000,000
Biovex [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Additional contingent consideration upon achievement of milestones					$ 325,000,000
Other government-related and corporate debt securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment maturity period	3 years

Derivative instruments - Narrat

Derivative instruments - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Foreign currency and cross currency swap contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps	$ (47)
Derivatives designated as hedging instruments [Member] | Foreign currency forward contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Notional amount	5,000	$ 4,500	$ 4,600
Derivatives designated as hedging instruments [Member] | Foreign currency option contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Notional amount		21	74
Derivatives designated as hedging instruments [Member] | Interest rate swap [Member]
Derivative Instruments Gain Loss [Line Items]
Notional amount	9,600	11,000
Derivatives not designated as hedging instruments [Member] | Foreign currency forward contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Notional amount	$ 1,200	$ 737	$ 757
Notes [Member] | Two Point One Two Five Percent Euro Notes Due 2019 [Member]
Derivative Instruments Gain Loss [Line Items]
Interest rate, stated percentage	2.125%

Derivative instruments - (Cross

Derivative instruments - (Cross-currency Swaps) (Details) - Cash flow hedge [Member] - Cross-currency swap contracts [Member] € in Millions, £ in Millions, SFr in Millions, $ in Millions	Dec. 31, 2019USD ($)	Dec. 31, 2019EUR (€)	Dec. 31, 2019CHF (SFr)	Dec. 31, 2019GBP (£)
1.25% 2022 euro Notes [Member]
Derivative [Line Items]
Notional amount	$ 1,388	€ 1,250
0.41% 2023 Swiss franc Bonds [Member]
Derivative [Line Items]
Notional amount	704		SFr 700
2.00% 2026 euro Notes [Member]
Derivative [Line Items]
Notional amount	833	€ 750
5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Notional amount	747			£ 475
4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Notional amount	$ 1,111			£ 700
Euro Member Countries, Euro [Member] | 1.25% 2022 euro Notes [Member]
Derivative [Line Items]
Interest rates	1.30%	1.30%	1.30%	1.30%
Euro Member Countries, Euro [Member] | 2.00% 2026 euro Notes [Member]
Derivative [Line Items]
Interest rates	2.00%	2.00%	2.00%	2.00%
Switzerland, Francs [Member] | 0.41% 2023 Swiss franc Bonds [Member]
Derivative [Line Items]
Interest rates	0.40%	0.40%	0.40%	0.40%
United Kingdom, Pounds [Member] | 5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	5.50%	5.50%	5.50%	5.50%
United Kingdom, Pounds [Member] | 4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	4.00%	4.00%	4.00%	4.00%
United States of America, Dollars [Member] | 1.25% 2022 euro Notes [Member]
Derivative [Line Items]
Interest rates	3.20%	3.20%	3.20%	3.20%
United States of America, Dollars [Member] | 0.41% 2023 Swiss franc Bonds [Member]
Derivative [Line Items]
Interest rates	3.40%	3.40%	3.40%	3.40%
United States of America, Dollars [Member] | 2.00% 2026 euro Notes [Member]
Derivative [Line Items]
Interest rates	3.90%	3.90%	3.90%	3.90%
United States of America, Dollars [Member] | 5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	6.00%	6.00%	6.00%	6.00%
United States of America, Dollars [Member] | 4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	4.50%	4.50%	4.50%	4.50%

Derivative instruments - (Effec

Derivative instruments - (Effective Portion of Unrealized Gain (Loss)) (Details) - Cash flow hedge [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Derivative Instruments Gain Loss [Line Items]
Total unrealized gains	$ 127	$ 61	$ 192
Foreign currency contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Total unrealized gains	148	348	(402)
Cross-currency swap contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Total unrealized gains	(21)	(287)	581
Forward interest rate contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Total unrealized gains	$ 0	$ 0	$ 13

Derivative instruments - (Hedge

Derivative instruments - (Hedged Liabilities and Cumulative Amount) (Details) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Derivative [Line Items]
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	$ 296	$ (53)
Current portion of long-term debt
Derivative [Line Items]
Carrying amounts of hedged liabilities	903	2,396
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	4	(3)
Carrying value with discontinued hedging relationships		1,000
Hedging adjustments on discontinued hedging relationships		3
Long-term debt
Derivative [Line Items]
Carrying amounts of hedged liabilities	8,814	9,361
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	292	(50)
Carrying value with discontinued hedging relationships	136	137
Hedging adjustments on discontinued hedging relationships	$ 36	$ 37

Derivative instruments - (Summa

Derivative instruments - (Summary of Income and Expense Line Items) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Derivative [Line Items]
Product sales									$ 23,362	$ 23,747	$ 22,849
Interest and other income, net									753	674	928
Interest expense, net									(1,289)	(1,392)	(1,304)
Interest rate swap agreements [Member]
Derivative [Line Items]
Gains (losses) on fair value hedging relationships, Hedged Items									(349)	65	127
Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments									352	(42)	(85)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Cross-currency swap contracts [Member]
Derivative [Line Items]
Interest and other income, net									110	(241)	574
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Forward interest rate contract [Member]
Derivative [Line Items]
Interest expense, net											(1)
Product sales [Member]
Derivative [Line Items]
Product sales	$ 5,881	$ 5,463	$ 5,574	$ 5,286	$ 6,001	$ 5,510	$ 5,679	$ 5,343	22,204	22,533	21,795
Product sales [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Foreign currency contracts [Member]
Derivative [Line Items]
Product sales									$ 101	$ (21)	$ 65

Derivative instruments - (Fair

Derivative instruments - (Fair Value of Derivatives) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Assets
Total derivative assets, fair value	$ 549	$ 408
Liabilities
Total derivative liabilities, fair value	346	576
Derivatives designated as hedging instruments [Member]
Assets
Total derivative assets, fair value	548	407
Liabilities
Total derivative liabilities, fair value	346	576
Derivatives designated as hedging instruments [Member] | Foreign currency contracts [Member] | Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	223	181
Derivatives designated as hedging instruments [Member] | Foreign currency contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	31	26
Derivatives designated as hedging instruments [Member] | Cross-currency swap contracts [Member] | Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	66	170
Derivatives designated as hedging instruments [Member] | Cross-currency swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	315	401
Derivatives designated as hedging instruments [Member] | Interest rate swap contracts [Member] | Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	259	56
Derivatives designated as hedging instruments [Member] | Interest rate swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	0	149
Derivatives not designated as hedging instruments [Member]
Assets
Total derivative assets, fair value	1	1
Liabilities
Total derivative liabilities, fair value	0	0
Derivatives not designated as hedging instruments [Member] | Foreign currency contracts [Member] | Other current assets [Member]
Assets
Total derivative assets, fair value	1	1
Derivatives not designated as hedging instruments [Member] | Foreign currency contracts [Member] | Accrued liabilities [Member]
Liabilities
Total derivative liabilities, fair value	$ 0	$ 0

Contingencies and commitments (

Contingencies and commitments (Sensipar ANDA Patent Litigation) (Details) - lawsuit	1 Months Ended
	Feb. 28, 2017	Sep. 30, 2016
Sensipar (cinacalcet) Patent Litigation
Gain Contingencies [Line Items]
Number of lawsuits filed		14
Amgen Inc. v. Aurobindo Pharma Ltd. et al
Gain Contingencies [Line Items]
Number of lawsuits consolidated	14

Contingencies and commitments_2

Contingencies and commitments (Sandoz Patent Litigation) (Details)	Apr. 30, 2019patentaffiliate	Feb. 26, 2016patentaffiliate	Jun. 30, 2018lawsuit
ENBREL (etanercept)
Gain Contingencies [Line Items]
Gain contingency, number of affiliates | affiliate	2	2
Number of patents allegedly infringed | patent	5	5
Otezla
Gain Contingencies [Line Items]
Number Of lawsuits | lawsuit			19

Contingencies and commitments_3

Contingencies and commitments (Repatha Patent Litigation) (Details) - Sanofi/Regeneron Patent Litigation - patent	Mar. 24, 2020	Dec. 06, 2017	Jan. 12, 2017	Mar. 18, 2016	Oct. 31, 2014
Other Commitments [Line Items]
Number of patents allegedly infringed		2	2		7
Length of trial				5 years
Forecast
Other Commitments [Line Items]
Length of trial	2 days

Contingencies and commitments_4

Contingencies and commitments (NEUPOGEN Patent Litigation) (Details) - patent	May 20, 2019	Mar. 08, 2018	May 22, 2017	Oct. 31, 2018
Adello NEUPOGEN Patent Litigation
Gain Contingencies [Line Items]
Number of patents allegedly infringed		17		4
Apotex NEUPOGEN/Neulasta Patent Litigation
Gain Contingencies [Line Items]
Number of patents allegedly infringed	1		1

Contingencies and commitments_5

Contingencies and commitments (EPOGEN Patent Litigation) (Details) $ in Millions	Sep. 22, 2017USD ($)	Jan. 23, 2017claim
Hospira EPOGEN Patent Litigation
Gain Contingencies [Line Items]
Aount awarded from other party | $	$ 70
Epoetin Alfa Litigation
Gain Contingencies [Line Items]
Number of patents allegedly infringed | claim		2
Length of trial	5 days

Contingencies and commitments_6

Contingencies and commitments (AMJEVITA Patent Litigation) (Details)	Jan. 24, 2019patent
AMJEVITA
Loss Contingencies [Line Items]
Loss contingency, patents allegedly infringed	3

Contingencies and commitments_7

Contingencies and commitments (KANJINTI Patent Litigation) (Details) - patent	Sep. 04, 2019	Jul. 24, 2019	Jan. 17, 2019	Nov. 07, 2018	Jul. 19, 2018	Jun. 21, 2018
KANJINTI Patent Litigation
Loss Contingencies [Line Items]
Loss contingency, patents allegedly infringed	4	8	1	10	18	37

Contingencies and commitments_8

Contingencies and commitments (MVASI Patent Litigation) (Details) - Mvasi Patent Litigation, Genentech, Inc. (Genentech) and the City of Hope	Oct. 29, 2019patent	Mar. 29, 2019patent	Aug. 31, 2018patentlawsuit	Oct. 18, 2017patent	Oct. 06, 2017patent
Other Commitments [Line Items]
Loss contingency, patents allegedly infringed	6		8	25	24
Number of patents allegedly infringed		14		27	27
Number of lawsuits filed | lawsuit			2

Contingencies and commitments_9

Contingencies and commitments (Additional Information) (Details)	Jul. 31, 2019lawsuit	Jun. 04, 2019lawsuit	Apr. 10, 2019lawsuit	Apr. 04, 2019agreement	May 10, 2019lawsuit	Apr. 10, 2019plaintiffslawsuit
Novartis Breach Of Contract Action
Loss Contingencies [Line Items]
Agreements breached | agreement				2
Sensipar Antitrust Class Actions
Loss Contingencies [Line Items]
Loss contingency, number of plaintiffs | plaintiffs						4
Loss contingency, number of lawsuits	4		4			2
Humira Biosimilar Antitrust Class Actions
Loss Contingencies [Line Items]
Loss contingency, number of lawsuits		12			12
Number of complaints stayed					6

Contingencies and commitment_10

Contingencies and commitments (U.S. Repatriation Tax Commitments) (Details) $ in Millions	Dec. 31, 2019USD ($)installment
Commitments and Contingencies Disclosure [Abstract]
U.S. repatriation tax commitments, number of annual installments | installment	8
U.S. repatriation tax commitments, 2020	$ 587
U.S. repatriation tax commitments, 2021	587
U.S. repatriation tax commitments, 2022	587
U.S. repatriation tax commitments, 2023	1,100
U.S. repatriation tax commitments, 2024	1,467
U.S. repatriation tax commitments, Thereafter	1,834
Total remaining U.S. repatriation tax commitments	$ 6,162

Quarterly financial data (una_3

Quarterly financial data (unaudited) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Effect of Fourth Quarter Events [Line Items]
Product sales									$ 23,362	$ 23,747	$ 22,849
Gross profit from product sales	$ 4,628	$ 4,427	$ 4,562	$ 4,231	$ 4,905	$ 4,473	$ 4,655	$ 4,399
Net income	$ 1,703	$ 1,968	$ 2,179	$ 1,992	$ 1,928	$ 1,859	$ 2,296	$ 2,311	$ 7,842	$ 8,394	$ 1,979
Earnings per share:
Basic (in usd per share)	$ 2.87	$ 3.29	$ 3.59	$ 3.20	$ 3.04	$ 2.88	$ 3.50	$ 3.27	$ 12.96	$ 12.70	$ 2.71
Diluted (in usd per share)	$ 2.85	$ 3.27	$ 3.57	$ 3.18	$ 3.01	$ 2.86	$ 3.48	$ 3.25	$ 12.88	$ 12.62	$ 2.69
Product [Member]
Effect of Fourth Quarter Events [Line Items]
Product sales	$ 5,881	$ 5,463	$ 5,574	$ 5,286	$ 6,001	$ 5,510	$ 5,679	$ 5,343	$ 22,204	$ 22,533	$ 21,795

Subsequent events - Narrative (

Subsequent events - Narrative (Details) - BeiGene - Subsequent Event $ in Millions	Jan. 01, 2020USD ($)	Jan. 02, 2020USD ($)oncology_assets
Subsequent Event [Line Items]
Ownership percentage		20.50%
Equity Method Investment, Aggregate Cost		$ 2,800
Projects to be developed | oncology_assets		20
Research and Development Expense	$ 1,250

SCHEDULE II - VALUATION AND Q_2

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Allowance for doubtful accounts [Roll Forward]
Balance at beginning of period	$ 48	$ 51	$ 51
Additions charged to costs and expenses	0	1	4
Other additions	0	0	0
Deductions	22	4	4
Balance at end of period	$ 26	$ 48	$ 51

Uncategorized Items - amgn-1231

Label	Element	Value
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 38,000,000